U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

CLASSIFICATION ORDER 1896

SEPTEMBER 7, 2010

PROJECT C-7157

The following classification changes will be effected by this order:

	Class	**Subclass**	**Art Unit**	**Ex'r Search Room**
Abolished:	514	2-21	1654	RND0000A51
Established:	514	1.1-1.9, 2.1-2.9, 3.1-3.9, 4.1-4.9, 5.1-5.9, 6.1-6.9, 7.1-7.9, 8.1-8.9, 9.1-9.9, 10.1-10.9, 11.1-11.9, 12.1-12.9, 13.1-13.9, 14.1-14.9, 15.1-15.9, 16.1-16.9, 17.1-17.9, 18.1-18.9, 19.1-19.9, 20.1-20.9, 21.1-21.9, 21.91, 21.92	1654	RND0000A51

The following classes are also impacted by this order:
106, 424, 435, 436, 530, 930

This order includes the following:

A. CLASSIFICATION MANUAL CHANGES

B. LISTING OF PRINCIPAL SOURCE OF ESTABLISHED AND DISPOSITION OF ABOLISHED SUBCLASSES

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

D. DEFINITION CHANGES AND NEW OR ADDITIONAL DEFINITIONS

CLASSIFICATION ORDER 1896

SEPTEMBER 7, 2010

PROJECT C-7157

Project Leader(s):	Patricia White
Project Classifier(s):	Edward Ward
Examiner(s):	Jon Weber
Editor(s):	Almeta Quinn
Publications Specialist(s):	Louise Bogans

This Class 514 is considered to be an integral part of Class 424 (see the Class 424 schedule for the position of this Class in schedule hierarchy). This Class retains all pertinent definitions and class lines of Class 424.

1 **DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)**

1.1 .Peptide (e.g., protein, etc.) containing DOAI

1.2 ..Transporter affecting or utilizing

1.3 ..Prodrug utilizing

1.4 ..Sepsis affecting

1.5 ..Respiratory distress syndrome (e.g., ARDS, IRDS, etc.) affecting

1.6 ..Pneumonia affecting

1.7 ..Asthma affecting

1.8 ..Cystic fibrosis affecting

1.9 ..Arteriosclerosis (e.g., atherosclerosis, etc.) affecting

2.1 ..Endotoxin (e.g., LPS, etc.) affecting

2.2 ..Bactericidal/permeability-increasing (BPI) protein affecting or utilizing

2.3 ..Micro-organism destroying or inhibiting

2.4 ...Bacterium (e.g., Bacillus, etc.) destroying or inhibiting

2.5 ....Lactoferrin

2.6 ....Streptococcus

2.7 ....Staphylococcus (e.g., Staphylococcus aureus, etc.)

2.8 ....Gram negative bacterium (e.g., Escherichia coli, salmonella, Helicobacter, etc.)

2.9 ....Cyclopeptide utilizing

3.1 ....Glycopeptide utilizing

3.2 ....Amphiphilic or oligomer modified peptide (e.g., magainin, peptide nucleic acid, or PEGylated peptide, etc.) utilizing

3.3 ...Fungus (e.g., athlete's foot, ringworm, etc.) destroying or inhibiting

3.4 ....Candida (e.g., Candida albicans, etc.)

3.5 ....Yeast

3.6 ....Cyclopeptide utilizing

3.7 ...Virus destroying or inhibiting

3.8 ....Human immunodeficiency virus (HIV)

3.9 .....Cluster of differentiation protein (e.g., CD4, etc.) affecting

4.1 .....HIV protease inhibitor affecting or utilizing

4.2 ....Herpesviridae

4.3 ....Hepatitis

4.4 ...Protozoa destroying or inhibiting

4.5 ..Insect destroying or inhibiting

4.6 ..Parasite (e.g., tapeworm, roundworm, nematode, etc.) destroying or inhibiting

4.7 ..Lactation affecting

4.8 ..Weight regulation affecting

4.9 ...Appetite or satiation affecting

5.1 ...Growth hormone (GH) or derivative utilizing

5.2 ...Neuropeptide (e.g., NPY, PYY, dynorphin, etc.) or derivative utilizing

5.3 ...Peptide hormone or derivative utilizing

5.4 ..Iron affecting

5.5 ..Nutrition enhancement or support

5.6 ...Containing whey

5.7 ...Containing casein

5.8 ..Leptin or derivative affecting or utilizing

5.9 ..Insulin or derivative utilizing

6.1 ...Truncated insulin

6.2 ...A-chain modified insulin

6.3 ...B-chain modified insulin

6.4 ...Zinc containing

6.5 ...With an additional active ingredient

6.6 ....With protamine

6.7 ..Insulin affecting

6.8 ..Blood sugar affecting

6.9 ...Diabetes

7.1 ....Somatostatin or derivative affecting or utilizing

7.2 ....Glucagon, glucagon-like peptide (e.g., GLP-1, etc.) or derivative affecting or utilizing
7.3 ....Type I diabetes
7.4 ..Lipid or cholesterol affecting (e.g., dyslipidemia, etc.)
7.5 ..Protein tyrosine kinase (PTK) affecting
7.6 ..Growth factor or derivative affecting or utilizing
7.7 ...Erythropoietin (EPO) or derivative
7.8 ...Thrombopoietin (TPO) or derivative
7.9 ...Hematopoiesis affecting
8.1 ...Vascular endothelial growth factor (e.g., VEGF-A, VEGF-B, etc.) or derivative
8.2 ...Platelet-derived growth factor (PDGF) or derivative
8.3 ...Nerve tissue or nerve cell growth affecting
8.4 ....Nerve growth factor (NGF) or derivative
8.5 ...Insulin-like growth factor (IGF) or derivative
8.6 ....Insulin-like growth factor 1 (IGF-1) or derivative
8.7 ....Insulin-like growth factor binding protein (IGFBP) or derivative
8.8 ...Bone morphogenic protein (BMP) or derivative
8.9 ...Transforming growth factor (TGF) or derivative
9.1 ...Fibroblast growth factor (FGF) or derivative
9.2 ....Keratinocyte growth factor (KGF) or derivative
9.3 ...Fibronectin or derivative
9.4 ...Wound healing or wound repair affecting
9.5 ...Hepatocyte growth factor (HGF) or derivative
9.6 ...Epidermal growth factor (EGF) or epidermal growth factor-like or derivative
9.7 ..Hormone or derivative affecting or utilizing
9.8 ...Fertility
9.9 ....Follicle-stimulating hormone (FSH) or derivative
10.1 ....Luteinizing hormone (LH) or derivative
10.2 ....Androgen (e.g., testosterone, etc.) or estrogen affecting
10.3 ....Gonadotropin-releasing hormone (GnRH) or derivative
10.4 .....Cetrorelix, leuprolide, or deslorelin utilizing
10.5 .....Ovulation affecting
10.6 .....Synthetic gonadotropin-releasing hormone antagonist
10.7 ...Melanocortin (e.g., Melanocyte-stimulating hormone (MSH), etc.) or derivative
10.8 ....Corticotropin or derivative
10.9 ...Vasopressin or derivative
11.1 ...Somatostatin or derivative
11.2 ...Growth-hormone-releasing hormone (GHRH) or derivative
11.3 ...Growth hormone (GH) or derivative
11.4 ....Human growth hormone (hGH) or derivative
11.5 ...Prolactin or derivative
11.6 ...Oxytocin or derivative
11.7 ...Glucagon, glucagon-like peptide (e.g., GLP-1, GLP-2, etc.) or derivative
11.8 ...Parathyroid hormone (PTH) or derivative
11.9 ...Calcitonin or derivative
12.1 ...Muscle contraction affecting (e.g., muscle twitch, muscle relaxation, etc.)
12.2 ...Anti-inflammatory
12.3 ...Gastrin hormone or derivative
12.4 ...Natriuretic peptide or derivative (e.g., atrial natriuretic peptide, brain natriuretic peptide, etc.)
12.5 ...Bradykinin or derivative
12.6 ...Cholecystokinin (CCK) or derivative
12.7 ...Relaxin or derivative
12.8 ...Secretin or derivative
12.9 ...Thymosin (e.g., thymosin (alpha 1, thymosin beta 4, etc.) or derivative
13.1 ...Vasoactive intestinal peptide (VIP) or derivative
13.2 ..Digestive tract ulcer affecting
13.3 ..Angiogenesis affecting
13.4 ..Blood substitute

13.5 ..Blood affecting or blood protein utilizing
13.6 ...Fibrin or derivative affecting or utilizing
13.7 ...Coagulation affecting
13.8 ....Platelet aggregation or adhesion affecting
13.9 .....Glycoprotein IIb/IIIa affecting
14.1 ....Factor VIII or derivative affecting or utilizing
14.2 ....Plasma protease affecting
14.3 .....Factor VIIa affecting
14.4 .....Factor Xa affecting
14.5 ......Tissue factor pathway inhibitor (TFPI) utilizing
14.6 .....Urokinase affecting
14.7 .....Thrombin affecting
14.8 ......Hirudin or derivative utilizing
14.9 ....Thrombosis affecting
15.1 ...Oxidative stress affecting
15.2 ...Albumin or derivative affecting or utilizing
15.3 ...Plasma protein affecting or utilizing
15.4 ..Kidney affecting
15.5 ..Surfactant protein (e.g., SP-A, SP-B, etc.) or derivative affecting or utilizing
15.6 ..Blood pressure affecting
15.7 ...Hypertension
15.8 ....Renin inhibitor affecting or utilizing
15.9 .....Dipeptide renin inhibitor
16.1 ....Endothelin (e.g., ET-2, ET-3, etc.) or derivative affecting or utilizing
16.2 ....Angiotensin converting enzyme (ACE) affecting
16.3 ..Angiotensin converting enzyme (ACE) affecting
16.4 ..Cardiac disease (i.e., heart disease) affecting
16.5 ..Tissue development affecting
16.6 ..Rheumatoid arthritis affecting
16.7 ..Bone affecting
16.8 ...Osteoarthritis
16.9 ...Osteoporosis
17.1 ..Cartilage affecting
17.2 ..Collagen or derivative affecting or utilizing
17.3 ..N-methyl-d-aspartate (NMDA) receptor affecting
17.4 ..Ion channel protein affecting
17.5 ..Mental disorder or mental illness (e.g., psychoses, etc.) affecting
17.6 ...Anti-depressant or derivative affecting or utilizing
17.7 ..Nervous system (e.g., central nervous system (CNS), etc.) affecting
17.8 ...Alzheimer's disease
17.9 ...Multiple sclerosis
18.1 ...Neurotransmitter or derivative affecting or utilizing
18.2 ...Neuropathy affecting
18.3 ...Pain affecting
18.4 ....Opioid receptor affecting
18.5 ....Enkephalin or derivative affecting or utilizing
18.6 ..Skin affecting
18.7 ...Anti-inflammatory
18.8 ...Cosmetic enhancement or care
18.9 ..Apoptosis affecting
19.1 ..Cellular adhesion affecting or cell adhesion molecule (CAM) affecting or utilizing
19.2 ..Neoplastic condition affecting
19.3 ...Cancer
19.4 ....Breast
19.5 ....Prostate
19.6 ....Leukemia
19.7 ....Bombesin or derivative affecting or utilizing
19.8 ....Metastasis affecting
19.9 ....Cyclopeptide utilizing
20.1 ..Protease inhibitor affecting or utilizing
20.2 ...Cysteine protease inhibitor affecting or utilizing
20.3 ...Serine protease inhibitor affecting or utilizing
20.4 ....Elastase inhibitor affecting or utilizing
20.5 ..Cyclosporine or derivative utilizing
20.6 ..G-protein coupled receptor (GPCR) affecting
20.7 ..Hair affecting
20.8 ..Eye affecting
20.9 ..Glycopeptide utilizing
21.1 ..Cyclopeptide utilizing
21.2 ..100 or more amino acid residues in the peptide chain
21.3 ..25 to 99 amino acid residues in the peptide chain
21.4 ..16 to 24 amino acid residues in the peptide chain

21.5 ..12 to 15 amino acid residues in the peptide chain
21.6 ..9 to 11 amino acid residues in the peptide chain
21.7 ..7 or 8 amino acid residues in the peptide chain
21.8 ..5 or 6 amino acid residues in the peptide chain
21.9 ..3 or 4 amino acid residues in the peptide chain
21.91 ..2 amino acid residues in the peptide chain
21.92 ..Produced by or extracted from animal tissue
22 .Lignin or derivative DOAI
23 .Carbohydrate (i.e., saccharide radical containing) DOAI
24 ..S-glycoside
25 ..O-glycoside
26 ...Cyclopentanohydrophenanthrene ring system
27 ...Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring
28 ....The hetero ring has 8 or more ring carbons
29 .....The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)
30 .....The hetero ring has exactly 15 ring carbons
31 .....The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.)
32 ...Oxygen of the saccharide radical bonded to a nonsaccharide hetero ring by acyclic carbon bonding
33 ...Oxygen of the saccharide radical bonded directly to a polycyclo ring system of three or more carbocyclic rings
34 ....Oxygen of the saccharide radical bonded directly to a polycyclo ring system of four carbocyclic rings (e.g., daunomycin, etc.)
35 ...Oxygen of the saccharide radical bonded directly to a cyclohexyl ring
36 ....Two or more nitrogen atoms bonded directly to the cyclohexyl ring
37 .....The nitrogen atoms are in N-C(=N)-N groups (e.g., streptomycin, etc.)
38 .....Two saccharide radicals bonded through only oxygen to adjacent ring carbons of the cyclohexyl ring
39 ......Three or more saccharide radicals (e.g., neomycin, etc.)
40 .....Two saccharide radicals bonded through only oxygen to 4- and 6- positions of the cyclohexyl ring
41 ......Kanamycin or derivative
42 ..N-glycoside
43 ...Nitrogen containing hetero ring
44 R ....Polynucleotide (e.g., RNA, DNA, etc.)
44 A .....Antisense or RNA interference
45 ....Purines (including hydrogenated) (e.g., adenine, guanine, etc.)
46 .....Adenosine or derivative
47 ......Phosphorus containing
48 .....Phosphorus containing
49 ....Pyrimidines (including hydrogenated) (e.g., cytosine, etc.)
50 .....2,4-diketone pyrimidine or derivative (e.g., uracil, etc.)
51 ......Phosphorus containing
52 ....Phosphorus containing (e.g., Vitamin B12, etc.)
53 ..Dissacharide
54 ..Polysaccharide
55 ...Chitin or derivative
56 ...Heparin or derivative
57 ...Cellulose or derivative
58 ...Dextrin or derivative
59 ...Dextran or derivative
60 ...Starch or derivative
61 ...Tri- or tetrasaccharide
62 ..Glucosamine or derivative
63 .Silicon containing DOAI
64 .Boron containing DOAI
65 .Pyrethrum plant derived material or plant derived rotenone compound containing DOAI

66 ..With heterocyclic compound
67 ...Methylenedioxyphenyl group containing (e.g., piperonyl butoxide, etc.)
68 ..With carboxylic acid ester
69 ..With carboxylic acid metal salt
70 ..With organic nitrogen containing compound
71 ...Sulfur containing organic nitrogen compound
72 ..With organic oxygen containing compound
73 ...Phosphorus or halogen containing organic oxygen compound
74 ..With hydrocarbon or halohydrocarbon
75 .Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI
76 ..Amine addition salt of organic phosphorus containing acid
77 ..Inner salt (e.g., betaine, etc.)
78 ...Lecithins
79 ..Nitrogen containing hetero ring
80 ...Polycylo ring system having a ring nitrogen in the system
81 ....Nonshared hetero atoms in at least two rings of the polycyclo ring system
82 ....Quinolinyl or isoquinolinyl (including hydrogenated)
83 ...Hetero ring is three-membered consisting of one nitrogen and two carbons
84 ...Hetero ring is six-membered consisting of three nitrogens and three carbons
85 ...Hetero ring is six-membered consisting of two nitrogens and four carbons
86 ....Nitrogen atoms occupy 1 and 3- positions
87 .....PX- bonded directly to 1,3-diazine at 2- position (X is chalcogen)
88 .....Two or more PX- groups attached to the same 1,3-diazine (X is chalcogen)
89 ...Hetero ring is six-membered and includes only one ring nitrogen
90 ....Chalcogen in the six-membered hetero ring
91 ...Hetero ring is five-membered
92 ....Two or more hetero atoms in the five-membered ring
93 .....Triazoles (including hydrogenated)
94 .....Diazoles (including hydrogenated)
95 ..Sulfur containing hetero ring
96 ...Polycyclo ring system having the hetero ring as one of the cyclos
97 ...Two or more sulfurs in the hetero ring
98 ...Oxygen in the hetero ring
99 ..Oxygen containing hetero ring
100 ...Polycyclo ring system having the hetero ring as one of the cyclos
101 ...Two or more oxygen in the hetero ring
102 ..Two or more phosphorus atoms directly or indirectly bonded together by only covalent bonds
103 ...Phosphorus acid ester of polyhydric alcohol or thioalcohol (e.g., P-X-R-X-P group, etc., wherein X is chalcogen and R is the residue of the polyhydric alcohol or thioalcohol)
104 ....Benzene ring in the alcohol moiety
105 ...Phosphorus is part of a ring
106 ...P-O-P or P-S-P containing (e.g., anhydrides, etc.)
107 ...Benzene ring containing
108 ...Acyclic and contains at least one carbon atom between the phosphorus atoms
109 ..P-X-X containing (X is chalcogen)
110 ..Phosphorus is part of a ring
111 ...Polycyclo ring system having the phosphorus containing ring as one of the cyclos
112 ..Cyano or isocyano containing
113 ...Cyano or isocyano bonded directly to a benzene ring
114 ..Nitrogen, other than nitro or nitroso, bonded indirectly to phosphorus
115 ...N-C(=X)-N containing (X is chalcogen)

116 ...Sulfur single bonded directly to nitrogen
117 ....N-(O=)S(=O) containing (i.e., sulfonamides)
118 ...Phosphorus single bonded directly to nitrogen
119 ...C(=O)N containing
120 ..C=O other than as ketone or aldehyde, attached directly or indirectly to phosphorus
121 ...Plural C=O groups, other than as ketone or aldehyde
122 ....Malathion
123 .....With N-C(=O)-O containing compound
124 ...C=O, other than as ketone or aldehyde, attached to a benzene ring
125 ..Ketone or aldehyde containing
126 ..Sulfur not bonded directly to phosphorus
127 ...Thioether, sulfoxide or sulfone
128 ....Sulfur bonded directly to a benzene ring
129 ..Oxygen bonded directly to a carbon or hydrogen and wherein the oxygen is not bonded directly to phosphorus
130 ...The oxygen is bonded directly to a benzene ring
131 ..Nitro group bonded to a carbon
132 ...Nitro group is directly bonded to a benzene ring which benzene ring is either bonded directly bonded to phosphorus or indirectly bonded to phosphorus through a chalcogen
133 ....Two or more such benzene rings
134 ..Acyclic carbon to carbon unsaturation
135 ...Alkyne
136 ...Phosphate ester having three ester groups (e.g., DDVP, etc.)
137 ..Nitrogen bonded directly to phosphorus
138 ...N-P-N or N-N-P containing
139 ..Phosphorus bonded directly to halogen
140 ..(C)(R)P=X(-XC) containing (i.e., Phosphinate (X is chalcogen; R is C or H)
141 ..(CX-) (C)P=X(XH) or (CX-) (R)P=X(XC) containing (e.g., phosphonate, etc.) (X is chalcogen; R is C or H)
142 ..(CX-)(C)P(C),(CX-)(RX-)P(C),(CX-)P(XH)(XH) or (CX-)(CX-)P(-XR) containing (X is chalcogen; R is C or H) (e.g., phosphinite, phosphite, etc.)
143 ..Ester of (HX)P=X(XH)(XH) (X is chalcogen) (e.g., phosphate, etc.)
144 ...Triester
145 ....Three benzene rings bonded directly to chalcogen
146 ....Two benzene rings bonded directly to chalcogen
147 ....One benzene ring bonded directly to chalcogen
148 ...Diester
149 .Azoxy DOAI
150 .Acyclic nitrogen double bonded to acyclic nitrogen, acyclic nitrogen triple bonded to acyclic nitrogen or azide DOAI
151 ..Acyclic C-N=N-N containing
152 .3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI
153 ..With stabilizer or preservative
154 ..With an additional active ingredient (excludes reaction product or complex)
155 .Para-N-benzene - sulfoxy-N containing DOAI, and said benzene ring is not part of a polycyclo ring system
156 ..Hetero ring containing
157 ...The hetero ring is six-membered and includes at least two nitrogens and no other hetero atoms
158 ...The hetero ring is five-membered
159 .Ortho-hydroxybenzoic acid (i.e., salicyclic acid) or derivative DOAI
160 ..With additional ortho-hydroxybenzoic acid compound
161 ..With heterocyclic compound
162 ..With organic nitrogen containing compound
163 ..With carboxylic acid, ester or metal salt thereof

164 ..With organic oxygen containing compound
165 ..Aspirin per se (i.e., 2-(acetyloxy)benozic acid)
166 ..Nitrogen containing (e.g., anilides, etc.)
167 .9,10-seco-cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI
168 ..With a vitamin type active ingredient
169 .Cyclopentanohydrophenanthrene ring system DOAI
170 ..Plural Compounds containing cyclopentanohydrophenanthrene ring systems
171 ..With additional active ingredient
172 ..Hetero ring containing
173 ...Spiro ring system
174 ...-O-C-O- is part of a hetero ring (e.g., acetonide, etc.)
175 ...-C(=O)-O-is part of a hetero ring (e.g., lactone, etc.)
176 ...Nitrogen containing hetero ring
177 ..Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
178 ...Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
179 ....Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)
180 .....9-position substituted
181 ....21-position substituted
182 ..Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
183 .Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI
184 ..Heavy metal containing (including salts)
185 ...Polycyclo ring system
186 ....Bicyclo ring system
187 .....Quinolines or isoquinolines (including hydrogenated)
188 ...Hetero ring is six-membered consisting of one nitrogen and five carbons
189 ...Tin
190 ...Mercury
191 ..Aluminum (including salts)
192 ..1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.)
193 ...Spiro or additional polycyclo ring system
194 ...6,6-di-substituted
195 ...3-position substituent contains -COOC- group
196 ...6-position substituent contains hetero ring
197 ...6-position substituent contains carbocyclic ring
198 ....Ampicillin per se or salt thereof
199 ....Penicillin G per se or salt thereof (e.g., procaine pencillin G, etc.)
200 ..1-thia-5-aza-bicyclo (4.2.0) octane ring containing (including dehydrogenated) (e.g., cephalosporins, etc.)
201 ...7,7-di-substituted
202 ...Additional hetero ring
203 ....3-position substituent contains pyridine ring
204 ....3-position substituent contains sulfur
205 .....The additional hetero ring is part of a polycyclo ring system
206 .....7-position substituent contains hetero ring
207 ....Alkyl, hydroxyalkyl, alkoxyalkyl or alkanoyloxyakyl bonded directly to 3-position
208 ...Sulfur containing substituent
209 ...Alkyl, hydroxyalkyl, alkoxyalkyl, or alkanoyloxyakyl bonded directly to 3-position
210.01 ..Hetero ring is four-membered and includes at least one ring nitrogen

210.02 ...Chalcogen double bonded directly to a ring carbon of the four-membered hetero ring which is adjacent to the ring nitrogen
210.03 ....Polycyclo ring system having the four-membered hetero ring as one of the cyclos
210.04 .....Bicyclo ring system having the four-membered hetero ring as one of the cyclos
210.05 ......Plural ring hetero atoms in the bicyclo ring system
210.06 ....Ring oxygen in the bicyclo ring system
210.07 ....The other cyclo of the bicyclo ring system is six-membered
210.08 ....1-oxa-5-aza-bicyclo (4.2.0) octanes (including unsaturated)
210.09 ......The other cyclo of the bicyclo ring system is five-membered
210.1 ....Sulfur bonded directly to the five-membered cyclo of the bicyclo ring system (e.g., thienamycin, etc.)
210.11 ....Additional hetero ring attached directly to the sulfur
210.12 ....The additional hetero ring contains ring nitrogen
210.13 ....Having -C(=X)-, wherein X is chalcogen, bonded directly to the additional hetero ring
210.14 ....Polycyclo ring system bonded directly to the five-membered cyclo of the bicyclo ring system
210.15 ....Chalcogen bonded directly to the ring nitrogen of the four-membered ring
210.16 ...Polycyclo ring system having the four-membered hetero ring as one of the cyclos
210.17 ...Having -C(=X)-, wherein X is chalcogen, bonded directly to the four-membered hetero ring
210.18 ....Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding
210.19 ...Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding
210.2 ....The additional hetero ring contains ring nitrogen
210.21 .....Polycyclo ring system having the additional hetero ring as one of the cyclos
211.01 ..Hetero ring contains seven members including nitrogen, carbon and chalcogen
211.02 ...Monocyclic cyclopentyl ring bonded directly to the seven-membered hetero ring (e.g., prostaglandins, etc.)
211.03 ...Chalcogen double bonded directly to a ring carbon which is adjacent to the ring nitrogen
211.04 ....Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos
211.05 .....Bicyclo ring system having the seven-membered hetero ring as one of the cyclos
211.06 ......Ring chalcogen and ring nitrogen are in the 1,5-positions of the seven-membered hetero ring
211.07 ....Nitrogen attached directly or indirectly to the ring nitrogen of the seven-membered hetero ring by acyclic nonionic bonding (e.g., Diltiazem, etc.)
211.08 ...Plural ring nitrogens in the seven-membered hetero ring
211.09 ...Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos
211.1 ....Three ring hetero atoms in the polycyclo ring system
211.11 ....Tricyclo ring system having the seven-mmbered hetero ring as one of the cyclos
211.12 .....Ring nitrogen is shared by plural cyclos of the tricyclo ring system
211.13 .....Nitrogen bonded directly to ring carbon of the seven-membered hetero ring

211.14 .....Having -C(=X)-, wherein X is chalcogen, bonded directly to the seven-membered hetero ring
211.15 ...Additional nitrogen containing hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding
212.01 ..Hetero ring is seven-membered consisting of one nitrogen and six carbons
212.02 ...Spiro
212.03 ...Chalcogen double bonded directly to a ring carbon of the seven-membered hetero ring which is adjacent to the ring nitrogen
212.04 ....Polycyclo ring system having the seven-membered hetero ring as one of the cyclos
212.05 .....Plural cyclos of the polycyclo ring system share ring nitrogen of the seven-membered hetero ring
212.06 .....Plural ring hetero atoms in the polycyclo ring system
212.07 .....Bicyclo ring system having the seven-membered hetero ring as one of the cyclos
212.08 ....Additional hetero ring attached directly or indirectly by nonionic bonding to the seven-membered hetero ring
213.01 ...Polycyclo ring system having the seven-membered hetero ring as one of the cyclos
214.01 ....Ring nitrogen of the seven-membered hetero ring is shared by an additional cyclo of the polycyclo ring system
214.02 .....Plural ring nitrogens in the polycyclo ring system
214.03 .....Two of the cyclos share at least three ring members (i.e., bridged)
215 ....Additional hetero atom in the polycyclo ring system
216 ....Two of the cyclos share at least three ring carbons (i.e., bridged)
217 ....Tricyclo ring system having the seven-membered hetero ring a one of the cyclos
217.01 ....3-Benzazepines (including hydrogenated)
217.02 .....Benzene ring bonded directly to ring carbon of the seven-membered hetero ring
217.03 ...Additional hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding
217.04 ....The additional hetero ring is six-membered and contains nitrogen
217.05 .....Plural ring hetero atoms in the additional hetero ring
217.06 ......The additional hetero ring is a 1,3 diazine (including hydrogenated)
217.07 .....Polycyclo ring system having the additional six-membered hetero ring as one of the cyclos
217.08 ....The additional hetero ring is five-membered and contains nitrogen
217.09 .....Plural ring hetero atoms in the additional hetero ring
217.1 ......Chalcogen is one of the ring hetero atoms
217.11 ...Nitrogen or C(=X), wherein X is chalcogen, bonded directly to the seven-membered hetero ring
217.12 ...Nitrogen or C(=X), wherein X is chalcogen, attached indirectly to the seven-membered hetero ring by acyclic nonionic bonding
218 ..Hetero ring is seven-membered consisting of two nitrogens and five carbon atoms
219 ...Polycyclo ring system having the seven-membered hetero ring as one of the cyclos
220 ....Tricyclo ring system having the seven-membered hetero ring as one of the cyclos
221 ....Bicyclo ring system having the seven-membered hetero ring as one of the cyclos
222.2 ..Hetero ring is six-membered and includes at least nitrogen and sulfur as ring members
222.5 ...Three or more ring hetero atoms in the six-membered hetero ring

222.8 ....Polycyclo ring system having the six-membered hetero ring as one of the cyclos
223.2 .....1,2,4 - Benzothiadiazine - 1,1 - dioxides (including hydrogenated)
223.5 ......With additional active ingredient
223.8 ....1,3,5-Thiadiazines
224.2 ...Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.)
224.5 ....At least three cyclos in the polycyclo ring system
224.8 .....Phenothiazines (including hydrogenated)
225.2 ......Hetero ring attached directly or indirectly to the phenothiazine ring nitrogen by acyclic nonionic bonding
225.5 ....The hetero ring is monocyclic piperidine
225.8 ....The hetero ring contains plural ring nitrogens
226.2 ......Chalcogen or nitrogen attached indirectly to the phenothiazine ring nitrogen by acyclic nonionic bonding
226.5 ....One of the cyclos is a 1,2-thiazine (e.g.,1,2-benzothiazines, etc.)
226.8 ...1,3-Thiazines
227.2 ....Chalcogen or nitrogen bonded directly to ring carbon of the six-membered hetero ring
227.5 ...1,4-Thiazines
227.8 ....Additional hetero ring attached directly or indirectly to the 1,4-thiazine by nonionic bonding
228.2 .....Polycyclo ring system having the additional hetero ring as one of the cyclos
228.5 ......Three or more ring hetero atoms in the polycyclo ring system
228.8 ..Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.)
229.2 ...Three or more ring hetero atoms in the six-membered hetero ring
229.5 ...Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., maytansinoids, etc.)
229.8 ....Tricyclo ring system having the six-membered hetero ring as one of the cyclos
230.2 .....Ring nitrogen shared by two of the cyclos
230.5 ....Bicyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,4-benzoxazines, etc.)
230.8 ...Chalcogen bonded directly to ring carbon of 1,4-oxazine ring
231.2 ...Morpholines (i.e., fully hydrogenated 1,4- oxazines)
231.5 ....Additional hetero ring attached directly or indirectly to the morpholine ring by nonionic bonding
231.8 .....Plural morpholine rings attached directly or indirectly to each other by nonionic bonding
232.2 ......Additional hetero ring attached directly or indirectly to the morpholines by nonionic bonding
232.5 ....Polycyclo ring system having the additional hetero ring as one of the cyclos
232.8 .....Polycyclo ring system having the additional hetero ring as one of the cyclos
233.2 ......Ring nitrogen shared by two of the cyclos
233.5 ......Bicyclo ring system having the additional hetero ring as one of the cyclos
233.8 ....Plural ring hetero atoms in the bicyclo ring system
234.2 ....Three or more ring hetero atoms in the bicyclo ring system
234.5 ....Plural ring nitrogens in the bicyclo ring system
234.8 ....Quinoxalines (including hydrogenated)
235.2 ....Ring nitrogen in the bicyclo ring system
235.5 .....Ring nitrogen in the additional hetero ring

235.8 ......Plural ring nitrogens in the additional hetero ring (e.g., imidazole, pyrazine, etc.)
236.2 ....Three or more ring hetero atoms in the additional hetero ring
236.5 ....The ring nitrogens are bonded directly to each other (e.g., pyridazine, etc.)
236.8 ......Ring chalcogen in the additional hetero ring (e.g., oxazole, etc.)
237.2 ......The additional hetero ring is attached indirectly to the morpholine ring by an acyclic chain having a hetero atom as a chain member
237.5 ....Having -C(=X)-, wherein X is chalcogen, bonded directly to the morpholine ring
237.8 ....Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding
238.2 .....Chalcogen attached directly to the nitrogen by nonionic bonding
238.5 .....The nitrogen is double or triple bonded directly to carbon
238.8 ....Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding
239.2 .....The chalcogen is bonded directly to two carbon atoms
239.5 ....Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding
241 ..Hetero ring is six-membered consisting of three nitrogens and three carbon atoms
242 ...Asymmetrical (e.g., 1,2,4-triazine, etc.)
243 ....Polycyclo ring system having the hetero ring as one of the cyclos
244 ...Hexamethylenetetramines
245 ...Nitrogen bonded directly to ring carbon of the hetero ring
246 ...Polycyclo ring system having a 1,3,5-triazine as one of the cyclos
247 ..Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)
248 ...Polycyclo ring system having a 1,2- or 1,4-diazine as one of the cyclos
249 ....1,4-diazine as one of the cyclos
250 .....At least three rings in the polycyclo ring system
251 ......Isoalloxazine (e.g., riboflavins, Vitamin B2, etc.)
252.01 ...1,2 diazine attached directly or indirectly to an additional hetero ring by nonionic bonding
252.02 ....The additional hetero ring is a diazine
252.03 ....The additional hetero ring is six-membered consisting of one nitrogen and five carbon atoms
252.04 .....Polycyclo ring system having the additional six-membered hetero ring as one of the cyclos
252.05 ....The additional hetero ring is a five-membered nitrogen hetero ring
252.06 .....Polycyclo ring system having the additional five-membered hetero ring as one of the cyclos
252.1 ...1,4 diazines
252.11 ....Plural 1,4-diazine rings attached directly or indirectly to each other by nonionic bonding
252.12 ....Piperazines (i.e., fully hydrogenated 1,4-diazines)
252.13 .....Additional hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding
252.14 ......The additional hetero ring is a 1,3 diazine ring
252.15 ....Spiro ring system containing
252.16 ....Polycyclo ring system having the additional 1,3-diazine ring as one of the cyclos
252.17 ....The polycyclo ring system is quinazoline (including hydrogenated)

252.18 .....Additional six-membered hetero ring consisting of five ring carbons and one ring nitrogen attached directly or indirectly to the 1,3-diazine by nonionic bonding
252.19 .....Five-membered nitrogen hetero ring attached directly or indirectly to the 1,3-diazine ring by nonionic bonding
252.2 .....Oxygen hetero ring attached directly or indirectly to the 1,3-diazine ring by nonionic bonding
253.01 .....The additional hetero ring is six-membered consisting of one nitrogen and five carbon atoms
253.02 .....Polycyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos
253.03 .....Tricyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos
253.04 .....Bicyclo ring having the additional six-membered nitrogen hetero ring as one of the cyclos
253.05 .....Isoquinolines (including hydrogenated)
253.06 .....Quinolines (including hydrogenated)
253.07 .....Chalcogen bonded directly to carbon of the hetero ring of the quinoline ring system
253.08 .....Having -C(=X)-, wherein X is chalcogen, bonded directly to carbon of the hetero ring of the quinoline ring system
253.09 .....Five-membered nitrogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding
253.1 .....The five-membered nitrogen hetero ring has chalcogen as a ring member
253.11 .....Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding
253.12 .....Chalcogen bonded directly to ring carbon of the additional six-membered nitrogen containing hetero ring
253.13 .....Having -C(=X)-, wherein X is chalcogen, bonded directly to the additional six-membered nitrogen hetero ring
254.01 .....The additional hetero ring is five-membered having ring nitrogen
254.02 .....The additional five-membered hetero ring also has chalcogen as a ring member
254.03 .....The additional five-membered hetero ring consists of two ring carbons, two ring nitrogens, and one ring chalcogen (e.g., oxadiazolyl, thiadiazolyl, etc.)
254.04 .....The additional five-membered hetero ring consists of three ring carbons, and of nitrogen and chalcogen in adjacent ring positions (e.g., isoxazolyl, isothiazolyl, etc.)
254.05 .....Plural nitrogens in the additional five-membered hetero ring
254.06 .....Polycyclo ring system having the plural nitrogen containing additional five-membered hetero ring as one of the cyclos
254.07 .....Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding
254.08 .....Polycyclo ring system having the additional five-membered nitrogen hetero ring as one of the cyclos
254.09 .....Indole ring system (including hydrogenated) attached directly or indirectly to the piperazine ring by nonionic bonding
254.1 .....Ring oxygen in the additional hetero ring
254.11 .....Polycyclo ring system having the additional oxygen hetero ring as one of the cyclos

255.01 .....Nitrogen or -C(=X)-, wherein X is chalcogen, bonded directly to the piperazine ring
255.02 .....Chalcogen bonded directly to a piperazine ring carbon
255.03 .....Carbocyclic ring bonded directly to the piperazine ring
255.04 .....Plural carbocyclic rings bonded directly to the same acyclic carbon atom which is attached directly or indirectly to the piperazine ring by nonionic bonding
255.05 ....Additional hetero ring attached directly or indirectly to the 1,4-diazine ring by nonionic bonding
255.06 ....Nitrogen or -C(=X)-, wherein X is chalcogen, bonded directly to ring carbon of the 1,4-diazine ring
256 ...1,3-diazines (e.g., pyrimidines, etc.)
257 ....Polycyclo ring system having 1,3-diazine as one of the cyclos
258.1 .....Bicyclo ring system having the 1,3-diazine as one of the cyclos
259.1 ......A ring nitrogen is shared by the two cyclos of the bicyclo ring system (e.g., pyrrolo [1,2-a]pyrimidine, imidazo[1,2-a]pyrimidine, etc.)
259.2 ....Ring chalcogen in the bicyclo ring system
259.3 ....The shared ring nitrogen is bonded directly to a ring nitrogen of the second ring of the bicyclo ring system (e.g., pyrazolo[1,5-a]pyrimidine, etc.)
259.31 ....The second ring of the bicyclo ring system is a five-membered hetero ring including three ring nitrogens (e.g., triazolo[1,5-a]pyrimidine, etc.)
259.4 ....The second ring of the bicyclo ring system is six-membered, consisting of five ring carbons and the shared ring nitrogen (e.g., pyrido[1,2-a]pyrimidine, etc.)
259.41 ....Additional hetero ring is attached directly or indirectly to the bicyclo ring system by nonionic bonding
259.5 ....Chalcogen bonded directly to a ring carbon of the 1,3-diazine ring
260.1 ......Ring chalcogen in the bicyclo ring system
261.1 ......Exactly five ring nitrogens in the bicyclo ring system (e.g., triazolo[4,5-d]pyrimidine, etc.)
262.1 ......Exactly four ring nitrogens in the bicyclo ring system
263.1 ....Purine (including hydrogenated)
263.2 ....Additional hetero ring attached directly or indirectly to the purine ring system by nonionic bonding
263.21 ....The additional hetero ring is a 1,3-diazine ring (including hydrogenated)
263.22 ....The additional hetero ring is six-membered consisting of one nitrogen and five carbons
263.23 ....The additional hetero ring consists of carbon and chalcogen as the only ring members
263.24 ....The additional chalcogen containing hetero ring is part of a polycyclo ring system
263.3 ....Chalcogen bonded directly to a ring carbon of the purine ring system
263.31 ....With perservative, stabilizer, or an additional active ingredient
263.32 ....Nitrogen containing hetero ring in the perservative, stabilizer, or additional active ingredient
263.33 ....Chalcogen bonded directly to the 2-,6-, and 8-positions of the purine ring system

263.34 .....Chalcogen bonded directly to the 2-and 6-positions of the purine ring system (e.g., theophylline, etc.)
263.35 .....Nitrogen attached indirectly to the purine ring system by acyclic nonionic bonding
263.36 .....Chalcogen attached indirectly to the purine ring system by acyclic nonionic bonding
263.37 .....Nitrogen bonded directly to a ring carbon of the purine ring system (e.g., guanine, etc.)
263.38 .....Chalcogen attached indirectly to the 9- position of the purine ring system by acyclic nonionic bonding
263.4 .....Nitrogen bonded directly to ring carbon of the purine ring system (e.g., adenine, etc.)
264.1 .....The other cyclo in the bicyclo ring system is a pyridine ring (including hydrogenated) (e.g., pyrido[2,3-d]pyrimidine, etc.)
264.11 .....Nitrogen bonded directly to ring carbon of the 1,3-diazine ring of the bicyclo ring system
265.1 .....The other cyclo in the bicyclo ring system is a pyrrole ring (including hydrogenated) (e.g., pyrrolo[3,2-d]pyrimidine, etc.)
266.1 .....Quinazoline (including hydrogenated)(i.e., the second cyclo in the bicyclo ring system is an ortho-fused six-membered carbocycle)
266.2 .....Additional hetero ring attached directly or indirectly to the quinazoline ring system by nonionic bonding
266.21 .....The additional hetero ring is six-membered consisting of one nitrogen and five carbons
266.22 .....Piperidinyl or tetrahydropyridyl
266.23 .....The additional hetero ring is five-membered consisting of carbon and plural nitrogens as the only ring members
266.24 .....The additional hetero ring consists of carbon and chalcogen as the only ring members
266.3 .....Chalcogen bonded directly to a ring carbon of the 1,3-diazine ring of the quinazoline ring system
266.31 .....Carbocyclic ring bonded directly to a ring carbon of the quinazoline ring system
266.4 .....Nitrogen bonded directly to ring carbon of the 1,3-diazine ring of the quinazoline ring system
267 .....Tricyclo ring system having 1,3-diazine as one of the cyclos
268 .....Perimidine (including hydrogenated)
269 ....Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety
270 .....Barbituric acid or derivative (including thioanalogs)
271 .....Two or more barbituric acid compounds or with an additional active ingredient or stabilizer
272 .....Nitrogen bonded directly to the 1,3-diazine at 2-position
273 .....The nitrogen is part of a hetero ring
274 .....Chalcogen bonded directly to pyrimidine at 2-position
275 ....Nitrogen bonded directly to the 1,3-diazine at 2-position by a single bond
276 ....Thiamines (e.g., vitamin B1, etc.)
277 ..Hetero ring is six-membered consisting of one nitrogen and five carbon atoms
278 ...Spiro ring system
279 ...Polycyclo ring system having the six-membered hetero ring as one of the cyclos

280 ....Pentacyclo ring system having the six-membered hetero ring as one of the cyclos
281 .....Two of the cyclos share at least three ring members (i.e., bridged)
282 ......One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)
283 .....Ring nitrogen in the pentacyclo ring system is shared by five-membered cyclo and six-membered cyclo (e.g., vincamine, etc.)
284 ....Tetracyclo ring system having the six-membered hetero ring as one of the cyclos
285 .....Plural hetero atoms in the tetracyclo ring system (e.g., acronycines, etc.)
286 ......Two of the cyclos share at least three ring members (i.e., bridged)
287 ......Three or more hetero atoms in the tetracyclo ring system
288 ......Ring carbon is shared by three of the cyclos
289 .....Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)
290 ....Tricyclo ring system having the six-membered hetero ring as one of the cyclos
291 .....Plural hetero atoms in the tricyclo ring system
292 ......Plural ring nitrogens in the tricyclo ring system
293 ....Three or more hetero atoms in the tricyclo ring system
294 .....Ring nitrogen is shared by two of the cyclos
295 .....Two of the cyclos share at least three ring carbons (i.e., bridged) (e.g., benzomorphans, etc.)
296 .....Ring carbons shared by each of the three cyclos (e.g., 1,8-naphthalimides, etc.)
297 .....Acridines (including hydrogenated)
298 .....Phenanthridines (including hydrogenated)
299 ....Bicyclo ring system having the six-membered hetero ring as one of the cyclos
300 .....Plural hetero atoms in the bicyclo ring system
301 ......Ring sulfur in the bicyclo ring system
302 ......Ring oxygen in the bicyclo ring system
303 ......Exactly three ring nitrogens in the bicyclo ring system
304 .....Tropanes (including nor or dehydro form)
305 .....Quinuclidines (including unsaturation)
306 .....Quinolizines (including hydrogenated)
307 .....Isoquinolines (including hydrogenated)
308 ......Plural isoquinoline ring systems attached directly or indirectly to each other by nonionic bonding
309 ......Chalcogen attached directly to the six-membered hetero ring by nonionic bonding
310 ......Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding
311 .....Quinolines (including hydrogenated)
312 ......Chalcogen attached directly to the six-membered hetero ring by nonionic bonding
313 ......Nitrogen, other than as nitro or nitroso, attached directly to the six membered hetero ring by nonionic bonding
314 ......Additional hetero ring attached directly or indirectly to the quinoline ring system by nonionic bonding
315 ...Piperidines
316 ....Plural piperidine rings
317 ....Additional ring containing
318 .....The additional ring is a six-membered hetero ring consisting of one nitrogen and five carbon atoms

319 .....The additional ring is one of the cyclos in a polycyclo ring system
320 ......Hetero ring in the polycyclo ring system
321 ....Plural hetero atoms in the polycyclo ring system
322 ....Plural ring nitrogens in the polycyclo ring system
323 ....Ring nitrogen in the polycyclo ring system
324 ....Ring sulfur in the polycyclo ring system
325 ......Polycyclo ring system is tricyclo-carbocyclic
326 .....The additional ring is a hetero ring
327 .....Chalcogen bonded directly to ring carbon of the piperidine ring
328 ......Plural chalcogens bonded directly to ring carbons of the piperidine ring
329 .....Nitrogen attached directly to the piperidine ring by nonionic bonding
330 .....C=X bonded directly to the piperidine ring (X is chalcogen)
331 .....Nitrogen attached indirectly to the piperidine ring by nonionic bonding
332 ...Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms
333 ....Additional hetero ring other than the six-membered hetero rings
334 ....The six-membered hetero rings are bonded directly to each other
335 ....Chalcogen bonded directly to a ring carbon of the six-membered hetero ring
336 ...Additional hetero ring containing
337 ....The additional hetero ring is one of the cyclos in a polycyclo ring system
338 .....Plural hetero atoms in the polycyclo ring system
339 .....Ring nitrogen in the polycyclo ring system
340 ....Ring nitrogen in the additional hetero ring (e.g., oxazole, etc.)
341 .....The additional hetero ring consists of two nitrogens and three carbons
342 .....Ring sulfur in the additional hetero ring
343 .....The additional hetero ring consists of one nitrogen and four carbons (e.g., nicotine, etc.)
344 ...Cyano bonded directly to the six-membered hetero ring
345 ...Chalcogen bonded directly to ring carbon of the six-membered hetero ring
346 ....Chalcogen and acyclic nitrogen bonded directly to the same carbon
347 ....Chalcogen bonded directly to chalcogen
348 ....Chalcogens bonded directly to at least two ring carbons of the six-membered hetero ring
349 ....Nitrogen attached directly to the six-membered hetero ring by nonionic bonding
350 ....C=O bonded directly to the six-membered hetero ring
351 ....Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding
352 ...Nitrogen attached directly to the six-membered hetero ring by nonionic bonding
353 ....Plural acyclic nitrogens bonded directly to the same carbon or bonded directly to each other
354 ...C=O bonded directly to the six-membered hetero ring
355 ....At 3-position
356 .....C=O in a C(=O)O group (e.g., nicotinic acid, etc.)
357 ...Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding
358 ...The ring nitrogen of the six-membered hetero ring is pentavalent (e.g., quaternary pyridinium salt, etc.)

359 ..Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)
360 ...Plural ring chalcogens in the hetero ring
361 ...Plural ring nitrogens and a single chalcogen in the hetero ring
362 ....1,2,5-thiadiazoles (including hydrogenated)
363 ....1,3,4-thiadiazoles (including hydrogenated)
364 ....Oxadiazoles (including hydrogenated)
365 ...1,3-thiazoles (including hydrogenated)
366 ....Polycyclo ring system having the thiazole ring as one of the cyclos
367 .....Bicyclo ring system having the thiazole ring as one of the cyclos
368 ......Ring nitrogen is shared by the cyclos of the bicyclo ring system (e.g., tetramisole, etc.)
369 ....Chalcogen bonded directly to ring carbon of the thiazole ring
370 ....Nitrogen bonded directly to ring carbon of the thiazole ring
371 .....C=X bonded directly to the nitrogen which is bonded directly to the thiazole ring (X is chalcogen)
372 ...1,2-thiazoles (including hydrogenated)
373 ....Polycyclo ring system having the thiazole ring as one of the cyclos
374 ...1,3-oxazoles (including hydrogenated)
375 ....Polycyclo ring system having the oxazole ring as one of the cyclos
376 ....Chalcogen bonded directly to ring carbon of the oxazole ring
377 ....Nitrogen bonded directly to ring carbon of the oxazole ring
378 ...1,2-oxazoles (including hydrogenated)
379 ....Polycyclo ring system having the oxazole ring as one of the cyclos
380 ....Chalcogen or nitrogen bonded directly to ring carbon of the oxazole ring
381 ...Tetrazoles (including hydrogenated)
382 ....Additional chalcogen containing hetero ring
383 ...1,2,4-triazoles (including hydrogenated)
384 ....Chalcogen bonded directly to the triazole ring
385 ...1,3-diazoles
386 ....Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent
387 .....Polycyclo ring system having the diazole ring as one of the cyclos
388 ......Nitrogen double bonded directly at 2-position of the diazole ring, or tautomeric equivalent
389 .....Divalent chalcogen or acyclic nitrogen double bonded directly at both 2- and 4-positions, or tautomeric equivalent (e.g., hydantoin, etc.)
390 ......Chalcogen or nitrogen bonded directly at 1-, 3-, or 5-position by nonionic bonding
391 ......Benzene ring bonded directly to the diazole ring by nonionic bonding
392 .....Divalent chalcogen or acyclic nitrogen double bonded at 2-position, or tautomeric equivalent
393 ....Polycyclo ring system having the diazole ring as one of the cyclos
394 .....Benzo fused at 4,5-positions of the diazole ring
395 ......Chalcogen or nitrogen bonded directly at 1-, 2- or 3-position of the diazole ring by nonionic bonding
396 ....Imidazoles
397 .....Additional hetero ring

398 .....Chalcogen or nitrogen bonded directly to the imidazole ring by nonionic bonding
399 .....Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding
400 ......At imidazole ring carbon
401 ....2-imidazolines
402 .....Additional hetero ring
403 ...1,2-diazoles
404 ....Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent
405 .....Polycyclo ring system having the diazole ring as one of the cyclos
406 ....Pyrazoles
407 .....Chalcogen or nitrogen bonded directly to the pyrazole ring by nonionic bonding
408 ...The five-membered hetero ring consists of one nitrogen and four carbons
409 ....Spiro ring system
410 ....Polycyclo ring system having the five-membered hetero ring as one of the cyclos
411 .....Tricyclo ring system having the five-membered hetero ring as one of the cyclos
412 .....Bicyclo ring system having the five-membered hetero ring as one of the cyclos
413 ......Ring nitrogen is shared by the cyclos of the bicyclo ring system
414 ......Additional hetero ring which is not part of the bicyclo ring system
415 ......The bicyclo ring system consists of the five-membered hetero ring and a benzene ring (e.g., indole, etc.)
416 ....The ring nitrogen is bonded directly to nonshared ring carbons of the five-membered hetero ring (e.g., isoindole, etc.)
417 ....Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.)
418 ....Chalcogen bonded directly to ring carbon of the five-membered hetero ring
419 ....C=X bonded directly or indirectly by an acyclic carbon or carbon chain to ring carbon of the five-membered hetero ring (e.g., tryptophan, etc.) (X is chalcogen)
420 ....Indomethacine per se or ester thereof
421 ......Chalcogen bonded directly to ring carbon of the five-membered hetero ring (e.g., adrenochrome, etc.)
422 ....Additional hetero ring
423 ....C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen)
424 ....Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding
425 .....Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding
426 ....Nitrogen bonded directly to the five-membered hetero ring by nonionic bonding
427 ....Two double bonds between ring members of the five-membered hetero ring (e.g., pyrrole, etc.)
428 ....Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding
429 ....Carbocyclic ring bonded directly to the five-membered hetero ring
430 ..Sulfur containing hetero ring
431 ...The hetero ring has at least seven members
432 ...The hetero ring is six-membered
433 ....Plural hetero atoms in the hetero ring
434 .....Polycyclo ring system having the hetero ring as one of the cyclos
435 .....Three or more hetero atoms in the hetero ring
436 .....Two ring sulfurs in the hetero ring

437 ....Tricyclo ring system having the hetero ring as one of the cyclos
438 ...The hetero ring is five-membered
439 ....Plural hetero atoms in the hetero ring
440 .....Only two ring sulfurs in the hetero ring
441 ......Chalcogen bonded directly to ring carbon of the hetero ring
442 ......Nitrogen bonded directly to the hetero ring by nonionic bonding
443 ....Polycyclo ring system having the hetero ring as one of the cyclos
444 ....Additional hetero ring
445 ....Chalcogen bonded directly to ring carbon of the hetero ring
446 ....Chalcogen bonded directly to ring sulfur by nonionic bonding
447 ....Nitrogen bonded directly to the hetero ring
448 ....C=O bonded directly to the hetero ring (X is chalcogen)
449 ..Oxygen containing hetero ring
450 ...The hetero ring has at least seven members
451 ...The hetero ring is six-membered
452 ....Plural ring oxygens in the hetero ring
453 ....Polycyclo ring system having the hetero ring as one of the cyclos
454 .....Tricyclo ring system having the hetero ring as one of the cyclos
455 ......Chalcogen bonded directly to ring carbon of the hetero ring
456 .....Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)
457 ......Coumarins (including hydrogenated)
458 ......Tocopherols (e.g., vitamin E, etc.)
459 ....Nitrogen containing
460 ....Chalcogen bonded directly to ring carbon of the hetero ring
461 ...The hetero ring is five-membered
462 ....Spiro ring system
463 ....Plural ring oxygens in the hetero ring
464 .....Bicyclo ring system having the hetero ring as one of the cyclos (e.g., methylenedioxyphenyl group, etc.)
465 ......The hetero ring is substituted
466 ......Nitrogen containing
467 .....Only two ring oxygens in the hetero ring which is not a polycyclo ring system (e.g., dioxolane, etc.)
468 ....Polycyclo ring system having the hetero ring as one of the cyclos
469 .....Bicyclo ring system having the hetero ring as one of the cyclos
470 ......Chalcogen or nitrogen bonded directly to the hetero ring
471 ....Nitrogen containing
472 .....The nitrogen bonded directly to the hetero ring
473 ....Chalcogen bonded directly to the hetero ring
474 .....Ascorbic acid or derivative (e.g., vitamin C, etc.)
475 ...The hetero ring is three-membered
476 .N-C(=X)X containing (X is chalcogen) DOAI
477 ..N-C(=X)-X-N containing
478 ..N-C(=X)-X-C containing
479 ...With an additional active ingredient
480 ...Polycyclo ring system attached by nonionic bonding
481 ....Naphthyl ring system
482 ...N-C(=X)-N, N-C(=N)N, N-N, nitrogen directly bonded to oxygen by nonionic bonding or cyano containing
483 ...Plural N-C(=X)-X groups
484 ...Ring in acid moiety
485 ....The ring is a benzene ring
486 .....Phenoxy in acid moiety
487 .....The benzene ring is attached to nitrogen through an acyclic carbon or carbon chain

488 .....Ring in alcohol moiety
489 ...Ring in alcohol moiety
490 ....Ring attached directly to oxygen of N-C(=0)-0
491 ..With an additional active ingredient
492 .Heavy metal containing DOAI
493 ..Tin
494 ..Zinc
495 ..Gold or silver
496 ..Mercury
497 ...Nitrogen containing
498 ..Lead
499 ..Copper
500 ...With an additional active ingredient
501 ..Nickel or cobalt
502 ..Iron
503 ..Antimony or bismuth
504 ..Arsenic
505 ..Cadmium or chromium
506 .Ester DOAI
507 ..R-C(=X)-N-X-C containing (e.g., hydroxamic acid ester, etc.) (R is C or H and X is chalcogen)
508 ..X-C=N containing (e.g., imidoester, etc.) (X is chalcogen)
509 ..(O=)N(=O)-O-C containing (e.g., nitrate ester, etc.)
510 ..Polycyclo ring system
511 ...Two of the cyclos share at least three ring members (i.e., bridged)
512 ..X-C(=X)-X containing (e.g., carbonic acid ester, thiocarbonic acid ester, etc.) (X is chalcogen)
513 ..C-C(=X)-X-C containing (X is chalcogen and at least one X is other than oxygen)
514 ..Carbon bonded to -NCX or -XCN (e.g., cyanate, thiocyanate or isothiocyanate, etc.) (X is chalcogen)
515 ...With an additional active ingredient
516 ...Containing plural -NCX or -XCN groups or a cyano
517 ..S-X-C containing (e.g., sulfates, etc.) (X is chalcogen)
518 ...S of S-X-C attached directly to a benzene ring
519 ..Cyano or isocyano bonded directly to carbon
520 ...Benzene ring containing
521 ....C=O other than as ketone or aldehyde
522 .....The cyano is bonded directly to a benzene ring
523 ....Additional nitrogen other than cyano
524 .....The cyano is bonded directly to a benzene ring
525 ....Two or more of the cyano groups
526 ...Acyclic
527 ....C=O other than as ketone or aldehyde
528 .....C(=O)N containing
529 ..Z-C(=O)-O-Y wherein Z is hydrogen or an organic radical bonded to the C(=O) by a carbon and Y is an organic radical bonded to the oxygen by a carbon
530 ...Z contains a cyclopentyl or cyclopentene ring
531 ...Z contains a cyclopropyl or cyclopropene ring
532 ...Z-C(=O)-O-Y, wherein Z contains a benzene ring
533 ....Compound contains two or more C(=O)O groups indirectly bonded together by only conalent bonds
534 ....Z or Y radical contains a nitrogen atom
535 .....The nitrogen of the Z radical is directly bonded to a benzene ring which is directly bonded to the C(=O) group
536 ......With an agent to enhance topical absorption or with a stabilizing agent
537 ......With an additional active ingredient
538 .....Nitrogen bonded to carbon in Z moiety
539 ......Plural separated benzene rings in Z moiety
540 ......Nitrogen in Y moiety
541 ......Aldehyde or ketone in Z or Y radical

542 .....Z radical contains two or more nitrogen atoms at least one of which forms a C(=X)N group (X is chalcogen)
543 ....Z forms a phenoxy alkyl or phenoxy alkenyl radical
544 ....C(=O)O attached directly through the carbon to a benzene ring
545 ....Ketone in Z radical
546 ...ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon
547 ....Compound contains two or more C(=O)O groups
548 .....Ring is alcohol moiety
549 ....Z radical contains carbon to carbon unsaturation
550 ....Z radical contains sulfur or halogen
551 ....Z radical contains nitrogen
552 ....Z contains an unbroken chain of at least seven carbon atoms bonded directly to the C(=O) group
553 .Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI
554 ..Amine addition salt of the acid
555 ...Benzene ring in acid moiety
556 ..Inner quaternary ammonium salt (e.g., betaine, etc.)
557 ..Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)
558 ...Higher fatty acid or salt thereof
559 ....Ring containing
560 ....Carbon to carbon unsaturation
561 ...Nitrogen other than as nitro or nitroso nonionically bonded
562 ....Sulfur nonionically bonded
563 ....RC(=O)N containing (i.e., carboxamide) (R is C or H)
564 ....Plural nitrogens nonionically bonded
565 .....N-N or N=C(-N)-N containing (e.g., hydrazines, hydrazones, or guanidines, etc.)
566 .....Polycarboxylic acid
567 ....Benzene ring nonionically bonded
568 ...Benzene ring nonionically bonded
569 ....Polycyclo ring system
570 ....Carboxy or salt thereof only attached indirectly to the benzene ring
571 .....Ether oxygen single bonded to carboxylic acid, percarboxylic acid or salt thereof through an acyclic carbon or acyclic carbon chain
572 ...Cyclic carboxylic acid containing three to five carbons or cyclic percarboxylic acid containing three to five carbons or salt thereof
573 ....Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.)
574 ...Polycarboxylic acid or salt thereof
575 ..Hydroxamic acid or salt thereof
576 ..Benzene ring containing
577 ...Polycyclo ring system
578 ..Acyclic acid or salt thereof
579 .Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI
580 ..Thioureas (i.e., N-C(=S)-N
581 ...Thiocarbazides or thiosemicarbazides (i.e., N-N-C(=S)-N containing)
582 ....Thiocarbazones or thiosemicarbazones (i.e., C=N-N-C(=S)-N containing)
583 .....Benzene ring containing
584 ...C=O, sulfur or cyano attached directly to thiourea nitrogen by nonionic bonding
585 ...Benzene ring containing
586 ....Nitrogen attached indirectly to the -C(=S)-group by nonionic bonding
587 ....Oxygen containing
588 ..Ureas (i.e., N-C(=O)-N)
589 ...Nitro or nitroso bonded directly to amino nitrogen (e.g., nitramine, nitrosamine, nitro-urea, etc.)
590 ...Carbazides or semicarbazides (i.e., N-N-C(=O)-N containing)
591 ...Biurets (i.e., N-C(=O)-N-C(=O)-N)

592 ...Sulfur attached directly to urea nitrogen by nonionic bonding
593 ....Sulfur is part of a substituent which contains additional nitrogen
594 ...Additional C=O bonded directly to urea nitrogen
595 ...Benzene ring containing
596 ....Benzene ring bonded directly to urea nitrogen
597 .....Benzene ring is part of a substituent which contains nitrogen
598 .....Benzene ring is part of a substituent which contains oxygen
599 ..Thiocarboxamides, (i.e., C(=S)-N)
600 ..Sulfamides (i.e., N-(O=)S(=O)-N)
601 ..Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E)
602 ...Q contains benzene ring
603 ....Nitrogen in Q
604 ....Q is monocyclic
605 ...Q is acyclic and benzene ring in a substituent E
606 ..N-S-S containing
607 ..N-S-N containing or contains a nitrogen bonded directly to a S=O group (e.g., sulfinamides, etc.)
608 ..Sulfur attached directly to amino nitrogen by nonionic bonding (e.g., sulfenamides, etc.)
609 ..Cyanamides (i.e., compounds containing cyano bonded directly to amino nitrogen)
610 ..Nitramines (i.e., compounds containing nitro bonded directly to amino nitrogen)
611 ..Nitrosamines (i.e., compounds containing nitroso bonded directly to amino nitrogen)
612 ..Haloamines (i.e., compounds containing halogen attached directly to amino nitrogen by nonionic bonding)
613 ..Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E)
614 ...N-N containing (e.g., aminimine, hydrazine, etc.)
615 ....R contains benzene ring
616 ...Plural carboxamide groups or plural C=O groups bonded directly to the same nitrogen
617 ...R contains benzene ring
618 ....Sulfur in R
619 ....Nitrogen in R
620 .....The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding
621 ....C=O in R
622 ....C-O- group in R
623 ...Plural alicyclic rings in R
624 ...Three-membered ring in R
625 ...R is acyclic
626 ....Nitrogen in R
627 ....Carbon to carbon unsaturation in R
628 ....Halogen bonded directly to carbon in R
629 ....R is hydrogen or a lower saturated alkyl of less than seven carbons
630 .....A ring or polycyclo ring system in a substituent E is attached indirectly to the carboxamide nitrogen or to an amino nitrogen in substituent E by acyclic nonionic bonding
631 ..Amidines (i.e., N=C-N)
632 ...Amidino hydrazines or hydrazones (i.e., N-N=C-N or N=C-N-N)
633 ...Amidoximes (i.e., N-C=N-O)
634 ...Guanidines (i.e., N=C(-N)-N)
635 ....Biguanides (i.e., N=C(-N)-N(N-)C=N)
636 ...Polyamidines
637 ...Benzene ring containing
638 ..Nitrogen double bonded directly to carbon
639 ...Hydrazones (i.e., C=N-N)
640 ...Oximes (i.e., C=N-O-)

641 ...Aldimines or ketimines which contain a benzene ring (i.e., RC=N wherein R is C or H)
642 ..Quaternary ammonium containing
643 ...Benzene ring containing
644 ..Amine oxides
645 ..Nitroxides, oxyamines or hydroxylamines (i.e., N-O or N-OH)
646 ..Benzene ring containing
647 ...Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings
648 ...Two aryl rings or aryl ring systems bonded directly to the same acyclic carbon
649 ...Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain
650 ....The aryl ring or aryl ring system is bonded directly to another ring or ring system
651 ....Ether oxygen is part of the chain
652 .....Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines)
653 ....Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.)
654 ....The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only
655 ....The aryl ring or aryl ring system and amino nitrogen are bonded directly to the same acylic carbon, which carbon additionally has only hydrogen or acyclic hydrocarbyl substituents bonded directly thereto
656 ...Polycyclo ring system
657 ....Bicyclo ring system
658 ...Two benzene rings bonded directly to the same nitrogen
659 ..Alicyclic ring or ring system and amino nitrogen are attached indirectly by an acyclic carbon or acyclic chain
660 ..Plural alicyclic rings
661 ...Polycyclo ring system
662 ....Tricyclo ring system
663 ..Acyclic
664 ...N-N containing (e.g., aminimine, hydrazine, etc.)
665 ...Sulfur containing
666 ...Aldehyde or ketone containing
667 ...C-O-group containing
668 ....Polyether
669 ....Polyhydroxy
670 ....Monoether
671 ...Carbon to carbon unsaturation
672 ...Halogen bonded directly to carbon
673 ...Plural amino nitrogens
674 ....Three or more amino nitrogens
675 .Ketone DOAI
676 ..Nitrogen containing
677 ...Bicyclo ring system having a benzene ring as one of the cyclos
678 ..Benzene ring containing
679 ...Plural rings
680 ....Polycyclo ring system
681 .....Bicyclo
682 ......Naphthyl ring system
683 ....Alicyclic ring
684 .....Five-membered alicyclic ring
685 ....C=O bonded directly to benzene ring
686 .....Two benzene rings bonded directly to the same C=O
687 ......Oxygen single bonded to carbon
688 ...C=O bonded directly to benzene ring (e.g., acetophenone, etc.)
689 ....Oxygen single bonded to carbon
690 ..Alicyclic ring containing
691 ...Plural alicyclic rings
692 ....Camphor or nuclear substituted derivatives thereof
693 .Aldehyde DOAI
694 ..Formaldehyde
695 ...With polycyclo compound
696 ...With alcohol

697 ...With nitrogen containing compound
698 ..With preservative or stabilizer
699 ..Benzene ring containing
700 ...Polycyclo ring system
701 ...Acyclic carbon to carbon unsaturation
702 ..Sulfur containing
703 ..Carbon to carbon unsaturation
704 ..Nitrogen containing
705 ..Plural C=O groups
706 .Sulfur, selenium or tellurium compound (e.g., thioalcohols, mercaptans, etc.)
707 ..Persulfide (e.g., R-S-S-R, etc.)
708 ..Oxygen bonded directly to sulfur (e.g., sulfoxides, etc.)
709 ...Plural oxygens bonded directly to the same sulfur (e.g., sulfones, etc.)
710 ....Acyclic carbon to carbon unsaturation
711 ....Acyclic
712 ..Thioether
713 ...Acyclic carbon to carbon unsaturation
714 .Peroxide DOAI
715 .Ether DOAI
716 ..Nitrogen containing
717 ..Benzene ring containing
718 ...Plural oxygens
719 ....Alicyclic ring
720 ....Acyclic carbon to carbon unsaturation
721 ....Plural benzene rings
722 ..Acyclic
723 ...Plural oxygens
724 .C-O-group (e.g., alcohol, alcoholate, etc.) DOAI
725 ..Vitamin A compound or derivative
726 ..Diphenyl-substituted acyclic alcohol or alcoholate
727 ..Nitrogen containing
728 ...C of C-O- group is nuclear C of a benzene ring (e.g., phenol, phenolate, etc.)
729 ..Alicyclic ring containing
730 ..Benzene ring containing
731 ...C of C-O- group is nuclear C of a benzene ring (e.g., phenol, phenolate, etc.)
732 ....Polycyclo ring system (e.g., naphthols, etc.)
733 ....Acyclic carbon to carbon unsaturation
734 ....Two or more separate aryl-O- groups
735 .....Nuclear halogenated
736 ....Additional benzene ring containing
737 ....Nuclear halogenated
738 ..Polyhydroxy
739 ..Carbon to carbon unsaturated
740 .Nitrogen containing compound DOAI
741 ..Benzene ring containing
742 ..Polynitro
743 .Halogenated hydrocarbon DOAI
744 ..Unsaturated aliphatic compound
745 ...Alkyne
746 ...Plural halogenated hydrocarbon compounds
747 ..Carbocyclic
748 ...Two benzene rings directly attached to an acyclic hydrocarbon or acyclic halogenated hydrocarbon (e.g., D.D.T., etc.)
749 ....Fluorine containing
750 ....With organic ether or -OH containing compound non-DOAI
751 ...Benzene ring containing
752 ....Alkyne
753 ....Polycyclo ring system
754 ....Plural benzene rings
755 ...Polycyclo ring system
756 ....Bicyclo
757 ..Two or more halogenated hydrocarbons
758 ..Chlorine as only halogen
759 ..Fluorine as only halogen
760 ..Bromine and chlorine as only halogens
761 ..Bromine and fluorine as only halogens
762 .Hydrocarbon DOAI
763 ..Carbocyclic
764 ...Benzene ring containing
765 ....Polycyclo ring system
766 ...Polycyclo ring system
767 ..With phosphorus containing non-DOAI
768 ..With sulfur containing non-DOAI
769 **DESIGNATED INORGANIC NONACTIVE INGREDIENT OR ELEMENTAL MATERIAL OTHER THAN WATER**

770 .Siliceous or calcareous material (e.g., clay, earth, etc.)
771 .Oxygen gas containing
772 **DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING OTHER THAN HYDROCARBON**
772.1 .Aftertreated solid synthetic organic polymer (e.g., grafting, blocking, etc.)
772.2 ..Polyvinyl alcohol
772.3 .Solid synthetic organic polymer
772.4 ..Polymer from ethylenic monomers only
772.5 ...Heterocyclic monomer
772.6 ...Carboxylic acid containing monomer
772.7 ..Heterocyclic monomer
773 .Peptide containing
774 ..Gelatin or derivative
775 ..Casein (milk protein) or derivative
776 ..Albumin or derivative
777 .Carbohydrate or lignin, or derivative
778 ..Starch or derivative
779 ..Algin or derivative
780 ..Locust bean gum
781 ..Cellulose or derivative
782 .Natural gum or resin
783 .Plant extract or plant material of undetermined constitution
784 .Carboxylic acid or salt thereof
785 .Carboxylic acid ester
786 ..Glyceride
787 ..Beeswax
788 .Nitrogen containing
788.1 **SOLID SYNTHETIC ORGANIC POLYMER DERIVED SOLELY FROM HYDROCARBON REACTANTS AS DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING**
789 **MISCELLANEOUS (e.g., HYDROCARBONS, etc.)**

CROSS-REFERENCE ART COLLECTIONS

800 **LHRH LIKE**
801 **COLLAGEN, GELATIN OR DERIVATIVES THEREOF**
802 **FIBRINOPEPTIDES, BLOOD-COAGULATION FACTORS OR DERIVATIVES**
803 **KININ OR DERIVATIVES**
804 **PHECMYCIN SERIES OR DERIVATIVES**
805 **ADRENOCORTICOTROPIC HORMONE OR DERIVATIVES**
806 **SOMATOSTATIN OR DERIVATIVES**
807 **OXYTOXIN, VASOPRESSIN OR DERIVATIVES**
808 **CALCITONIN OR DERIVATIVES**
809 **ENKEPHALIN OR ENDORPHIN OR DERIVATIVES**
810 **ADDICTION**
811 .Alcohol
812 .Narcotic
813 .Tobacco
814 **ANEMIA**
815 .Sickle cell
816 **ANESTHETIC, GENERAL**
817 **ANESTHETIC, TOPICAL**
818 **ANESTHETIC, LOCAL**
819 **ANTACID, ORAL**
820 .With antiflatulent
821 **ANTIARRHYTHMIC**
822 **ANTICOAGULATION**
823 **ANTIDOTE**
824 **ARTERIOSCLEROSIS**
825 **ARTHRITIS**
826 **ASTHMA**
827 **ASTRINGENT, NONFACIAL**
828 .Topical for the skin
829 **BITE OR STING**
830 .Insect
831 .Animal (nonpoisonous)
832 **BLOOD SUBSTITUTE**
833 **BLOOD PLASMA EXTENDER**
834 **COAGULANT**
835 **CARIES**
836 **CHELATE**
837 **CHOLERA**
838 **CIRRHOSIS**
839 **CONTACT LENS TREATMENT**
840 .Chemical sterilizing
841 **CONTRACEPTIVE**
842 .Non-mammal
843 .Female (mammal)
844 **COSMETIC, FACIAL**
845 .Liquid make-up
846 .Cleansing cream or lotion
847 .Facial moisturizer
848 .Facial astringent
849 **COUGH AND COLD PREPARATION**
850 .Antitussive
851 **CYSTIC FIBROSIS**
852 **DANDRUFF**
853 **DECONGESTANT**

854 .Vasoconstrictor
855 .Expectorant
DERMATITIS
858 .Athlete's foot
859 .Acne
860 .Cellulitis
861 .Eczema
862 .Poison (ivy, oak, sumac)
863 .Psoriasis
864 .Seborrhea
865 .Diaper rash
866 **DIABETES**
867 **DIARRHEA**
868 **DISTEMPER**
869 **DIURETIC**
870 **EDEMA**
871 .Topical
872 **EMESIS (motion sickness-nausea)**
873 **EMOLLIENT**
874 **ESTROGENIC AGENT (noncontraceptive)**
875 **FLEA CONTROL**
876 .Collar type
877 **GALLSTONE**
878 **GERIATRICS**
879 .Senility
880 **HAIR TREATMENT (therapeutic-scalp)**
881 .Shampoo
882 **HEMORRHOID PREPARATION**
883 **HODGKIN'S DISEASE**
884 **HYPOGLYCEMIA**
885 **IMMUNE RESPONSE AFFECTING DRUG**
886 **INFLAMMATION, SKIN**
887 .Topical Treatment
888 **INFLUENZA**
889 **INTERFERON INDUCER**
890 **IRRITANT (e.g., tear gas, etc.)**
891 **KIDNEY STONE**
892 **LAXATIVE**
893 **LIVER DISORDER**
894 .Hepatitis
895 **MALARIA**
896 **MEASLES**
897 .Rubella
898 **MENINGITIS**
899 **MENSTRUAL DISORDER**
MOUTH TREATMENT
900 .Periodontitis
901 .Mouthwash
902 .Gingival
903 **MULTIPLE SCLEROSIS**
904 **MULTIPLE VITAMINS**
905 .With mineral
906 **MUSCLE RELAXANT**
907 **MUSCULAR DYSTROPHY**
908 **LEUKEMIA**
909 **OBESITY**
910 .Anorectic
911 .Bulking agent
912 **OPHTHALMIC**
913 .Glaucoma
914 .Inflammation
915 .Wetting agent
916 **PYRETIC**
917 **RADIOACTIVE, ANTI-**
918 **REPELLENT**
919 .Insect
920 .Mammal
921 **SHOCK**
922 **SIDE EFFECT REDUCTION BY INCORPORATION OF A SECOND DESIGNATED INGREDIENT**
923 **SLEEP AID (Insomnia)**
924 **TUBERCULOSIS**
925 **ULCER TREATMENT**
926 .Duodenal
927 .Peptic
928 .Topical
929 **VASODILATOR**
930 **VASOCONSTRICTOR (nondecongestant)**
931 **VENERAL DISEASE**
932 .Gonorrhea
933 .Syphilis
934 .Virus
935 **UTERINE MOTILITY**
LIQUID CARRIER, DILUENT OR SOLVENT
936 **DMSO CONTAINING**
937 **DISPERSION OR EMULSION**
938 .Oil-water type
939 ..Mineral oil-water type
940 ...Quick break type
941 ...Polyoxyalkylated compound containing
942 ...Organic sulfonate, sulfate or sulfite containing
943 ...Higher fatty acid or derivative containing
944 **GEL**
945 **FOAM**
946 **PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED)**
947 .Topical application
SOLID CARRIER OR SOLID DILUENT
948 **SOLID CANDY TYPE**

949 **NATURALLY DERIVED CLAY (E.G., BENTONITE, ETC.)**
950 **MACROMOLECULAR (OTHER THAN SYNTHETIC RESINS)**
951 **POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE**
952 .Wettable
953 **SHAPED FORMS ADAPTED FOR NONINGESTIBLE USE OTHER THAN SUPPOSITORY TYPE (E.G., FILMS, INSERTS, ETC.)**
954 .Ocular
955 ..Biodegradable type
956 .Aural or otic (i.e., ear)
GASEOUS OR GAS EMITTING CARRIER OR PROPELLANT
957 **VAPOR EMMITTING COMPOSITION**
958 **FOR SMOKING OR INHALING**
959 **BREATHING GASES**
PILL, LOZENGE, TABLET OR CAPSULE
960 **SIGNIFICANT, TABLET FORMULATION (E.G., DESIGNATED EXCIPIENT, DISINTEGRANT, GLYDENT OR LUBRICANT, ETC.)**
961 .Binder therefor
962 **CAPSULE (E.G., GELATIN, ETC.)**
963 .Microcapsule-sustained or differential release
964 **SUSTAINED OR DIFFERENTIAL RELEASE TYPE**
965 .Discrete particles in supporting matrix
SUPPOSITORY, BOUGIE OR BASE
966 **RECTAL**
967 **VAGINAL**
968 **URETHRAL**
969 **OINTMENT OR SALVE BASE**
SPECIAL DESIGNATED INGREDIENT
970 **CONTAINING DESIGNATED INGREDIENT TO STABILIZE AN ACTIVE INGREDIENT**
971 .Crystallization point depressant or cold stabilizer containing
972 .Ultraviolet light stabilizer containing
973 .Sulfur compound additive as stabilizer (e.g., sulfites, etc.)
974 **CONTAINING DESIGNATED INGREDIENT TO REDUCE NOXIOUS EFFECTS OF ACTIVE INGREDIENT (E.G., TASTE MASKING, ODOR REDUCING, ETC.)**
975 **CHARACTERIZED BY THE DESIGNATED SURFACTANT USED**

FOREIGN ART COLLECTIONS

FOR 000 **CLASS-RELATED FOREIGN DOCUMENTS**

Any foreign patents or non-patent literature from subclasses that have been reclassified have been transferred directly to FOR Collections listed below. These Collections contain ONLY foreign patents or non-patent literature. The parenthetical references in the Collection titles refer to the abolished subclasses from which these Collections were derived.

DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) (514/1)
.Heterocyclic carbon cpmpounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI (514/183)
..Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.) (514/247)
FOR 100 ...1,2- or 1,4-diazine compound having two or more hetero rings (514/252)
FOR 101 ....Hetero ring other than 1,2- or 1,4-diazine is part of a polycyclo ring system (514/253)
FOR 102 .....Diazine is bonded directly to the polycyclo ring system (514/254)
FOR 103 ...1,4-diazines (514/255)
FOR 104 **Hetero ring is four-membered and includes at least one nitrogen atom (514/210)**
FOR 105 **Hetero ring is seven-membered and includes at least one nitrogen atom and at least one hetero atom other than nitrogen (514/211)**
FOR 106 **Hetero ring is seven-membered consisting of one nitrogen and six carbon atoms (514/212)**
FOR 107 .Polycyclo ring system having the seven-membered hetero ring as one of the cyclos (514/213)

FOR 108 ..Ring nitrogen is shared by two or three of the cyclos (514/214)
FOR 109 .Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI (514/2)
FOR 110 ..Insulin or derivative (514/3)
FOR 111 ...With an additional active ingredient (514/4)
FOR 112 ..Iodine containing (514/5)
FOR 113 ..Heavy metal containing (e.g., hemoglobin, etc.) (514/6)
FOR 114 ..Phosphorus containing (514/7)
FOR 115 ..Glycoprotein (carbohydrate containing) (514/8)
FOR 116 ..Cyclopeptides (514/9)
FOR 117 ...Bicyclic (514/10)
FOR 118 ...Monocyclic (514/11)
FOR 119 ..25 or more peptide repeating units in known peptide chain structure (514/12)
FOR 120 ..16 to 24 peptide repeating units in known peptide chain (514/13)
FOR 121 ..12 to 15 peptide repeating units in known peptide chain (514/14)
FOR 122 ..9 to 11 peptide repeating units in known peptide chain (514/15)
FOR 123 ..7 or 8 peptide repeating units in known peptide chain (514/16)
FOR 124 ..5 or 6 peptide repeating units in known peptide chain (514/17)
FOR 125 ..3 or 4 peptide repeating units in known peptide chain (514/18)
FOR 126 ..2 peptide repeating units in known peptide chain (514/19)
FOR 127 ...Guanidine containing (514/20)
FOR 128 ..Produced by or extracted from animal tissue (514/21)

DIGESTS

DIG 1 .RU 486 (i.e., RU 38486, RU 486-6, Mifepristone, Mifestone, Mifegyne, (11B-[4-(N, N-dimethylamino) phenyl]-17a-(prop-1-ynyl)-^ 4,9-estradiene-17B-ol-3-one, (11B,17B)11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-dien-3-one)

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
128/844	1	514/2	2369
324/307	1	514/9	340
424/1.11	1	514/16	263
	2	514/12	2747
424/1.37	1	514/11	602
424/1.49	1	514/12	2747
	1	514/14	230
	1	514/2	2369
	2	514/13	322
424/1.57	1	514/6	223
424/1.65	1	514/12	2747
	1	514/17	311
	1	514/21	546
424/1.69	1	514/11	602
	1	514/16	263
	1	514/17	311
	1	514/18	732
	1	514/21	546
	2	514/14	230
	5	514/13	322
	5	514/9	340
	10	514/2	2369
	20	514/12	2747
424/10.1	1	514/11	602
	1	514/2	2369
	5	514/12	2747
424/10.2	2	514/12	2747
	5	514/11	602
424/10.3	1	514/2	2369
424/115	3	514/9	340
424/123	1	514/2	2369
424/130.1	1	514/13	322
	1	514/15	444
	1	514/18	732
	1	514/7	64
	2	514/8	597
	4	514/2	2369
	4	514/21	546
	5	514/12	2747
424/131.1	1	514/2	2369
	1	514/21	546
424/133.1	1	514/21	546
	1	514/8	597

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/133.1	2	514/12	2747
	2	514/2	2369
	2	514/3	267
424/134.1	1	514/11	602
	1	514/21	546
	1	514/6	22
	1	514/7	64
	1	514/9	340
	11	514/2	2369
	24	514/12	2747
424/139.1	1	514/17	311
	1	514/18	732
	1	514/2	2369
	1	514/21	546
	4	514/12	2747
424/141.1	1	514/15	444
	1	514/8	597
	1	514/9	340
	2	514/12	2747
	2	514/2	2369
	2	514/21	546
424/143.1	2	514/2	2369
424/144.1	1	514/2	2369
424/145.1	1	514/6	223
	1	514/9	340
	2	514/2	2369
	6	514/12	2747
424/153.1	1	514/12	2747
424/155.1	1	514/2	2369
	1	514/21	546
424/158.1	1	514/18	732
	1	514/2	2369
	1	514/21	546
424/164.1	1	514/12	2747
424/165.1	1	514/16	263
424/178.1	1	514/1.1	1
	1	514/21	546
	3	514/12	2747
	7	514/2	2369
424/184.1	1	514/13	322
	1	514/17	311
	1	514/21	546
	1	514/6	223

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/184.1	2	514/2	2369
	6	514/12	2747
424/185.1	1	514/15	444
	2	514/11	602
	2	514/8	597
	3	514/21	546
	6	514/13	322
	21	514/2	2369
	23	514/12	2747
424/186.1	1	514/8	597
424/189.1	1	514/12	2747
424/192.1	1	514/12	2747
424/193.1	1	514/12	2747
	1	514/2	2369
424/195.11	1	514/12	2747
	1	514/14	230
	1	514/2	2369
424/195.15	1	514/9	340
424/195.16	1	514/6	223
424/195.17	1	514/9	340
424/197.11	1	514/12	2747
	1	514/2	2369
424/198.1	1	514/12	2747
	2	514/2	2369
424/217.1	1	514/2	2369
424/234.1	1	514/2	2369
424/237.1	1	514/13	322
	1	514/2	2369
424/256.1	1	514/2	2369
424/278.1	1	514/17	311
	2	514/11	602
	2	514/13	322
	2	514/19	605
	3	514/12	2747
	3	514/9	340
	5	514/14	230
	6	514/18	732
	8	514/2	2369
	9	514/8	597
424/279.1	1	514/12	2747
	1	514/18	732
	1	514/19	605
	1	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/279.1	6	514/8	597
424/282.1	1	514/2	2369
424/400	1	514/21	546
	1	514/6	223
	2	514/12	2747
424/405	1	514/12	2747
424/408	1	514/18	732
	1	514/8	597
424/422	1	514/2	2369
	1	514/4	99
	2	514/11	602
	8	514/21	546
	14	514/12	2747
424/423	1	514/8	597
	2	514/2	2369
	6	514/12	2747
	6	514/21	546
424/425	1	514/2	2369
424/426	2	514/2	2369
424/427	4	514/12	2747
424/428	3	514/2	2369
424/429	1	514/12	2747
424/43	2	514/11	602
	5	514/12	2747
424/430	1	514/19	605
	2	514/12	2747
424/431	1	514/12	2747
	1	514/21	546
	1	514/8	597
424/433	1	514/12	2747
	1	514/15	444
	1	514/2	2369
	1	514/8	597
	2	514/11	602
	2	514/21	546
	2	514/3	267
424/439	1	514/2	2369
	1	514/3	267
	2	514/6	223
	4	514/12	2747
424/440	1	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/442	1	514/18	732
	1	514/9	340
	2	514/21	546
424/443	2	514/2	2369
	5	514/12	2747
	8	514/21	546
424/445	1	514/13	322
	1	514/6	223
	1	514/8	597
	2	514/2	2369
	4	514/21	546
424/447	1	514/21	546
424/449	1	514/11	602
	1	514/12	2747
	1	514/15	444
424/45	1	514/2	2369
424/450	1	514/7	64
	1	514/8	597
	2	514/15	444
	2	514/6	223
	4	514/2	2369
	5	514/11	602
	8	514/21	546
	16	514/12	2747
424/451	1	514/12	2747
	1	514/15	444
	1	514/19	605
	2	514/2	2369
	2	514/21	546
	11	514/11	602
424/456	1	514/15	444
	1	514/21	546
	1	514/3	267
	2	514/12	2747
	10	514/11	602
424/457	1	514/11	602
	1	514/12	2747
	1	514/17	311
	1	514/2	2369
424/461	1	514/8	597
	1	514/9	340
424/463	1	514/11	602
	1	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/464	1	514/11	602
	1	514/18	732
	1	514/21	546
	1	514/8	597
	3	514/12	2747
424/465	1	514/18	732
424/468	1	514/12	2747
424/47	4	514/11	602
424/474	1	514/11	602
	1	514/2	2369
424/479	1	514/19	605
424/48	1	514/18	732
	1	514/19	605
	2	514/8	597
424/484	1	514/10	70
	1	514/13	322
	1	514/16	263
	2	514/2	2369
	4	514/21	546
	9	514/12	2747
424/485	1	514/12	2747
	1	514/21	546
	1	514/6	223
424/486	1	514/19	605
	1	514/2	2369
	5	514/12	2747
424/487	1	514/4	99
	2	514/3	267
424/488	1	514/12	2747
	1	514/2	2369
	3	514/21	546
424/489	1	514/13	322
	2	514/3	267
	2	514/4	99
	2	514/6	223
	3	514/11	602
	3	514/2	2369
	5	514/21	546
	15	514/12	2747
424/49	1	514/2	2369
	3	514/12	2747
424/491	2	514/12	2747
	6	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/493	1	514/2	2369
424/497	1	514/11	602
	1	514/12	2747
	1	514/15	444
424/499	1	514/18	732
	1	514/21	546
	1	514/6	223
	1	514/8	597
	1	514/9	340
	6	514/12	2747
424/50	1	514/13	322
424/501	1	514/11	602
424/520	1	514/5	14
424/529	1	514/3	267
	2	514/2	2369
424/530	1	514/21	546
424/532	1	514/8	597
424/533	1	514/12	2747
424/535	4	514/21	546
424/562	1	514/21	546
424/581	1	514/21	546
424/604	1	514/2	2369
424/606	1	514/12	2747
424/656	1	514/2	2369
424/718	1	514/11	602
	1	514/21	546
	5	514/2	2369
	8	514/12	2747
	9	514/6	223
424/725	1	514/2	2369
	1	514/8	597
424/729	1	514/21	546
424/754	1	514/12	2747
424/757	2	514/21	546
424/78.37	1	514/2	2369
424/780	1	514/3	267
	1	514/6	223
	1	514/8	597
	2	514/10	70
	2	514/14	230
	6	514/21	546
	6	514/9	340
	16	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/780	17	514/2	2369
424/85.1	1	514/13	322
	1	514/15	444
	1	514/3	267
	1	514/6	223
	2	514/21	546
	7	514/8	597
	14	514/2	2369
	16	514/12	2747
424/85.2	1	514/10	70
	1	514/14	230
	1	514/15	444
	1	514/17	311
	1	514/19	605
	1	514/4	99
	1	514/9	340
	2	514/16	263
	4	514/8	597
	5	514/18	732
	5	514/21	546
	5	514/3	267
	5	514/6	223
	22	514/12	2747
	38	514/2	2369
424/85.4	1	514/10	70
	1	514/19	605
	1	514/21	546
	1	514/3	267
	1	514/6	223
	1	514/8	597
	2	514/11	602
	3	514/15	444
	3	514/18	732
	4	514/9	340
	9	514/12	2747
	16	514/2	2369
424/9.1	1	514/11	602
	1	514/12	2747
	1	514/2	2369
	1	514/21	546
	2	514/15	444
424/9.3	1	514/12	2747
	1	514/17	311

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/9.34	1	514/2	2369
424/9.52	1	514/12	2747
424/9.6	1	514/2	2369
424/93.2	1	514/12	2747
424/93.45	1	514/12	2747
	1	514/8	597
424/93.51	2	514/2	2369
424/93.6	1	514/12	2747
	1	514/8	597
	2	514/2	2369
424/93.7	1	514/12	2747
	1	514/21	546
424/93.71	1	514/12	2747
424/94.1	1	514/6	223
	1	514/7	64
	4	514/2	2369
	5	514/12	2747
424/94.2	1	514/12	2747
	3	514/2	2369
424/94.3	1	514/12	2747
	1	514/6	223
424/94.4	1	514/10	70
	1	514/11	602
	1	514/3	267
	1	514/8	597
	4	514/2	2369
	5	514/12	2747
	7	514/6	223
	8	514/21	546
424/94.5	2	514/2	2369
	4	514/12	2747
424/94.6	2	514/12	2747
	2	514/2	2369
424/94.61	1	514/3	267
	1	514/6	223
	4	514/2	2369
	7	514/12	2747
424/94.62	1	514/2	2369
	1	514/21	546
	1	514/8	597
424/94.63	2	514/2	2369
	6	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
424/94.64	1	514/6	223
	1	514/7	64
	1	514/8	597
	2	514/11	602
	2	514/13	322
	2	514/15	444
	4	514/2	2369
	6	514/21	546
	13	514/12	2747
424/94.65	2	514/12	2747
424/94.66	1	514/12	2747
424/94.67	2	514/2	2369
426/130	1	514/21	546
426/133	1	514/12	2747
426/15	1	514/21	546
426/326	2	514/6	223
433/167	1	514/12	2747
433/201.1	1	514/12	2747
435/13	1	514/18	732
435/14	1	514/2	2369
435/188	1	514/2	2369
435/219	1	514/2	2369
435/325	1	514/21	546
435/4	1	514/12	2747
435/5	1	514/9	340
435/6	1	514/12	2747
	1	514/13	322
	2	514/2	2369
435/68.1	1	514/8	597
	2	514/2	2369
435/69.1	3	514/12	2747
	4	514/2	2369
435/7.1	1	514/14	230
	1	514/6	223
	1	514/7	64
	1	514/8	597
	1	514/9	340
	3	514/2	2369
	5	514/12	2747
435/7.21	1	514/19	605
435/7.24	1	514/2	2369
435/7.5	1	514/8	597
435/7.92	1	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
435/71.3	1	514/10	70
	1	514/2	2369
436/11	1	514/6	223
436/173	1	514/2	2369
436/501	2	514/13	322
	4	514/12	2747
436/63	1	514/12	2747
436/86	1	514/18	732
514/1.1	1	514/13	322
	1	514/3	267
	1	514/4	99
	1	514/5	14
	2	514/10	70
	2	514/20	40
	3	514/4	99
	4	514/10	70
	4	514/7	64
	7	514/11	602
	7	514/9	340
	9	514/14	230
	9	514/21	546
	9	514/21	546
	10	514/16	263
	11	514/6	223
	12	514/15	444
	13	514/17	311
	14	514/8	597
	18	514/16	263
	18	514/18	732
	21	514/19	605
	25	514/17	311
	28	514/14	230
	29	514/19	605
	29	514/8	597
	30	514/15	444
	30	514/3	267
	37	514/11	602
	37	514/13	322
	37	514/9	340
	44	514/18	732
	45	514/12	2747
	102	514/2	2369
	285	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/1.1	362	514/2	2369
514/1.2	1	514/11	602
	1	514/18	732
	1	514/18	732
	1	514/20	40
	1	514/4	99
	2	514/11	602
	2	514/12	2747
	2	514/16	263
	2	514/16	263
	2	514/21	546
	2	514/9	340
	3	514/17	311
	3	514/2	2369
	3	514/6	223
	4	514/14	230
	4	514/19	605
	4	514/3	267
	4	514/8	597
	5	514/13	322
	6	514/15	444
	28	514/12	2747
	36	514/2	2369
514/1.3	1	514/15	444
	1	514/4	99
	1	514/6	223
	1	514/6	223
	2	514/13	322
	2	514/16	263
	2	514/2	2369
	2	514/9	340
	3	514/11	602
	4	514/17	311
	6	514/8	597
	7	514/12	2747
	12	514/19	605
	18	514/2	2369
	25	514/18	732
514/1.4	1	514/10	70
	1	514/12	2747
	1	514/21	546
	1	514/9	340
	2	514/17	311

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/1.4	3	514/2	2369
	3	514/21	546
	3	514/8	597
	4	514/18	732
	4	514/6	223
	6	514/13	322
	6	514/2	2369
	7	514/19	605
	11	514/12	2747
514/1.5	1	514/10	70
	1	514/2	2369
	1	514/7	64
	1	514/8	597
	2	514/13	322
	2	514/2	2369
	5	514/18	732
	8	514/12	2747
	8	514/19	605
514/1.6	1	514/11	602
	1	514/18	732
	1	514/19	605
	2	514/9	340
	3	514/8	597
514/1.7	1	514/14	230
	1	514/16	263
	1	514/3	267
	2	514/13	322
	2	514/9	340
	3	514/17	311
	3	514/18	732
	3	514/2	2369
	4	514/8	597
	9	514/12	2747
	17	514/19	605
514/1.8	1	514/12	2747
	1	514/19	605
	1	514/9	340
	3	514/18	732
	4	514/2	2369
514/1.9	1	514/10	70
	1	514/12	2747
	1	514/14	230
	1	514/15	444

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/1.9	1	514/16	263
	1	514/8	597
	2	514/15	444
	3	514/11	602
	4	514/21	546
	5	514/17	311
	5	514/9	340
	7	514/18	732
	8	514/13	322
	8	514/19	605
	17	514/2	2369
	23	514/12	2747
514/10.1	1	514/17	311
	1	514/21	546
	1	514/3	267
	2	514/16	263
	3	514/11	602
	3	514/13	322
	3	514/14	230
	3	514/9	340
	4	514/8	597
	6	514/12	2747
	8	514/2	2369
	18	514/15	444
514/10.2	1	514/18	732
	1	514/3	267
	2	514/2	2369
	3	514/15	444
	4	514/21	546
	7	514/12	2747
514/10.3	1	514/14	230
	1	514/17	311
	1	514/6	223
	1	514/8	597
	2	514/16	263
	4	514/12	2747
	9	514/2	2369
	111	514/15	444
514/10.5	1	514/3	267
514/10.6	1	514/15	444
	1	514/19	605
	1	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/10.7	1	514/12	2747
	1	514/12	2747
	1	514/13	322
	1	514/15	444
	1	514/16	263
	1	514/17	311
	1	514/6	223
	1	514/9	340
	4	514/14	230
	4	514/18	732
	5	514/2	2369
514/10.8	1	514/10	70
	1	514/14	230
	1	514/16	263
	2	514/18	732
	2	514/21	546
	3	514/2	2369
	4	514/6	223
	5	514/13	322
	38	514/12	2747
514/10.9	1	514/10	70
	1	514/12	2747
	1	514/3	267
	2	514/2	2369
	3	514/16	263
	4	514/15	444
	4	514/9	340
	25	514/11	602
514/11.1	1	514/10	70
	1	514/10	70
	1	514/20	40
	2	514/14	230
	5	514/16	263
	8	514/12	2747
	9	514/9	340
	30	514/11	602
514/11.2	1	514/10	70
	1	514/16	263
	1	514/19	605
	2	514/17	311
	37	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/11.3	1	514/13	322
	1	514/15	444
	1	514/9	340
	2	514/8	597
	3	514/14	230
	4	514/11	602
	4	514/18	732
	5	514/16	263
	7	514/19	605
	8	514/21	546
	12	514/17	311
	17	514/2	2369
	57	514/12	2747
514/11.4	1	514/13	322
	1	514/17	311
	1	514/2	2369
	1	514/8	597
	2	514/12	2747
514/11.5	1	514/14	230
	1	514/17	311
	1	514/18	732
	1	514/21	546
	2	514/2	2369
	5	514/12	2747
514/11.6	1	514/15	444
	1	514/17	311
	1	514/2	2369
	2	514/12	2747
	2	514/9	340
	7	514/11	602
514/11.7	1	514/3	267
	1	514/5	14
	4	514/2	2369
	21	514/12	2747
514/11.8	1	514/16	263
	1	514/9	340
	3	514/11	602
	7	514/2	2369
	32	514/12	2747
514/11.9	1	514/12	2747
	1	514/13	322
	1	514/8	597
	2	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/11.9	2	514/9	340
	4	514/21	546
	7	514/11	602
	8	514/2	2369
	19	514/12	2747
514/12.1	1	514/13	322
	1	514/6	223
	2	514/21	546
	3	514/12	2747
	4	514/2	2369
514/12.2	1	514/21	546
	2	514/14	230
	2	514/17	311
	4	514/12	2747
	9	514/16	263
	9	514/8	597
	10	514/19	605
	11	514/15	444
	14	514/18	732
	24	514/2	2369
514/12.3	1	514/2	2369
	2	514/11	602
	2	514/14	230
	2	514/19	605
	6	514/18	732
514/12.4	1	514/12	2747
	1	514/9	340
	3	514/13	322
514/12.5	1	514/3	267
514/12.6	1	514/15	444
	1	514/18	732
	1	514/2	2369
	1	514/21	546
514/12.8	1	514/2	2369
	3	514/12	2747
514/12.9	1	514/12	2747
	1	514/14	230
	1	514/17	311
	1	514/21	546
514/129	2	514/7	64
514/13.1	1	514/12	2747
	1	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/13.2	1	514/12	2747
	1	514/13	322
	2	514/11	602
	2	514/17	311
	2	514/9	340
	3	514/16	263
	3	514/19	605
	3	514/8	597
	5	514/18	732
	6	514/12	2747
	6	514/2	2369
514/13.3	1	514/12	2747
	1	514/13	322
	1	514/14	230
	1	514/20	40
	1	514/4	99
	1	514/6	223
	2	514/17	311
	2	514/18	732
	4	514/11	602
	4	514/2	2369
	4	514/8	597
	5	514/16	263
	6	514/15	444
	6	514/19	605
	6	514/21	546
	6	514/9	340
	30	514/12	2747
	31	514/2	2369
514/13.4	1	514/11	602
	1	514/17	311
	2	514/12	2747
	5	514/21	546
	7	514/2	2369
	65	514/6	223
514/13.5	1	514/12	2747
	1	514/14	230
	1	514/14	230
	1	514/17	311
	1	514/17	311
	1	514/21	546
	2	514/18	732
	2	514/18	732

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/13.5	2	514/19	605
	2	514/2	2369
	3	514/11	602
	3	514/16	263
	3	514/19	605
	3	514/6	223
	4	514/21	546
	5	514/8	597
	19	514/12	2747
	19	514/2	2369
514/13.6	1	514/17	311
	1	514/6	223
	3	514/11	602
	3	514/13	322
	3	514/19	605
	4	514/18	732
	4	514/8	597
	9	514/12	2747
	11	514/2	2369
	15	514/21	546
514/13.7	1	514/12	2747
	1	514/5	14
	2	514/2	2369
	3	514/9	340
	4	514/14	230
	4	514/20	40
	7	514/15	444
	8	514/17	311
	17	514/8	597
	19	514/21	546
	22	514/19	605
	27	514/18	732
	41	514/2	2369
	54	514/12	2747
514/13.8	1	514/13	322
	1	514/18	732
	1	514/19	605
	1	514/8	597
	2	514/2	2369
	2	514/21	546
	4	514/9	340
514/13.9	1	514/13	322
	1	514/19	605

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/13.9	1	514/8	597
	1	514/9	340
514/14.1	1	514/8	597
	1	514/9	340
	3	514/2	2369
514/14.2	1	514/21	546
	3	514/12	2747
514/14.3	1	514/13	322
	1	514/2	2369
	2	514/19	605
	3	514/21	546
	4	514/8	597
	10	514/2	2369
	12	514/12	2747
514/14.4	1	514/18	732
	1	514/19	605
	1	514/8	597
514/14.6	1	514/11	602
	1	514/17	311
	1	514/7	64
	2	514/12	2747
	2	514/18	732
	2	514/9	340
	5	514/2	2369
514/14.7	1	514/2	2369
	1	514/8	597
	1	514/8	597
	2	514/13	322
	3	514/20	40
	4	514/19	605
	5	514/18	732
514/14.8	1	514/14	230
	1	514/15	444
	1	514/21	546
	1	514/4	99
	1	514/6	223
	1	514/8	597
	10	514/12	2747
514/14.9	1	514/14	230
	2	514/15	444
	2	514/17	311
	2	514/21	546
	3	514/16	263

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/14.9	3	514/9	340
	4	514/20	40
	8	514/8	597
	11	514/11	602
	13	514/19	605
	19	514/2	2369
	25	514/18	732
	40	514/12	2747
514/15.1	1	514/11	602
	1	514/8	597
	3	514/6	223
	4	514/12	2747
	4	514/19	605
	5	514/13	322
	6	514/18	732
	6	514/2	2369
514/15.2	1	514/4	99
	1	514/6	223
	1	514/9	340
	2	514/2	2369
	2	514/8	597
	3	514/21	546
	5	514/12	2747
	5	514/21	546
	9	514/2	2369
514/15.3	1	514/11	602
	1	514/18	732
	3	514/12	2747
	4	514/2	2369
	5	514/6	223
	6	514/21	546
514/15.4	1	514/6	223
	2	514/15	444
	2	514/21	546
	2	514/8	597
	3	514/16	263
	4	514/13	322
	5	514/12	2747
	7	514/19	605
	8	514/18	732
	9	514/11	602
	16	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/15.5	1	514/12	2747
	1	514/18	732
	1	514/19	605
	2	514/13	322
514/15.6	1	514/10	70
	1	514/12	2747
	1	514/16	263
	1	514/19	605
	2	514/11	602
	2	514/13	322
	2	514/15	444
	3	514/2	2369
	6	514/16	263
	6	514/18	732
514/15.7	1	514/11	602
	1	514/20	40
	1	514/6	223
	1	514/9	340
	2	514/10	70
	2	514/21	546
	2	514/8	597
	3	514/13	322
	3	514/14	230
	4	514/7	64
	5	514/11	602
	6	514/17	311
	7	514/12	2747
	7	514/15	444
	8	514/16	263
	13	514/2	2369
	29	514/18	732
	37	514/19	605
514/15.8	5	514/15	444
	7	514/11	602
	8	514/16	263
	9	514/17	311
	22	514/19	605
	39	514/18	732
514/15.9	7	514/19	605
514/150	1	514/15	444
	1	514/6	223
	2	514/4	99

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/16.1	1	514/2	2369
	2	514/13	322
	2	514/17	311
	3	514/11	602
	3	514/9	340
	10	514/18	732
514/16.2	1	514/2	2369
	2	514/18	732
	7	514/19	605
514/16.3	1	514/16	263
	1	514/18	732
	1	514/7	64
	2	514/15	444
	2	514/2	2369
	10	514/19	605
514/16.4	1	514/11	602
	1	514/14	230
	1	514/16	263
	1	514/8	597
	2	514/13	322
	2	514/17	311
	2	514/18	732
	2	514/7	64
	2	514/9	340
	4	514/15	444
	4	514/2	2369
	5	514/19	605
	5	514/21	546
	10	514/12	2747
514/16.5	1	514/13	322
	1	514/14	230
	1	514/16	263
	2	514/12	2747
	2	514/18	732
	2	514/19	605
	2	514/21	546
	3	514/8	597
	6	514/2	2369
514/16.6	1	514/11	602
	1	514/12	2747
	1	514/14	230
	1	514/15	444
	1	514/17	311

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/16.6	1	514/6	223
	1	514/9	340
	1	514/9	340
	2	514/18	732
	2	514/19	605
	3	514/12	2747
	3	514/13	322
	5	514/2	2369
	5	514/8	597
514/16.7	1	514/10	70
	1	514/12	2747
	1	514/17	311
	1	514/19	605
	1	514/7	64
	1	514/8	597
	2	514/14	230
	2	514/15	444
	2	514/16	263
	3	514/18	732
	4	514/13	322
	5	514/8	597
	10	514/11	602
	13	514/2	2369
	15	514/12	2747
	17	514/21	546
514/16.8	1	514/11	602
	1	514/12	2747
	1	514/14	230
	1	514/15	444
	1	514/16	263
	1	514/20	40
	2	514/18	732
	3	514/19	605
	7	514/2	2369
514/16.9	1	514/15	444
	1	514/16	263
	1	514/9	340
	2	514/13	322
	2	514/19	605
	3	514/7	64
	4	514/2	2369
	9	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/17.1	2	514/19	605
	2	514/21	546
	2	514/8	597
	4	514/12	2747
	7	514/2	2369
514/17.2	1	514/12	2747
	1	514/14	230
	1	514/15	444
	1	514/19	605
	1	514/2	2369
	2	514/17	311
	2	514/6	223
	2	514/7	64
	5	514/12	2747
	6	514/18	732
	6	514/8	597
	13	514/21	546
	19	514/2	2369
514/17.3	1	514/12	2747
	1	514/8	597
	4	514/13	322
	4	514/2	2369
514/17.4	2	514/2	2369
	3	514/13	322
	3	514/9	340
	13	514/12	2747
514/17.5	1	514/12	2747
	1	514/14	230
	1	514/15	444
	1	514/18	732
	1	514/19	605
	1	514/2	2369
	1	514/9	340
	2	514/11	602
	2	514/13	322
	5	514/17	311
	6	514/16	263
	7	514/17	311
	7	514/18	732
	8	514/2	2369
514/17.6	1	514/12	2747
	1	514/13	322
	1	514/15	444

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/17.6	1	514/2	2369
	1	514/21	546
	1	514/9	340
	4	514/19	605
	5	514/18	732
514/17.7	1	514/12	2747
	1	514/13	322
	1	514/20	40
	1	514/7	64
	1	514/9	340
	2	514/21	546
	3	514/14	230
	3	514/2	2369
	3	514/8	597
	5	514/15	444
	7	514/11	602
	7	514/16	263
	9	514/12	2747
	9	514/17	311
	19	514/19	605
	20	514/2	2369
	22	514/18	732
514/17.8	1	514/21	546
	1	514/21	546
	1	514/7	64
	2	514/9	340
	3	514/15	444
	4	514/16	263
	4	514/18	732
	5	514/17	311
	5	514/19	605
	8	514/12	2747
	8	514/14	230
	10	514/2	2369
514/17.9	1	514/16	263
	1	514/21	546
	1	514/9	340
	3	514/12	2747
	3	514/13	322
	4	514/15	444
	5	514/14	230
	7	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/18.1	1	514/14	230
	1	514/8	597
	2	514/15	444
	2	514/18	732
	2	514/9	340
	3	514/11	602
	4	514/12	2747
	4	514/13	322
	4	514/19	605
	4	514/2	2369
514/18.2	1	514/11	602
	1	514/12	2747
	1	514/19	605
	1	514/21	546
	2	514/14	230
	3	514/2	2369
514/18.3	1	514/18	732
	1	514/7	64
	2	514/9	340
	3	514/13	322
	3	514/14	230
	4	514/11	602
	6	514/17	311
	8	514/16	263
	10	514/12	2747
	10	514/15	444
	11	514/2	2369
	13	514/19	605
	14	514/18	732
514/18.4	1	514/11	602
	1	514/12	2747
	1	514/15	444
	1	514/2	2369
	1	514/9	340
	2	514/14	230
	2	514/16	263
	2	514/17	311
	2	514/18	732
	3	514/19	605
	4	514/13	322
	4	514/2	2369
	9	514/18	732

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/18.5	1	514/2	2369
	2	514/18	732
	2	514/19	605
	9	514/17	311
514/18.6	1	514/11	602
	1	514/12	2747
	1	514/14	230
	1	514/14	230
	1	514/6	223
	1	514/9	340
	1	514/9	340
	2	514/12	2747
	4	514/15	444
	4	514/18	732
	4	514/19	605
	4	514/21	546
	6	514/17	311
	6	514/8	597
	10	514/2	2369
514/18.7	1	514/14	230
	1	514/16	263
	1	514/19	605
	1	514/2	2369
	1	514/2	2369
	1	514/21	546
	1	514/6	223
	2	514/11	602
	2	514/17	311
	2	514/18	732
	3	514/12	2747
	3	514/8	597
	3	514/9	340
514/18.8	1	514/10	70
	1	514/13	322
	1	514/14	230
	1	514/19	605
	1	514/6	223
	1	514/8	597
	2	514/17	311
	2	514/2	2369
	3	514/16	263
	4	514/18	732
	7	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/18.8	16	514/2	2369
514/18.9	1	514/13	322
	1	514/14	230
	1	514/15	444
	1	514/16	263
	1	514/18	732
	1	514/6	223
	1	514/9	340
	2	514/10	70
	2	514/21	546
	3	514/19	605
	3	514/8	597
	12	514/12	2747
	14	514/2	2369
514/183	1	514/8	597
514/185	1	514/6	223
514/188	1	514/6	223
514/19.1	1	514/18	732
	1	514/4	99
	2	514/13	322
	2	514/19	605
	2	514/21	546
	4	514/14	230
	4	514/17	311
	5	514/11	602
	6	514/15	444
	6	514/8	597
	7	514/9	340
	8	514/2	2369
	12	514/12	2747
514/19.2	1	514/10	70
	1	514/16	263
	1	514/9	340
	2	514/11	602
	2	514/15	444
	2	514/17	311
	3	514/12	2747
	3	514/14	230
	3	514/21	546
	4	514/19	605
	7	514/18	732
	8	514/8	597
	11	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/19.3	1	514/14	230
	1	514/16	263
	1	514/4	99
	1	514/6	223
	2	514/12	2747
	2	514/13	322
	2	514/18	732
	2	514/19	605
	2	514/21	546
	4	514/13	322
	4	514/14	230
	5	514/9	340
	6	514/10	70
	7	514/21	546
	11	514/15	444
	12	514/16	263
	14	514/11	602
	15	514/17	311
	15	514/8	597
	18	514/2	2369
	19	514/19	605
	26	514/18	732
	38	514/12	2747
	45	514/2	2369
514/19.4	1	514/12	2747
	1	514/2	2369
	1	514/21	546
	1	514/6	223
	2	514/14	230
	2	514/15	444
	2	514/16	263
	2	514/17	311
	2	514/8	597
	3	514/18	732
	3	514/19	605
	3	514/9	340
	8	514/12	2747
	13	514/2	2369
514/19.5	1	514/12	2747
	1	514/16	263
	1	514/18	732
	1	514/19	605
	1	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/19.5	1	514/9	340
	2	514/12	2747
	2	514/15	444
	2	514/16	263
	2	514/8	597
	7	514/2	2369
514/19.6	1	514/11	602
	1	514/19	605
	1	514/2	2369
	1	514/2	2369
514/19.7	4	514/16	263
	7	514/15	444
514/19.8	1	514/15	444
	1	514/18	732
514/19.9	1	514/11	602
	2	514/9	340
514/2.1	1	514/6	223
	1	514/9	340
	4	514/13	322
	7	514/12	2747
	9	514/2	2369
514/2.2	1	514/11	602
	1	514/14	230
	1	514/8	597
	2	514/2	2369
	11	514/12	2747
514/2.3	1	514/15	444
	1	514/19	605
	1	514/4	99
	2	514/17	311
	2	514/19	605
	2	514/21	546
	3	514/13	322
	3	514/6	223
	4	514/14	230
	5	514/18	732
	7	514/11	602
	9	514/9	340
	16	514/8	597
	18	514/12	2747
	19	514/2	2369
514/2.4	1	514/15	444
	1	514/20	40

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/2.4	1	514/4	99
	1	514/5	14
	2	514/12	2747
	4	514/9	340
	5	514/10	70
	5	514/6	223
	6	514/16	263
	7	514/17	311
	8	514/7	64
	9	514/14	230
	10	514/13	322
	11	514/15	444
	13	514/21	546
	16	514/18	732
	19	514/19	605
	44	514/8	597
	56	514/11	602
	75	514/2	2369
	99	514/12	2747
514/2.5	1	514/11	602
	1	514/2	2369
	1	514/21	546
	3	514/6	223
	6	514/8	597
	9	514/12	2747
514/2.6	1	514/7	64
	2	514/12	2747
	2	514/2	2369
	2	514/8	597
	3	514/13	322
	7	514/9	340
514/2.7	1	514/18	732
	1	514/21	546
	2	514/11	602
	2	514/13	322
	2	514/15	444
	2	514/19	605
	2	514/7	64
	5	514/9	340
	6	514/14	230
	6	514/8	597
	8	514/12	2747
	9	514/2	2369

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/2.8	1	514/12	2747
	1	514/18	732
	1	514/19	605
	1	514/2	2369
	1	514/6	223
	1	514/8	597
	2	514/13	322
	3	514/7	64
	4	514/12	2747
	4	514/9	340
	8	514/2	2369
514/2.9	1	514/11	602
	1	514/12	2747
	1	514/16	263
	1	514/7	64
	3	514/2	2369
	6	514/10	70
	12	514/11	602
	18	514/8	597
	25	514/9	340
514/20.1	1	514/10	70
	1	514/15	444
	1	514/2	2369
	1	514/6	223
	2	514/12	2747
	2	514/9	340
	3	514/21	546
	6	514/17	311
	7	514/2	2369
	13	514/18	732
	14	514/19	605
	16	514/20	40
	27	514/12	2747
514/20.2	1	514/13	322
	1	514/8	597
	2	514/2	2369
	4	514/12	2747
	5	514/19	605
	6	514/18	732
514/20.3	1	514/12	2747
	1	514/18	732
	1	514/19	605
	1	514/19	605

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/20.3	1	514/8	597
514/20.4	1	514/8	597
	1	514/9	340
	2	514/17	311
	3	514/2	2369
	5	514/19	605
	10	514/12	2747
	18	514/18	732
514/20.5	1	514/15	444
	2	514/11	602
	2	514/13	322
	2	514/2	2369
	18	514/9	340
	53	514/11	602
514/20.6	1	514/11	602
	1	514/13	322
	1	514/17	311
	1	514/8	597
	2	514/12	2747
	2	514/13	322
	2	514/14	230
	2	514/16	263
	2	514/18	732
	2	514/2	2369
	4	514/12	2747
	5	514/2	2369
514/20.7	1	514/10	70
	1	514/12	2747
	1	514/15	444
	1	514/16	263
	1	514/19	605
	1	514/8	597
	2	514/6	223
	3	514/18	732
	3	514/21	546
	7	514/2	2369
514/20.8	1	514/10	70
	1	514/11	602
	1	514/17	311
	1	514/2	2369
	1	514/20	40
	2	514/16	263
	2	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/20.8	4	514/12	2747
	5	514/8	597
	7	514/18	732
	7	514/19	605
	7	514/2	2369
514/20.9	1	514/14	230
	1	514/19	605
	1	514/19	605
	1	514/2	2369
	5	514/12	2747
	7	514/8	597
	8	514/2	2369
	18	514/8	597
514/201	1	514/2	2369
514/21.1	1	514/12	2747
	1	514/14	230
	1	514/8	597
	3	514/11	602
	4	514/10	70
	8	514/2	2369
	11	514/9	340
	15	514/11	602
514/21.2	1	514/14	230
	1	514/17	311
	1	514/3	267
	2	514/17	311
	2	514/6	223
	2	514/8	597
	3	514/2	2369
	4	514/21	546
	37	514/2	2369
	66	514/12	2747
514/21.3	1	514/12	2747
	1	514/13	322
	1	514/2	2369
	1	514/21	546
	1	514/8	597
	10	514/2	2369
	32	514/12	2747
514/21.4	1	514/11	602
	1	514/12	2747
	1	514/14	230
	1	514/16	263

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/21.4	1	514/2	2369
	1	514/7	64
	2	514/15	444
	3	514/2	2369
	11	514/13	322
514/21.5	1	514/17	311
	2	514/14	230
	2	514/15	444
	2	514/15	444
	4	514/2	2369
	9	514/14	230
514/21.6	1	514/14	230
	1	514/17	311
	1	514/2	2369
	1	514/8	597
	2	514/15	444
	2	514/2	2369
	16	514/15	444
514/21.7	1	514/12	2747
	1	514/15	444
	1	514/15	444
	1	514/17	311
	1	514/18	732
	1	514/19	605
	2	514/16	263
	2	514/2	2369
	8	514/16	263
514/21.8	1	514/15	444
	1	514/18	732
	1	514/18	732
	1	514/19	605
	1	514/19	605
	1	514/8	597
	4	514/2	2369
	5	514/17	311
	15	514/17	311
514/21.9	2	514/19	605
	2	514/2	2369
	4	514/19	605
	6	514/2	2369
	10	514/18	732
	23	514/18	732

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/21.91	1	514/12	2747
	1	514/17	311
	1	514/18	732
	1	514/18	732
	1	514/20	40
	1	514/8	597
	3	514/2	2369
	3	514/2	2369
	8	514/19	605
	20	514/19	605
514/21.92	1	514/8	597
	2	514/21	546
	3	514/12	2747
	5	514/8	597
	8	514/2	2369
	11	514/21	546
514/210.16	1	514/7	64
514/23	1	514/21	546
	1	514/3	267
	1	514/8	597
514/237.8	1	514/3	267
514/252.12	1	514/19	605
514/255.02	1	514/19	605
514/269	1	514/18	732
514/291	1	514/9	340
514/3.1	1	514/7	64
	1	514/8	597
	3	514/9	340
	15	514/8	597
514/3.2	1	514/8	597
	2	514/2	2369
	4	514/13	322
514/3.3	1	514/12	2747
	1	514/15	444
	1	514/17	311
	1	514/18	732
	2	514/16	263
	2	514/21	546
	2	514/7	64
	3	514/14	230
	3	514/9	340
	4	514/19	605
	5	514/13	322

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/3.3	8	514/12	2747
	9	514/8	597
	18	514/2	2369
	45	514/11	602
514/3.4	1	514/2	2369
	1	514/7	64
	2	514/12	2747
	3	514/2	2369
	8	514/9	340
514/3.5	2	514/9	340
514/3.6	1	514/11	602
	1	514/15	444
	9	514/9	340
514/3.7	1	514/10	70
	1	514/5	14
	1	514/6	223
	1	514/9	340
	2	514/12	2747
	3	514/14	230
	3	514/16	263
	4	514/11	602
	7	514/13	322
	7	514/15	444
	8	514/17	311
	9	514/19	605
	14	514/18	732
	15	514/21	546
	17	514/8	597
	19	514/12	2747
	27	514/2	2369
514/3.8	1	514/6	223
	2	514/9	340
	3	514/13	322
	3	514/7	64
	4	514/15	444
	4	514/16	263
	5	514/14	230
	5	514/17	311
	6	514/11	602
	6	514/21	546
	6	514/8	597
	10	514/18	732
	10	514/19	605

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/3.8	17	514/12	2747
	33	514/2	2369
514/3.9	1	514/14	230
	1	514/2	2369
	1	514/8	597
514/317	1	514/11	602
	1	514/9	340
514/348	1	514/9	340
514/4.1	1	514/13	322
	1	514/17	311
	1	514/18	732
	2	514/2	2369
	2	514/8	597
	3	514/19	605
514/4.2	1	514/12	2747
	1	514/12	2747
	1	514/2	2369
	1	514/8	597
	1	514/9	340
	2	514/17	311
	9	514/18	732
514/4.3	1	514/10	70
	1	514/11	602
	1	514/2	2369
	1	514/2	2369
	2	514/13	322
	2	514/19	605
	3	514/17	311
	5	514/11	602
	5	514/12	2747
	5	514/9	340
	7	514/18	732
514/4.4	1	514/17	311
	1	514/2	2369
	1	514/21	546
	1	514/8	597
	2	514/10	70
	2	514/11	602
	2	514/2	2369
	4	514/12	2747
514/4.5	1	514/12	2747
	1	514/15	444
	1	514/18	732

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/4.5	1	514/7	64
	1	514/8	597
	2	514/14	230
	2	514/17	311
	2	514/9	340
	4	514/11	602
	14	514/2	2369
	36	514/12	2747
514/4.6	1	514/12	2747
	1	514/19	605
	1	514/19	605
	1	514/2	2369
	1	514/5	14
	2	514/9	340
514/4.7	1	514/2	2369
514/4.8	1	514/11	602
	1	514/2	2369
	1	514/5	14
	2	514/13	322
	2	514/15	444
	2	514/19	605
	4	514/14	230
	4	514/17	311
	5	514/16	263
	6	514/21	546
	7	514/8	597
	8	514/18	732
	27	514/2	2369
	66	514/12	2747
514/4.9	1	514/12	2747
	1	514/2	2369
	1	514/3	267
	2	514/13	322
	2	514/18	732
	4	514/2	2369
514/400	1	514/14	230
514/42	1	514/7	64
514/44 R	1	514/12	2747
	1	514/20	40
	2	514/2	2369
514/45	1	514/7	64
514/476	1	514/8	597

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/478	1	514/12	2747
	1	514/19	605
514/5.1	1	514/19	605
	1	514/2	2369
	4	514/14	230
514/5.2	1	514/12	2747
	1	514/13	322
	1	514/2	2369
	1	514/2	2369
514/5.3	1	514/12	2747
	1	514/18	732
	1	514/19	605
	1	514/3	267
	2	514/13	322
	2	514/21	546
	3	514/5	14
514/5.4	1	514/21	546
	1	514/5	14
	2	514/8	597
	3	514/12	2747
	3	514/13	322
	5	514/2	2369
	9	514/6	223
514/5.5	1	514/13	322
	1	514/16	263
	1	514/17	311
	1	514/18	732
	1	514/3	267
	2	514/10	70
	2	514/2	2369
	3	514/7	64
	3	514/9	340
	4	514/11	602
	7	514/18	732
	9	514/19	605
	9	514/6	223
	24	514/12	2747
	35	514/21	546
	41	514/2	2369
514/5.6	1	514/2	2369
514/5.8	1	514/16	263
	1	514/3	267
	2	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/5.8	6	514/2	2369
	10	514/12	2747
514/5.9	1	514/14	230
	1	514/15	444
	1	514/17	311
	1	514/3	267
	1	514/8	597
	2	514/10	70
	2	514/16	263
	2	514/18	732
	2	514/9	340
	3	514/13	322
	3	514/19	605
	7	514/4	99
	15	514/2	2369
	30	514/12	2747
	43	514/3	267
514/506	2	514/19	605
514/507	1	514/19	605
514/546	1	514/12	2747
514/6.1	3	514/4	99
	22	514/3	267
514/6.2	1	514/4	99
	21	514/3	267
514/6.3	1	514/13	322
	1	514/2	2369
	1	514/2	2369
	1	514/3	267
	5	514/4	99
	29	514/3	267
514/6.4	5	514/4	99
	19	514/3	267
514/6.5	1	514/12	2747
	1	514/13	322
	1	514/14	230
	1	514/17	311
	1	514/3	267
	2	514/11	602
	2	514/18	732
	2	514/2	2369
	2	514/2	2369
	30	514/3	267
	47	514/4	99

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/6.6	4	514/3	267
	7	514/4	99
514/6.7	1	514/11	602
	1	514/13	322
	1	514/2	2369
	2	514/12	2747
	3	514/2	2369
	5	514/3	267
514/6.8	1	514/11	602
	1	514/14	230
	1	514/21	546
	1	514/7	64
	2	514/13	322
	2	514/19	605
	2	514/21	546
	2	514/3	267
	3	514/2	2369
	16	514/12	2747
514/6.9	1	514/13	322
	1	514/14	230
	1	514/15	444
	1	514/6	223
	1	514/8	597
	1	514/9	340
	2	514/10	70
	2	514/4	99
	3	514/12	2747
	3	514/17	311
	5	514/19	605
	7	514/16	263
	7	514/18	732
	7	514/21	546
	14	514/11	602
	28	514/2	2369
	51	514/12	2747
514/600	1	514/19	605
514/602	1	514/14	230
514/61	2	514/18	732
514/613	1	514/17	311
	1	514/18	732
	1	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/7.1	1	514/16	263
	1	514/9	340
	3	514/11	602
	4	514/11	602
514/7.2	1	514/2	2369
	5	514/12	2747
514/7.3	1	514/11	602
	1	514/12	2747
	1	514/2	2369
	1	514/3	267
	1	514/4	99
	1	514/9	340
	4	514/13	322
	6	514/2	2369
514/7.4	1	514/10	70
	1	514/14	230
	1	514/3	267
	1	514/5	14
	1	514/8	597
	1	514/9	340
	2	514/11	602
	2	514/16	263
	2	514/2	2369
	3	514/15	444
	4	514/19	605
	5	514/13	322
	6	514/18	732
	8	514/21	546
	11	514/12	2747
	23	514/2	2369
514/7.5	1	514/11	602
	1	514/2	2369
	1	514/21	546
	1	514/7	64
	2	514/13	322
	2	514/14	230
	3	514/18	732
	13	514/12	2747
	13	514/2	2369
514/7.6	1	514/11	602
	1	514/12	2747
	1	514/15	444
	1	514/17	311

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/7.6	1	514/18	732
	2	514/18	732
	2	514/19	605
	2	514/6	223
	3	514/16	263
	4	514/2	2369
	7	514/8	597
	13	514/21	546
	34	514/2	2369
	52	514/12	2747
514/7.7	1	514/3	267
	1	514/6	223
	2	514/16	263
	6	514/12	2747
	20	514/2	2369
	41	514/8	597
514/7.8	1	514/14	230
	1	514/3	267
	2	514/12	2747
	2	514/2	2369
	5	514/13	322
514/7.9	1	514/10	70
	1	514/13	322
	1	514/16	263
	1	514/19	605
	1	514/21	546
	2	514/14	230
	2	514/6	223
	4	514/15	444
	4	514/8	597
	5	514/17	311
	6	514/18	732
	8	514/2	2369
	11	514/12	2747
514/723	1	514/10	70
514/75	1	514/2	2369
514/773	1	514/17	311
514/8.1	1	514/11	602
	1	514/13	322
	1	514/13	322
	1	514/16	263
	1	514/17	311
	1	514/9	340

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/8.1	2	514/12	2747
	2	514/8	597
	16	514/2	2369
	20	514/12	2747
514/8.2	1	514/11	602
	1	514/14	230
	1	514/17	311
	1	514/18	732
	3	514/8	597
	6	514/2	2369
	6	514/21	546
	22	514/12	2747
514/8.3	1	514/12	2747
	1	514/9	340
	2	514/14	230
	3	514/11	602
	4	514/13	322
	5	514/21	546
	28	514/2	2369
	37	514/12	2747
514/8.4	1	514/14	230
	1	514/2	2369
	1	514/4	99
	1	514/7	64
	1	514/8	597
	1	514/9	340
	2	514/11	602
	10	514/21	546
	23	514/2	2369
	49	514/12	2747
514/8.5	1	514/12	2747
	1	514/19	605
	1	514/3	267
	1	514/8	597
	2	514/15	444
	4	514/21	546
	16	514/2	2369
	68	514/12	2747
514/8.6	1	514/3	267
	3	514/12	2747
	4	514/2	2369
	8	514/3	267

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/8.7	1	514/12	2747
	1	514/3	267
514/8.8	1	514/11	602
	1	514/17	311
	1	514/2	2369
	2	514/21	546
	3	514/12	2747
	12	514/2	2369
	37	514/12	2747
514/8.9	2	514/13	322
	2	514/17	311
	3	514/18	732
	3	514/8	597
	6	514/21	546
	21	514/2	2369
	35	514/12	2747
514/9.1	1	514/10	70
	1	514/14	230
	1	514/17	311
	2	514/13	322
	2	514/8	597
	3	514/21	546
	6	514/12	2747
	19	514/2	2369
	40	514/12	2747
514/9.2	1	514/8	597
	3	514/2	2369
	12	514/12	2747
514/9.3	1	514/15	444
	1	514/16	263
	1	514/9	340
	2	514/17	311
	2	514/21	546
	3	514/13	322
	3	514/14	230
	9	514/11	602
	9	514/8	597
	11	514/2	2369
	12	514/12	2747
514/9.4	1	514/11	602
	1	514/12	2747
	1	514/13	322
	1	514/15	444

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/9.4	1	514/19	605
	1	514/5	14
	1	514/9	340
	2	514/2	2369
	3	514/14	230
	5	514/17	311
	5	514/18	732
	6	514/13	322
	6	514/6	223
	7	514/21	546
	11	514/8	597
	12	514/16	263
	18	514/12	2747
	23	514/2	2369
514/9.5	1	514/12	2747
	1	514/12	2747
	2	514/2	2369
514/9.6	1	514/2	2369
	2	514/12	2747
514/9.7	1	514/10	70
	1	514/12	2747
	1	514/14	230
	1	514/16	263
	1	514/17	311
	1	514/18	732
	1	514/2	2369
	1	514/3	267
	1	514/6	223
	1	514/9	340
	2	514/16	263
	3	514/14	230
	3	514/17	311
	4	514/21	546
	4	514/8	597
	5	514/11	602
	6	514/19	605
	7	514/18	732
	9	514/15	444
	10	514/13	322
	15	514/2	2369
	84	514/12	2747
514/9.8	1	514/11	602
	1	514/13	322

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
514/9.8	1	514/14	230
	1	514/19	605
	3	514/18	732
	4	514/21	546
	5	514/16	263
	6	514/8	597
	7	514/15	444
	9	514/12	2747
	10	514/2	2369
514/9.9	1	514/16	263
	1	514/2	2369
	1	514/9	340
	2	514/13	322
	2	514/21	546
	10	514/2	2369
	10	514/8	597
	14	514/12	2747
	21	514/15	444
525/420	1	514/12	2747
525/54.1	1	514/19	605
526/258	1	514/12	2747
527/207	1	514/2	2369
530/300	1	514/14	230
	1	514/8	597
	2	514/12	2747
	2	514/19	605
	4	514/2	2369
530/303	1	514/2	2369
	3	514/3	267
530/308	1	514/12	2747
530/311	1	514/11	602
530/315	1	514/11	602
530/317	1	514/12	2747
	1	514/13	322
	1	514/16	263
	1	514/8	597
	2	514/11	602
	3	514/2	2369
	7	514/9	340
530/320	1	514/11	602
530/321	1	514/11	602
530/322	2	514/10	70
	3	514/8	597

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
530/323	1	514/12	2747
530/324	1	514/13	322
	1	514/2	2369
	1	514/21	546
	20	514/12	2747
530/325	1	514/12	2747
530/326	4	514/13	322
530/327	1	514/16	263
	2	514/14	230
	2	514/2	2369
530/328	1	514/15	444
	1	514/2	2369
	2	514/12	2747
	4	514/16	263
530/329	1	514/16	263
	1	514/17	311
	1	514/18	732
	1	514/2	2369
	1	514/9	340
530/330	1	514/19	605
	2	514/17	311
	6	514/18	732
530/331	1	514/2	2369
	3	514/19	605
	6	514/18	732
530/333	1	514/19	605
530/344	1	514/12	2747
	2	514/21	546
530/345	1	514/6	223
530/350	1	514/8	597
	2	514/6	223
	8	514/2	2369
	12	514/12	2747
530/351	2	514/8	597
530/356	1	514/12	2747
	1	514/2	2369
	1	514/21	546
530/358	1	514/12	2747
530/360	1	514/21	546
530/363	1	514/2	2369
	1	514/21	546
530/364	1	514/12	2747
	1	514/21	546

SEPTEMBER 7, 2010

PROJECT C-7157

SOURCE CLASSIFICATION(S) OF PATENTS
IN NEWLY ESTABLISHED SUBCLASSES REPORT

Generated by Data Control Division

New Classification	Number of ORs	Source Classification	Number of ORs
530/370	3	514/2	2369
530/379	1	514/12	2747
530/380	1	514/12	2747
530/382	1	514/21	546
530/383	1	514/2	2369
	2	514/12	2747
530/384	1	514/12	2747
530/385	1	514/6	223
530/392	1	514/21	546
530/395	1	514/2	2369
530/398	1	514/21	546
530/402	1	514/2	2369
530/416	1	514/2	2369
	1	514/20	40
530/417	1	514/21	546
530/424	1	514/2	2369
544/283	1	514/19	605
544/359	1	514/19	605
548/300.1	2	514/19	605
564/123	3	514/18	732
	4	514/19	605
564/152	1	514/7	64
	4	514/19	605
564/32	1	514/18	732
564/80	3	514/19	605
568/374	1	514/9	340
604/19	1	514/21	546
604/20	1	514/12	2747
604/27	2	514/12	2747
604/307	1	514/21	546
604/4.01	2	514/12	2747
604/5.01	1	514/2	2369
604/5.02	1	514/12	2747
	1	514/2	2369
604/501	1	514/2	2369
604/890.1	1	514/16	263
	2	514/12	2747
604/891.1	1	514/21	546
604/892.1	1	514/2	2369
	2	514/12	2747

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	424/423	6
514/2	2369	424/85.1	14
514/12	2747	424/93.2	1
514/19	605	530/331	3
514/18	732	514/269	1
514/12	2747	530/325	1
514/3	267	514/237.8	1
514/13	322	424/50	1
514/21	546	424/85.1	2
514/19	605	530/330	1
514/4	99	424/422	1
514/13	322	424/1.69	5
514/18	732	424/158.1	1
514/2	2369	424/94.64	4
514/11	602	424/134.1	1
514/9	340	424/442	1
514/2	2369	530/327	2
514/21	546	424/134.1	1
514/2	2369	424/9.6	1
514/6	223	424/780	1
514/18	732	424/278.1	6
514/21	546	424/133.1	1
514/11	602	424/463	1
		424/1.69	1
514/3	267	424/94.4	1
514/2	2369	424/433	1
514/12	2747	435/6	1
514/18	732	424/48	1
514/2	2369	424/725	1
514/10	70	435/71.3	1
514/12	2747	424/94.63	6
514/13	322	424/185.1	6
514/8	597	424/130.1	2
514/6	223	424/94.61	1
514/11	602	424/449	1
514/13	322	436/501	2
		424/489	1
514/2	2369	530/424	1
514/17	311	424/278.1	1
514/4	99	424/489	2
514/12	2747	424/85.1	16
		424/488	1
514/19	605	514/507	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	424/178.1	7
		424/193.1	1
514/11	602	424/85.4	2
514/6	223	424/94.1	1
514/7	64	514/129	2
514/2	2369	424/425	1
514/21	546	424/1.69	1
514/8	597	424/461	1
514/13	322	424/1.49	2
514/2	2369	424/144.1	1
514/20	40	514/2.4	1
514/12	2747	514/3.8	17
514/8	597	514/4.5	1
514/2	2369	514/4.9	4
514/11	602	514/7.3	1
514/10	70	514/7.9	1
514/16	263	514/9.3	1
514/11	602	514/9.8	1
514/8	597	514/9.8	6
514/21	546	514/10.1	1
514/6	223	514/12.1	1
514/12	2747	514/12.1	3
514/19	605	514/13.5	3
514/18	732	514/13.7	27
514/21	546	514/16.7	17
514/9	340	514/18.3	2
514/11	602	514/19.1	5
514/9	340	514/19.3	5
514/16	263	514/19.5	2
514/18	732	514/19.8	1
514/8	597	514/1.5	1
		514/2.3	16
514/2	2369	514/2.8	8
514/18	732	514/4.5	1
514/11	602	514/4.8	1
514/12	2747	514/7.8	2
514/6	223	514/9.4	6
514/15	444	514/10.1	18
514/2	2369	514/11.6	1
514/14	230	514/13.5	1
514/2	2369	514/15.6	3
514/6	223	514/15.7	1
514/17	311	514/16.1	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/17.7	20
514/13	322	514/18.1	4
514/8	597	514/18.6	6
514/2	2369	514/19.2	11
514/21	546	514/19.3	7
514/8	597	514/19.4	2
514/17	311	514/21.7	1
514/16	263	514/21.7	8
514/19	605	514/21.8	1
514/7	64	514/1.5	1
514/17	311	514/2.4	7
514/12	2747	514/3.3	8
514/21	546	514/3.8	6
514/11	602	514/4.3	1
514/17	311	514/4.5	2
514/8	597	514/4.8	7
514/4	99	514/6.1	3
		514/6.6	7
514/16	263	514/7.4	2
514/2	2369	514/8.5	16
514/8	597	514/8.5	1
514/2	2369	514/9.5	2
		514/10.2	2
514/8	597	514/10.3	1
514/2	2369	514/11.3	17
		514/11.7	4
514/7	64	514/14.6	1
514/2	2369	514/14.9	19
514/19	605	514/15.7	37
514/9	340	514/15.7	1
514/20	40	514/15.7	1
514/2	2369	514/16.6	5
514/8	597	514/16.6	5
514/2	2369	514/17.1	7
514/17	311	514/17.2	2
		514/18.7	2
514/2	2369	514/18.9	14
514/15	444	514/20.7	1
514/11	602	514/21.1	15
514/2	2369	514/21.4	3
514/9	340	514/3.3	3
514/14	230	514/3.9	1
514/13	322	514/6.3	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/4	99	514/6.4	5
514/14	230	514/6.8	1
514/11	602	514/8.1	1
514/13	322	514/9.3	3
514/15	444	514/9.3	1
514/9	340	514/9.4	1
514/10	70	514/9.7	1
514/12	2747	514/11.8	32
514/17	311	514/13.2	2
		514/13.7	8
514/21	546	514/14.8	1
514/12	2747	514/15.5	1
514/21	546	514/15.7	2
514/2	2369	514/15.7	13
514/8	597	514/16.5	3
514/16	263	514/16.9	1
514/13	322	514/20.5	2
514/12	2747	514/20.6	4
514/19	605	514/20.7	1
514/15	444	514/1.1	30
514/18	732	514/1.4	4
514/9	340	514/1.8	1
514/13	322	514/2.7	2
514/2	2369	514/3.3	18
514/9	340	514/3.6	9
514/6	223	514/3.8	1
514/18	732	514/5.5	7
514/17	311	514/7.6	1
514/14	230	514/7.9	2
514/13	322	514/9.9	2
		514/10.1	3
514/16	263	514/10.3	2
514/2	2369	514/10.3	9
		514/11.4	1
514/16	263	514/14.9	3
514/8	597	514/15.2	2
514/12	2747	514/17.1	4
514/2	2369	514/18.3	11
514/16	263	514/18.8	3
514/2	2369	514/19.1	8
514/15	444	514/19.5	2
514/2	2369	514/20.2	2
514/14	230	514/21.2	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/1.7	3
514/13	322	514/2.3	3
514/18	732	514/2.7	1
514/11	602	514/3.3	45
514/17	311	514/3.7	8
514/12	2747	514/3.7	19
514/2	2369	514/8.9	21
514/21	546	514/10.8	2
514/2	2369	514/10.9	2
514/17	311	514/11.4	1
514/16	263	514/12.2	9
514/12	2747	514/14.3	12
514/18	732	514/15.3	1
514/21	546	514/18.7	1
514/2	2369	514/18.8	16
514/9	340	514/19.1	7
514/19	605	514/19.1	2
514/18	732	514/19.1	1
514/6	223	514/19.3	1
514/2	2369	514/20.5	2
514/13	322	514/21.4	11
514/19	605	514/1.1	21
514/12	2747	514/1.5	8
514/18	732	514/1.9	7
514/10	70	514/1.9	1
514/12	2747	514/4.5	36
514/2	2369	514/5.4	5
514/16	263	514/5.9	2
514/21	546	514/6.9	7
514/6	223	514/6.9	1
514/9	340	514/9.3	1
514/14	230	514/9.7	3
514/2	2369	514/10.1	8
514/9	340	514/10.9	4
514/15	444	514/11.6	1
514/12	2747	514/14.8	10
514/21	546	514/15.2	5
514/19	605	514/15.6	1
514/11	602	514/16.1	3
514/2	2369	514/17.3	4
514/15	444	514/17.7	5
514/14	230	514/18.1	1
514/12	2747	514/18.3	10

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/8	597	514/18.7	3
514/11	602	514/1.6	1
514/19	605	514/1.8	1
514/6	223	514/2.5	3
514/12	2747	514/5.5	24
		514/5.9	30
514/9	340	514/9.7	1
514/2	2369	514/12.1	4
514/8	597	514/13.6	4
514/13	322	514/13.8	1
514/15	444	514/14.9	2
514/9	340	514/16.1	3
514/19	605	514/17.1	2
514/21	546	514/18.6	4
514/15	444	514/20.5	1
514/12	2747	514/21.4	1
514/18	732	514/21.7	1
514/12	2747	514/8.3	1
514/18	732	514/9.7	1
514/17	311	514/9.7	1
514/2	2369	514/19.3	18
514/11	602	514/19.9	1
514/4	99	514/6.2	1
514/2	2369	514/17.7	3
514/21	546	514/19.3	2
514/16	263	514/1.7	1
514/12	2747	514/3.3	1
514/2	2369	514/5.6	1
		514/19.5	1
514/19	605	514/19.6	1
514/11	602	514/20.5	2
514/2	2369	514/21.4	1
		514/21.6	2
		514/7.5	1
514/21	546	514/13.5	1
514/13	322	514/19.3	2
514/12	2747	514/20.6	2
514/17	311	514/20.6	1
514/15	444	514/1.1	12
514/12	2747	514/1.2	2
514/10	70	514/4.3	1
514/18	732	514/17.5	1
514/14	230	514/9.7	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/16	263	514/19.3	1
514/15	444	514/19.8	1
514/11	602	514/6.7	1
514/2	2369	514/13.3	4
		514/13.7	2
514/8	597	424/85.1	7
514/21	546	514/613	1
514/18	732	530/329	1
514/2	2369	424/491	6
514/12	2747	424/468	1
514/2	2369	424/198.1	2
514/6	223	530/350	2
514/13	322	424/484	1
514/7	64	424/94.1	1
514/21	546	530/398	1
		424/178.1	1
		530/360	1
		424/562	1
514/4	99	424/85.2	1
514/6	223	424/1.57	1
514/2	2369	530/402	1
514/19	605	424/279.1	1
514/1.1	1	424/178.1	1
514/21	546	424/581	1
514/15	444	424/451	1
514/21	546	424/85.2	5
514/18	732	514/613	1
514/12	2747	424/10.2	2
		424/491	2
		433/201.1	1
		424/431	1
514/17	311	424/85.2	1
514/12	2747	424/278.1	3
514/15	444	424/456	1
514/12	2747	514/546	1
514/2	2369	530/383	1
514/21	546	424/85.4	1
514/8	597	424/186.1	1
		424/464	1
514/6	223	424/145.1	1
514/2	2369	424/85.4	16
514/21	546	424/141.1	2
514/2	2369	424/94.6	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/9	340	530/317	7
514/10	70	514/723	1
514/7	64	435/7.1	1
514/16	263	424/1.11	1
514/2	2369	530/328	1
514/15	444	424/85.4	3
514/19	605	564/152	4
514/21	546	424/423	6
514/12	2747	530/328	2
514/19	605	514/252.12	1
514/14	230	424/1.69	2
514/11	602	424/422	2
514/2	2369	424/423	2
514/12	2747	424/94.2	1
514/9	340	514/291	1
514/2	2369	435/219	1
514/8	597	424/780	1
514/21	546	530/324	1
514/6	223	424/489	2
		514/150	1
514/19	605	435/7.21	1
514/12	2747	424/94.1	5
514/2	2369	436/173	1
514/18	732	564/32	1
514/2	2369	435/7.24	1
514/8	597	424/93.6	1
514/12	2747	530/317	1
514/16	263	530/327	1
514/6	223	514/188	1
514/19	605	544/283	1
514/13	322	424/130.1	1
514/2	2369	424/49	1
514/10	70	424/85.4	1
514/12	2747	424/451	1
514/21	546	514/1.1	9
514/19	605	514/1.6	1
514/14	230	514/2.2	1
514/8	597	514/2.4	44
514/21	546	514/2.5	1
514/8	597	514/4.4	1
514/12	2747	514/5.3	1
514/21	546	514/5.5	35
514/15	444	514/5.9	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	514/5.9	1
514/9	340	514/6.9	1
514/8	597	514/7.9	4
514/14	230	514/9.1	1
514/2	2369	514/9.9	10
514/18	732	514/10.2	1
514/9	340	514/11.3	1
514/12	2747	514/11.5	5
514/9	340	514/11.9	2
514/14	230	514/12.3	2
514/18	732	514/13.6	4
514/19	605	514/13.6	3
514/11	602	514/15.8	7
514/17	311	514/16.4	2
514/12	2747	514/16.8	1
514/14	230	514/16.8	1
514/8	597	514/17.2	6
514/15	444	514/19.2	2
514/2	2369	514/21.8	4
514/19	605	514/2.3	2
514/18	732	514/5.9	2
514/10	70	514/6.9	2
514/16	263	514/7.1	1
514/12	2747	514/7.7	6
514/15	444	514/9.8	7
		514/10.3	111
514/11	602	514/10.9	25
514/12	2747	514/11.7	21
514/21	546	514/13.4	5
514/8	597	514/13.8	1
514/4	99	514/14.8	1
514/11	602	514/15.3	1
514/13	322	514/15.6	2
514/15	444	514/15.6	2
514/12	2747	514/15.7	7
514/18	732	514/16.6	2
514/13	322	514/16.7	4
514/19	605	514/17.5	1
514/12	2747	514/17.6	1
514/19	605	514/17.6	4
514/8	597	514/17.7	3
514/16	263	514/17.9	1
514/12	2747	514/18.1	4

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	514/18.2	2
514/8	597	514/19.3	15
514/6	223	514/19.4	1
514/17	311	514/1.7	3
514/9	340	514/2.7	5
		514/3.7	1
514/4	99	514/7.3	1
514/12	2747	514/7.5	13
		514/7.6	52
514/19	605	514/7.6	2
514/21	546	514/8.3	5
514/12	2747	514/8.4	49
514/2	2369	514/9.7	15
514/6	223	514/10.3	1
514/15	444	514/10.6	1
514/10	70	514/11.1	1
514/12	2747	514/12.4	1
514/6	223	514/13.6	1
514/13	322	514/13.9	1
514/8	597	514/14.3	4
514/19	605	514/16.8	3
514/13	322	514/17.5	2
514/21	546	514/17.6	1
514/17	311	514/18.5	9
514/8	597	514/18.8	1
514/2	2369	514/19.4	13
514/8	597	514/21.1	1
514/12	2747	514/21.1	1
514/6	223	514/21.2	2
514/21	546	514/21.3	1
		514/2.3	2
514/19	605	514/2.4	19
514/18	732	514/2.8	1
514/13	322	514/3.8	3
514/19	605	514/3.8	10
514/18	732	514/3.8	10
514/12	2747	514/4.2	1
514/17	311	514/5.9	1
514/8	597	514/7.4	1
514/12	2747	514/8.2	22
514/3	267	514/9.7	1
514/2	2369	514/11.5	2
514/11	602	514/13.5	3

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/6	223	514/15.2	1
514/19	605	514/15.8	22
514/2	2369	514/17.4	2
514/12	2747	514/20.3	1
514/16	263	514/20.7	1
514/12	2747	514/21.3	32
514/6	223	514/1.1	11
514/14	230	514/1.9	1
514/8	597	514/3.8	6
514/13	322	514/4.1	1
514/3	267	514/5.5	1
514/11	602	514/6.9	14
514/13	322	514/6.9	1
514/19	605	514/7.4	4
514/12	2747	514/9.6	2
514/14	230	514/11.1	2
514/21	546	514/11.9	4
514/5	14	514/13.7	1
514/2	2369	514/16.2	1
514/14	230	514/16.7	2
514/18	732	514/16.8	2
514/12	2747	514/18.4	1
514/15	444	514/18.6	4
514/18	732	514/19.2	7
514/14	230	514/19.4	2
514/18	732	514/4.1	1
514/2	2369	514/5.1	1
514/19	605	514/10.6	1
514/17	311	514/11.5	1
514/11	602	514/11.6	7
514/2	2369	514/11.9	8
514/9	340	514/15.2	1
514/7	64	514/16.4	2
514/12	2747	514/16.7	15
514/2	2369	514/16.7	13
514/16	263	514/16.8	1
514/18	732	514/18.5	2
514/13	322	514/18.9	1
514/11	602	514/19.2	2
514/12	2747	514/20.1	27
514/17	311	514/20.4	2
		514/21.5	1
514/19	605	514/21.9	4

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/21.92	8
		514/1.2	36
514/18	732	514/1.6	1
514/4	99	514/2.3	1
514/21	546	514/2.4	13
514/15	444	514/4.8	2
514/12	2747	514/7.9	11
514/17	311	514/8.9	2
514/3	267	514/10.1	1
514/8	597	514/11.4	1
514/17	311	514/11.6	1
514/2	2369	514/12.8	1
514/13	322	514/13.3	1
514/2	2369	514/14.1	3
514/13	322	514/14.3	1
514/9	340	514/14.6	2
514/2	2369	514/16.3	2
514/12	2747	514/16.6	3
514/9	340	514/16.6	1
514/12	2747	514/17.3	1
514/15	444	514/17.5	1
514/18	732	514/17.7	22
514/15	444	514/18.1	2
514/21	546	514/18.2	1
514/6	223	514/18.6	1
514/19	605	514/18.7	1
514/9	340	514/19.2	1
		514/20.4	1
514/16	263	514/21.4	1
514/17	311	514/21.8	15
514/11	602	514/1.2	2
514/8	597	514/2.2	1
514/6	223	514/2.4	5
514/7	64	514/2.4	8
514/8	597	514/2.6	2
514/19	605	514/2.7	2
514/6	223	514/3.7	1
514/12	2747	514/5.4	3
514/4	99	514/6.5	47
514/14	230	514/6.5	1
514/3	267	514/6.5	30
514/11	602	514/8.8	1
514/16	263	514/9.7	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/19	605	514/11.3	7
514/14	230	514/11.3	3
514/13	322	514/12.4	3
514/2	2369	514/14.6	5
514/18	732	514/15.1	6
514/10	70	514/15.7	2
514/7	64	514/16.7	1
514/2	2369	514/21.1	8
514/12	2747	514/21.2	66
514/8	597	514/16.7	1
514/3	267	514/1.1	1
514/2	2369	514/17.2	1
514/18	732	514/19.3	2
514/2	2369	514/20.6	2
514/16	263	514/1.1	10
514/17	311	514/1.1	13
514/2	2369	514/3.4	1
		514/9.7	1
514/8	597	514/3.1	1
514/3	267	514/5.8	1
514/2	2369	514/11.9	2
514/12	2747	514/19.3	2
514/14	230	514/20.6	2
514/2	2369	514/1.5	1
		514/20.9	1
514/3	267	514/5.9	1
514/12	2747	514/9.1	6
514/7	64	514/42	1
514/11	602	530/320	1
		424/451	11
514/6	223	424/445	1
514/21	546	424/484	4
514/12	2747	530/350	12
514/21	546	424/489	5
		424/433	2
514/12	2747	424/1.49	1
		604/5.02	1
514/15	444	424/449	1
514/5	14	424/520	1
514/21	546	424/780	6
514/6	223	424/94.4	7
514/3	267	424/85.4	1
514/21	546	424/131.1	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/19	605	424/486	1
514/18	732	435/13	1
514/2	2369	424/78.37	1
514/12	2747	530/300	2
514/2	2369	424/234.1	1
514/12	2747	435/4	1
514/2	2369	424/155.1	1
514/21	546	424/158.1	1
514/18	732	530/331	6
514/12	2747	424/94.5	4
514/14	230	424/780	2
514/2	2369	435/69.1	4
514/13	322	424/445	1
514/12	2747	530/380	1
514/21	546	530/364	1
514/8	597	530/322	3
514/7	64	424/94.64	1
514/21	546	514/23	1
514/2	2369	424/486	1
		604/892.1	1
		424/780	17
514/12	2747	424/185.1	23
		530/324	20
514/21	546	424/485	1
514/17	311	530/330	2
514/6	223	424/485	1
514/2	2369	424/94.2	3
514/12	2747	530/308	1
514/11	602	424/185.1	2
514/9	340	424/115	3
514/21	546	424/442	2
514/12	2747	424/153.1	1
		424/499	6
514/21	546	530/356	1
		424/184.1	1
514/19	605	548/300.1	2
514/2	2369	604/5.01	1
514/12	2747	424/141.1	2
514/2	2369	424/139.1	1
514/9	340	424/134.1	1
514/8	597	435/68.1	1
514/21	546	424/535	4
514/3	267	424/529	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/11	602	424/464	1
514/12	2747	424/484	9
514/15	444	424/497	1
514/12	2747	424/192.1	1
514/6	223	424/85.2	5
514/2	2369	424/134.1	11
514/12	2747	424/1.65	1
514/21	546	424/729	1
		424/155.1	1
514/11	602	530/311	1
514/21	546	426/130	1
514/11	602	424/457	1
		424/474	1
514/12	2747	604/27	2
514/16	263	424/484	1
514/21	546	435/325	1
514/12	2747	424/130.1	5
514/2	2369	424/45	1
514/12	2747	435/7.1	5
		530/364	1
		424/93.71	1
514/3	267	514/1.2	4
514/13	322	514/1.9	8
514/12	2747	514/2.7	8
514/11	602	514/3.8	6
514/17	311	514/4.4	1
514/7	64	514/5.5	3
514/13	322	514/7.9	1
514/11	602	514/8.4	2
514/3	267	514/8.7	1
514/16	263	514/11.1	5
514/8	597	514/13.5	5
514/2	2369	514/15.1	6
514/15	444	514/15.4	2
514/19	605	514/17.2	1
514/11	602	514/17.5	2
514/16	263	514/18.3	8
514/2	2369	514/19.3	45
514/16	263	514/19.7	4
514/10	70	514/20.1	1
514/19	605	514/20.3	1
514/12	2747	514/2.2	11
514/2	2369	514/2.3	19

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/8	597	514/3.7	17
514/19	605	514/4.3	2
514/12	2747	514/4.4	4
514/3	267	514/6.2	21
		514/7.3	1
514/13	322	514/7.5	2
514/21	546	514/7.6	13
514/2	2369	514/7.8	2
514/21	546	514/8.5	4
514/14	230	514/14.9	1
514/19	605	514/15.5	1
514/2	2369	514/17.2	19
514/14	230	514/19.2	3
514/9	340	514/19.4	3
514/11	602	514/19.6	1
514/2	2369	514/20.8	7
514/21	546	514/20.8	2
514/2	2369	514/21.7	2
		514/1.9	17
514/9	340	514/2.9	25
514/13	322	514/6.5	1
514/12	2747	514/6.7	2
514/21	546	514/7.9	1
514/8	597	514/8.4	1
514/4	99	514/13.3	1
514/2	2369	514/14.3	10
514/6	223	514/15.3	5
		514/15.4	1
514/2	2369	514/16.1	1
514/15	444	514/16.3	2
514/9	340	514/17.5	1
514/14	230	514/17.7	3
514/2	2369	514/17.9	7
514/18	732	514/18.1	2
514/19	605	514/18.4	3
514/2	2369	514/19.5	7
514/17	311	514/21.6	1
514/16	263	514/2.4	6
514/2	2369	514/2.6	2
514/12	2747	514/4.3	5
514/2	2369	514/4.8	27
514/13	322	514/5.9	3
514/4	99	514/6.3	5

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/7.5	13
514/17	311	514/9.3	2
514/12	2747	514/9.4	18
		514/11.1	8
514/11	602	514/11.9	7
514/19	605	514/13.8	1
		514/14.3	2
514/18	732	514/14.9	25
514/13	322	514/16.1	2
514/9	340	514/16.4	2
514/13	322	514/19.3	4
514/17	311	514/20.1	6
514/3	267	514/21.2	1
514/2	2369	514/21.5	4
514/17	311	514/1.4	2
514/16	263	514/1.9	1
514/9	340	514/4.2	1
514/6	223	514/5.5	9
514/2	2369	514/6.9	28
514/8	597	514/7.7	41
514/6	223	514/7.7	1
		514/13.3	1
514/8	597	514/13.3	4
514/18	732	514/13.5	2
514/12	2747	514/14.9	40
514/13	322	514/15.5	2
514/19	605	514/16.3	10
514/13	322	514/16.4	2
514/14	230	514/16.5	1
514/21	546	514/17.1	2
514/8	597	514/19.1	6
514/2	2369	514/21.2	37
514/13	322	514/21.3	1
514/12	2747	514/1.1	285
514/4	99	514/1.2	1
514/14	230	514/2.3	4
514/8	597	514/8.1	2
514/13	322	514/9.8	1
		514/13.6	3
514/21	546	514/15.4	2
514/11	602	514/18.7	2
514/6	223	514/18.8	1
514/15	444	514/18.9	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	514/20.9	1
514/12	2747	514/21.92	3
514/9	340	514/3.4	8
514/21	546	514/4.4	1
		514/8.9	6
514/20	40	514/11.1	1
514/11	602	514/12.3	2
514/12	2747	514/14.2	3
514/13	322	514/17.3	4
514/16	263	514/18.7	1
514/4	99	514/19.1	1
514/17	311	514/19.4	2
514/19	605	514/19.5	1
514/2	2369	514/20.9	8
514/11	602	514/21.4	1
514/14	230	514/1.2	4
514/10	70	514/1.5	1
514/3	267	514/1.7	1
514/21	546	514/4.8	6
514/13	322	514/5.2	1
514/18	732	514/6.5	2
514/12	2747	514/6.9	51
514/18	732	514/7.5	3
514/21	546	514/9.1	3
514/12	2747	514/9.9	14
514/14	230	514/10.1	3
514/15	444	514/10.9	4
514/9	340	514/11.8	1
514/12	2747	514/14.6	2
514/17	311	514/15.7	6
514/18	732	514/17.2	6
514/2	2369	514/17.6	1
514/20	40	514/17.7	1
514/2	2369	514/18.4	1
514/14	230	514/19.3	1
514/12	2747	514/17.2	1
		514/19.4	1
514/8	597	514/21.92	1
514/2	2369	514/14.3	1
514/9	340	514/1.1	7
514/18	732	514/7.6	1
514/15	444	514/12.6	1
514/17	311	514/21.2	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	514/21.3	1
514/11	602	514/13.4	1
514/7	64	514/3.1	1
514/19	605	514/1.1	29
514/12	2747	514/4.5	1
514/2	2369	514/13.5	2
514/15	444	514/21.6	2
514/19	605	514/21.7	1
514/16	263	514/9.7	1
514/21	546	424/451	2
514/2	2369	424/133.1	2
514/8	597	530/350	1
514/11	602	424/43	2
514/2	2369	424/439	1
514/18	732	424/130.1	1
514/9	340	424/461	1
		424/195.17	1
514/12	2747	424/85.4	9
514/21	546	424/499	1
514/12	2747	424/94.61	7
		424/94.3	1
514/17	311	424/1.65	1
514/2	2369	424/279.1	1
514/12	2747	424/1.11	2
514/2	2369	424/130.1	4
		514/44 R	2
514/11	602	424/94.64	2
514/12	2747	424/463	1
		424/94.6	2
514/8	597	424/85.4	1
514/11	602	530/317	2
514/2	2369	424/195.11	1
		424/9.34	1
514/9	340	568/374	1
514/2	2369	424/217.1	1
		424/426	2
514/19	605	514/478	1
514/2	2369	424/450	4
514/12	2747	530/383	2
514/6	223	424/499	1
514/8	597	424/433	1
514/3	267	424/780	1
514/21	546	424/400	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	424/184.1	2
514/18	732	424/442	1
514/2	2369	530/300	4
514/12	2747	424/198.1	1
514/16	263	424/1.69	1
514/2	2369	424/428	3
		424/94.5	2
514/21	546	424/94.62	1
		424/185.1	3
514/18	732	564/123	3
514/12	2747	424/422	14
		424/489	15
514/2	2369	424/143.1	2
514/9	340	424/499	1
514/19	605	514/600	1
514/12	2747	604/20	1
514/2	2369	128/844	1
514/8	597	514/183	1
514/2	2369	514/201	1
514/7	64	564/152	1
514/8	597	424/85.2	4
514/6	223	514/185	1
514/14	230	530/300	1
514/2	2369	424/197.11	1
		424/604	1
514/12	2747	424/430	2
514/8	597	424/431	1
514/15	444	424/433	1
514/16	263	604/890.1	1
514/2	2369	435/71.3	1
		530/324	1
514/12	2747	424/450	16
514/6	223	424/450	2
514/2	2369	424/85.2	38
514/19	605	424/85.2	1
514/21	546	604/19	1
514/12	2747	424/10.1	5
		433/167	1
514/6	223	426/326	2
514/17	311	424/1.69	1
514/12	2747	424/497	1
514/8	597	424/445	1
514/2	2369	424/145.1	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/21	546	514/1.2	2
514/19	605	514/1.4	7
514/12	2747	514/1.8	1
514/9	340	514/2.1	1
514/13	322	514/3.2	4
514/7	64	514/3.4	1
514/12	2747	514/8.3	37
514/11	602	514/8.3	3
514/17	311	514/9.7	3
514/16	263	514/10.1	2
514/17	311	514/10.3	1
		514/11.2	2
514/21	546	514/13.3	6
514/20	40	514/14.7	3
514/16	263	514/17.5	6
514/15	444	514/17.9	4
514/10	70	514/19.3	6
514/6	223	514/20.1	1
514/8	597	514/20.8	5
514/2	2369	514/1.4	6
514/19	605	514/3.3	4
514/2	2369	514/3.8	33
		514/5.2	1
514/13	322	514/5.4	3
514/16	263	514/5.8	1
514/14	230	514/7.4	1
514/6	223	514/7.9	2
514/9	340	514/10.1	3
514/5	14	514/11.7	1
514/3	267	514/11.7	1
514/13	322	514/12.1	1
514/21	546	514/12.2	1
514/2	2369	514/13.2	6
514/18	732	514/14.4	1
514/6	223	514/14.8	1
514/11	602	514/18.2	1
514/19	605	514/18.5	2
514/18	732	514/18.6	4
514/17	311	514/18.6	6
514/16	263	514/18.9	1
514/12	2747	514/19.4	8
514/15	444	514/20.1	1
514/20	40	514/20.1	16

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/9	340	514/20.5	18
514/13	322	514/1.2	5
514/9	340	514/1.4	1
514/18	732	514/1.8	3
514/11	602	514/2.9	12
514/9	340	514/3.1	3
514/2	2369	514/3.4	3
514/11	602	514/3.6	1
514/17	311	514/4.1	1
514/19	605	514/4.8	2
514/5	14	514/4.8	1
514/9	340	514/5.9	2
514/3	267	514/6.8	2
514/8	597	514/8.9	3
514/11	602	514/9.3	9
514/16	263	514/9.4	12
514/2	2369	514/10.7	5
514/17	311	514/13.3	2
514/15	444	514/15.7	7
514/18	732	514/16.4	2
514/9	340	514/17.8	2
514/15	444	514/18.3	10
514/11	602	514/18.4	1
514/21	546	514/20.7	3
514/15	444	514/21.4	2
514/2	2369	514/21.6	1
514/19	605	514/21.91	20
514/20	40	514/1.2	1
514/12	2747	514/2.3	18
514/13	322	514/3.3	5
		514/4.3	2
514/19	605	514/5.3	1
514/13	322	514/5.5	1
514/3	267	514/6.3	29
514/18	732	514/7.6	2
		514/10.8	2
514/8	597	514/11.3	2
514/19	605	514/13.9	1
514/15	444	514/16.7	2
514/12	2747	514/17.5	1
514/18	732	514/17.8	4
514/14	230	514/18.6	1
514/16	263	514/19.2	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/1.1	362
514/9	340	514/1.7	2
514/2	2369	514/1.8	4
514/6	223	514/2.3	3
514/18	732	514/4.2	9
514/15	444	514/8.5	2
514/12	2747	514/8.9	35
514/2	2369	514/9.4	23
514/15	444	514/10.2	3
514/6	223	514/10.8	4
514/10	70	514/10.9	1
514/12	2747	514/13.4	2
514/15	444	514/13.7	7
514/17	311	514/14.6	1
514/14	230	514/14.8	1
514/12	2747	514/15.1	4
514/18	732	514/15.4	8
514/8	597	514/16.4	1
514/15	444	514/16.4	4
514/14	230	514/16.4	1
514/12	2747	514/16.5	2
514/19	605	514/16.5	2
514/12	2747	514/17.7	9
514/17	311	514/17.8	5
514/14	230	514/17.8	8
514/2	2369	514/18.6	10
514/17	311	514/20.8	1
514/8	597	514/21.3	1
514/2	2369	514/21.9	6
514/11	602	514/1.1	37
514/17	311	514/2.3	2
514/12	2747	514/2.4	99
514/14	230	514/2.4	9
514/2	2369	514/3.2	2
514/18	732	514/3.3	1
514/12	2747	514/3.4	2
514/2	2369	514/4.1	2
514/11	602	514/5.5	4
514/4	99	514/5.9	7
514/3	267	514/7.4	1
514/16	263	514/7.7	2
514/12	2747	514/8.7	1
514/17	311	514/9.4	5

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/9	340	514/9.9	1
514/21	546	514/10.2	4
514/14	230	514/10.8	1
514/12	2747	514/11.2	37
514/2	2369	514/12.3	1
514/19	605	514/14.7	4
514/18	732	514/18.9	1
		514/19.4	3
514/8	597	514/19.5	2
514/9	340	514/21.1	11
514/8	597	514/21.6	1
514/17	311	514/1.3	4
514/12	2747	514/1.4	11
514/2	2369	514/1.5	2
514/8	597	514/2.5	6
514/2	2369	514/2.9	3
514/9	340	514/4.3	5
514/11	602	514/4.5	4
514/8	597	514/5.4	2
514/7	64	514/7.5	1
514/12	2747	514/10.2	7
514/17	311	514/10.7	1
514/12	2747	514/10.8	38
514/8	597	514/12.2	9
514/15	444	514/13.3	6
514/12	2747	514/13.7	54
514/14	230	514/15.7	3
514/15	444	514/15.8	5
		514/17.6	1
514/18	732	514/18.4	9
514/15	444	514/19.1	6
514/21	546	514/19.4	1
		514/20.1	3
514/11	602	514/20.6	1
514/18	732	514/21.8	1
514/15	444	514/2.3	1
514/2	2369	514/2.7	9
514/13	322	514/6.8	2
514/2	2369	514/7.6	34
514/16	263	514/7.9	1
514/18	732	514/8.2	1
514/21	546	514/8.4	10
514/8	597	514/9.1	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/6	223	514/9.7	1
514/16	263	514/10.8	1
514/11	602	514/11.1	30
514/21	546	514/12.1	2
514/14	230	514/13.7	4
514/18	732	514/14.6	2
514/21	546	514/16.5	2
514/13	322	514/17.9	3
514/11	602	514/18.1	3
514/18	732	514/20.8	7
514/19	605	514/13.5	2
514/16	263	514/19.5	1
514/13	322	514/1.1	1
514/2	2369	514/20.8	1
514/11	602	514/2.9	1
514/12	2747	514/7.6	1
514/2	2369	514/19.4	1
514/14	230	514/21.6	1
514/8	597	514/21.8	1
514/19	605	514/21.91	8
514/3	267	514/6.3	1
514/12	2747	514/19.5	1
514/2	2369	514/1.1	102
514/18	732	514/1.1	18
514/2	2369	514/9.4	2
514/13	322	514/9.4	1
514/16	263	514/10.7	1
514/2	2369	514/18.8	2
514/12	2747	514/1.4	1
514/15	444	514/1.9	2
514/2	2369	514/14.7	1
514/17	311	514/17.5	7
514/12	2747	514/18.6	1
514/17	311	514/21.8	5
514/12	2747	514/21.91	1
514/2	2369	514/8.8	1
514/12	2747	514/9.7	1
514/2	2369	514/17.5	1
514/14	230	424/85.2	1
514/11	602	424/9.1	1
514/3	267	530/303	3
514/21	546	424/450	8
514/9	340	424/145.1	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	424/754	1
514/2	2369	424/10.1	1
514/12	2747	424/433	1
514/9	340	435/7.1	1
		424/780	6
514/6	223	424/400	1
514/2	2369	530/350	8
514/12	2747	424/405	1
514/8	597	435/7.1	1
514/14	230	424/195.11	1
514/18	732	424/85.4	3
514/7	64	424/130.1	1
514/16	263	530/329	1
514/15	444	424/450	2
514/12	2747	424/780	16
514/8	597	514/23	1
514/2	2369	424/185.1	21
514/12	2747	424/145.1	6
514/21	546	424/93.7	1
		424/456	1
514/2	2369	424/94.4	4
		435/6	2
514/20	40	514/44 R	1
514/11	602	424/489	3
514/6	223	424/439	2
514/2	2369	424/718	5
514/12	2747	604/890.1	2
514/11	602	424/47	4
514/6	223	424/85.4	1
514/2	2369	604/5.02	1
514/18	732	514/61	2
514/12	2747	424/134.1	24
		424/457	1
514/2	2369	424/474	1
514/12	2747	424/456	2
514/8	597	435/7.5	1
514/9	340	424/85.4	4
		424/85.2	1
514/21	546	424/464	1
514/19	605	564/123	4
514/12	2747	424/718	8
514/2	2369	424/443	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/19	605	530/333	1
		424/430	1
514/2	2369	435/188	1
514/18	732	424/465	1
514/15	444	424/185.1	1
514/2	2369	530/356	1
514/6	223	514/1.2	3
514/8	597	514/1.6	3
514/17	311	514/4.8	4
514/21	546	514/5.4	1
514/2	2369	514/6.5	2
514/3	267	514/6.7	5
514/17	311	514/8.2	1
514/14	230	514/8.4	1
514/2	2369	514/8.6	4
514/17	311	514/9.1	1
514/11	602	514/9.4	1
514/19	605	514/9.7	6
514/9	340	514/11.6	2
514/18	732	514/13.3	2
514/8	597	514/13.7	17
514/18	732	514/16.1	10
514/13	322	514/16.6	3
514/16	263	514/16.7	2
		514/17.8	4
514/7	64	514/18.3	1
514/17	311	514/18.4	2
514/2	2369	514/18.4	4
514/13	322	514/1.1	37
514/18	732	514/1.2	1
514/19	605	514/1.9	8
514/2	2369	514/2.2	2
514/18	732	514/2.4	16
514/15	444	514/4.5	1
514/9	340	514/4.5	2
514/14	230	514/9.4	3
514/12	2747	514/10.3	4
514/2	2369	514/13.4	7
514/20	40	514/13.7	4
514/18	732	514/13.8	1
514/9	340	514/14.1	1
514/19	605	514/14.4	1
514/21	546	514/15.3	6

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/10	70	514/15.6	1
514/16	263	514/16.4	1
514/15	444	514/16.9	1
514/19	605	514/19.4	3
514/9	340	514/19.5	1
514/2	2369	514/20.1	7
514/18	732	514/20.4	18
514/19	605	514/1.5	8
514/18	732	514/1.7	3
514/7	64	514/2.7	2
		514/4.5	1
514/2	2369	514/5.9	15
514/11	602	514/7.5	1
514/16	263	514/7.6	3
514/18	732	514/9.4	5
514/15	444	514/9.4	1
514/19	605	514/13.2	3
514/13	322	514/13.2	1
514/11	602	514/14.6	1
514/16	263	514/15.4	3
		514/16.5	1
514/14	230	514/16.6	1
514/21	546	514/17.7	2
514/18	732	514/20.1	13
514/13	322	514/2.1	4
514/7	64	514/2.6	1
514/9	340	514/2.6	7
514/12	2747	514/2.8	4
514/15	444	514/3.3	1
514/16	263	514/6.9	7
514/14	230	514/8.2	1
514/13	322	514/8.3	4
514/18	732	514/9.8	3
514/2	2369	514/11.8	7
514/12	2747	514/13.3	30
514/21	546	514/13.5	4
514/9	340	514/13.7	3
514/8	597	514/13.9	1
		514/14.4	1
514/11	602	514/15.1	1
514/16	263	514/15.6	6
514/18	732	514/15.8	39
514/12	2747	514/16.4	10

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	514/17.2	1
514/12	2747	514/17.9	3
514/17	311	514/21.2	2
514/4	99	514/1.3	1
514/11	602	514/1.9	3
514/12	2747	514/2.1	7
514/8	597	514/3.1	15
514/21	546	514/3.7	15
514/12	2747	514/7.2	5
514/2	2369	514/9.1	19
514/8	597	514/9.4	11
514/14	230	514/10.3	1
514/3	267	514/10.5	1
514/20	40	514/13.3	1
514/9	340	514/13.3	6
514/12	2747	514/15.3	3
514/2	2369	514/15.3	4
		514/15.4	16
514/13	322	514/16.5	1
514/16	263	514/19.4	2
514/11	602	514/1.3	3
514/15	444	514/1.3	1
514/21	546	514/1.4	3
514/6	223	514/2.8	1
514/7	64	514/2.9	1
514/14	230	514/6.9	1
514/5	14	514/7.4	1
514/4	99	514/8.4	1
514/13	322	514/9.1	2
514/15	444	514/9.7	9
514/13	322	514/10.7	1
514/12	2747	514/12.2	4
514/9	340	514/12.4	1
		514/13.9	1
514/21	546	514/14.3	3
514/19	605	514/15.9	7
514/6	223	514/17.2	2
514/13	322	514/17.7	1
514/9	340	514/18.7	3
514/10	70	514/20.7	1
514/12	2747	514/1.3	7
514/13	322	514/1.5	2
514/8	597	514/1.7	4

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/9	340	514/3.8	2
514/8	597	514/9.2	1
514/12	2747	514/9.8	9
514/21	546	514/11.3	8
		514/12.6	1
514/12	2747	514/13.2	6
514/17	311	514/13.5	1
514/2	2369	514/13.5	19
514/13	322	514/15.1	5
514/21	546	514/16.4	5
514/19	605	514/16.6	2
514/13	322	514/18.4	4
514/18	732	514/18.8	4
514/10	70	514/19.2	1
514/11	602	514/19.3	14
514/12	2747	514/20.7	1
514/7	64	514/21.4	1
514/15	444	514/21.6	16
514/19	605	514/1.2	4
514/14	230	514/3.3	3
514/2	2369	514/6.7	3
514/8	597	514/7.6	7
514/11	602	514/8.2	1
514/21	546	514/8.8	2
514/13	322	514/8.9	2
514/12	2747	514/9.7	84
514/14	230	514/10.7	4
514/12	2747	514/10.9	1
514/16	263	514/11.2	1
514/21	546	514/13.7	19
514/13	322	514/15.7	3
514/12	2747	514/16.9	9
514/8	597	514/17.1	2
514/2	2369	514/17.5	8
514/9	340	514/18.1	2
514/13	322	514/18.8	1
514/15	444	514/19.7	7
514/8	597	514/21.2	2
		514/21.91	1
514/4	99	514/1.1	1
514/2	2369	514/4.9	1
514/17	311	514/21.91	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/1.3	2
		514/1.4	3
514/19	605	514/2.3	1
514/15	444	514/2.4	1
514/2	2369	514/2.8	1
514/12	2747	514/12.9	1
514/2	2369	514/20.1	1
514/11	602	514/4.3	5
514/18	732	514/18.3	1
		514/21.9	10
514/12	2747	514/9.4	1
514/21	546	514/12.9	1
514/16	263	514/16.3	1
514/8	597	514/20.9	7
514/12	2747	514/1.1	45
		514/1.9	1
514/2	2369	514/18.5	1
		514/5.5	2
514/11	602	514/7.1	4
		514/15.7	1
514/3	267	514/6.5	1
514/12	2747	514/6.9	3
514/14	230	514/21.5	2
514/12	2747	424/94.66	1
514/21	546	530/417	1
514/12	2747	424/485	1
		424/443	5
514/14	230	514/602	1
514/16	263	424/165.1	1
514/18	732	436/86	1
514/21	546	604/891.1	1
514/19	605	514/255.02	1
514/15	444	514/150	1
514/6	223	424/195.16	1
514/10	70	424/484	1
514/12	2747	424/93.6	1
514/8	597	530/351	2
		424/423	1
514/12	2747	424/606	1
514/13	322	530/324	1
514/12	2747	424/9.52	1
514/18	732	424/139.1	1
514/2	2369	424/457	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/21	546	604/307	1
514/8	597	424/278.1	9
514/3	267	514/23	1
514/13	322	424/237.1	1
514/21	546	530/344	2
514/9	340	514/317	1
514/2	2369	424/1.69	10
514/6	223	424/184.1	1
514/2	2369	424/93.6	2
514/14	230	424/1.49	1
514/12	2747	424/197.11	1
514/2	2369	424/1.49	1
514/11	602	424/278.1	2
514/9	340	530/329	1
514/2	2369	530/329	1
514/8	597	424/279.1	6
514/12	2747	526/258	1
		424/429	1
514/2	2369	424/158.1	1
514/17	311	424/139.1	1
514/12	2747	530/344	1
514/2	2369	424/94.1	4
514/16	263	530/328	4
514/21	546	424/139.1	1
514/9	340	424/278.1	3
514/13	322	424/278.1	2
514/7	64	514/45	1
514/21	546	424/9.1	1
514/6	223	530/345	1
514/13	322	424/184.1	1
514/6	223	424/94.3	1
514/11	602	530/315	1
514/15	444	424/85.1	1
514/6	223	424/718	9
514/4	99	514/150	2
514/19	605	424/451	1
514/9	340	324/307	1
514/2	2369	424/94.67	2
		530/317	3
514/12	2747	424/178.1	3
514/2	2369	530/331	1
514/15	444	530/328	1
514/2	2369	424/529	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	424/94.4	5
514/21	546	424/1.65	1
514/3	267	424/489	2
514/19	605	424/278.1	2
514/12	2747	424/193.1	1
514/21	546	424/718	1
514/16	263	424/85.2	2
514/2	2369	424/422	1
514/17	311	424/184.1	1
514/15	444	424/85.2	1
514/21	546	424/94.4	8
514/17	311	424/457	1
514/8	597	424/141.1	1
514/10	70	424/85.2	1
514/6	223	514/1.3	1
514/13	322	514/2.6	3
514/14	230	514/2.7	6
514/19	605	514/2.8	1
514/14	230	514/4.5	2
514/21	546	514/5.8	2
514/4	99	514/6.9	2
514/13	322	514/7.3	4
514/21	546	514/7.4	8
514/13	322	514/8.1	1
514/9	340	514/10.7	1
514/15	444	514/11.3	1
514/8	597	514/14.7	1
514/19	605	514/15.1	4
514/8	597	514/16.7	5
514/10	70	514/16.7	1
514/12	2747	514/17.4	13
514/18	732	514/20.3	1
514/2	2369	514/1.3	18
514/16	263	514/1.3	2
514/6	223	514/1.4	4
514/10	70	514/2.4	5
514/15	444	514/2.4	11
514/21	546	514/2.7	1
514/8	597	514/3.3	9
514/16	263	514/3.8	4
514/2	2369	514/4.4	2
		514/5.8	6
514/11	602	514/6.5	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/15	444	514/7.4	3
514/18	732	514/8.9	3
514/2	2369	514/9.3	11
514/13	322	514/9.7	10
514/8	597	514/14.9	8
514/12	2747	514/17.2	5
514/2	2369	514/18.2	3
514/17	311	514/18.8	2
514/6	223	514/18.9	1
514/8	597	514/20.2	1
		514/20.6	1
514/18	732	514/20.7	3
514/12	2747	514/20.8	4
514/17	311	514/1.1	25
514/18	732	514/1.3	25
514/17	311	514/1.9	5
514/11	602	514/2.2	1
514/5	14	514/2.4	1
514/13	322	514/2.8	2
514/9	340	514/3.5	2
514/18	732	514/4.3	7
514/17	311	514/5.5	1
514/2	2369	514/6.8	3
514/7	64	514/6.8	1
514/9	340	514/8.1	1
514/7	64	514/8.4	1
514/12	2747	514/9.5	1
514/2	2369	514/10.6	1
514/17	311	514/11.3	12
514/13	322	514/11.4	1
514/12	2747	514/11.4	2
514/21	546	514/11.5	1
514/11	602	514/11.8	3
514/12	2747	514/11.9	19
514/17	311	514/12.2	2
514/2	2369	514/12.2	24
514/14	230	514/18.4	2
514/21	546	514/18.9	2
514/18	732	514/19.5	1
514/2	2369	514/20.7	7
514/16	263	514/1.2	2
514/12	2747	514/6.5	1
514/9	340	514/7.4	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/3	267	514/7.7	1
514/21	546	514/9.8	4
514/16	263	514/9.9	1
514/10	70	514/10.8	1
514/13	322	514/10.8	5
514/16	263	514/10.9	3
514/11	602	514/13.2	2
514/21	546	514/14.2	1
514/18	732	514/16.3	1
		514/16.7	3
514/17	311	514/16.7	1
514/2	2369	514/16.8	7
514/19	605	514/18.2	1
514/14	230	514/19.1	4
514/15	444	514/19.3	11
514/12	2747	514/20.2	4
514/8	597	514/20.9	18
514/2	2369	514/21.91	3
514/9	340	514/1.2	2
514/8	597	514/2.8	1
514/2	2369	514/4.2	1
514/3	267	514/6.1	22
514/12	2747	514/8.5	68
514/13	322	514/9.4	6
514/21	546	514/9.9	2
514/11	602	514/10.1	3
514/6	223	514/10.7	1
514/18	732	514/11.3	4
514/15	444	514/14.8	1
514/20	40	514/14.9	4
514/4	99	514/15.2	1
514/11	602	514/16.4	1
514/19	605	514/16.9	2
514/21	546	514/19.1	2
514/17	311	514/19.2	2
514/13	322	514/1.3	2
514/12	2747	514/1.9	23
514/6	223	514/2.1	1
514/13	322	514/2.4	10
514/2	2369	514/2.5	1
514/11	602	514/2.7	2
514/18	732	514/5.3	1
514/9	340	514/5.5	3

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/3	267	514/6.4	19
514/12	2747	514/7.3	1
		514/11.6	2
514/8	597	514/14.8	1
514/17	311	514/14.9	2
514/2	2369	514/18.1	4
514/14	230	514/18.3	3
514/10	70	514/18.8	1
		514/21.1	4
514/8	597	514/1.1	29
		514/1.3	6
514/9	340	514/1.3	2
514/11	602	514/2.3	7
514/8	597	514/3.2	1
514/14	230	514/3.7	3
514/19	605	514/5.5	9
514/10	70	514/5.9	2
514/12	2747	514/6.8	16
514/11	602	514/7.1	3
514/15	444	514/7.6	1
514/13	322	514/7.8	5
514/15	444	514/7.9	4
514/17	311	514/8.1	1
514/21	546	514/8.2	6
514/2	2369	514/8.4	23
514/3	267	514/8.6	8
514/11	602	514/11.3	4
514/2	2369	514/12.6	1
		514/13.6	11
514/15	444	514/16.6	1
514/13	322	514/17.6	1
514/19	605	514/17.7	19
514/9	340	514/18.4	1
514/14	230	514/18.7	1
514/9	340	514/18.9	1
514/21	546	514/19.2	3
514/11	602	514/20.8	1
514/10	70	514/20.8	1
514/15	444	514/21.8	1
514/7	64	514/1.1	4
514/18	732	514/2.3	5
514/17	311	514/3.3	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/3.9	1
		514/4.7	1
514/14	230	514/5.1	4
514/3	267	514/5.9	43
514/9	340	514/7.1	1
514/2	2369	514/8.2	6
514/17	311	514/8.8	1
514/10	70	514/9.1	1
514/2	2369	514/9.8	10
514/19	605	514/9.8	1
514/17	311	514/12.9	1
514/11	602	514/13.3	4
514/2	2369	514/13.3	31
		514/13.7	41
514/21	546	514/14.9	2
514/16	263	514/17.7	7
514/14	230	514/17.9	5
514/19	605	514/18.1	4
514/12	2747	514/8.8	3
514/5	14	514/1.1	1
514/2	2369	514/7.3	1
514/11	602	514/21.1	3
514/20	40	514/1.1	2
514/2	2369	514/4.8	1
514/15	444	514/3.6	1
514/21	546	514/6.8	1
514/12	2747	514/8.5	1
		514/17.7	1
514/2	2369	514/21.9	2
514/20	40	514/21.91	1
514/11	602	514/1.1	7
514/21	546	514/1.4	1
514/12	2747	514/16.7	1
		514/20.1	2
514/10	70	514/1.1	2
514/3	267	514/8.6	1
514/12	2747	514/13.2	1
		514/13.5	1
514/21	546	514/15.2	3
514/2	2369	514/7.6	4
514/18	732	424/279.1	1
514/10	70	424/780	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/3	267	424/456	1
		424/85.2	5
514/21	546	424/488	3
		435/7.92	1
514/2	2369	424/489	3
514/3	267	424/439	1
514/13	322	424/85.1	1
514/14	230	530/327	2
514/11	602	424/10.2	5
514/19	605	525/54.1	1
514/12	2747	424/93.7	1
514/6	223	530/385	1
514/2	2369	424/9.1	1
514/6	223	435/7.1	1
514/12	2747	424/139.1	4
		424/85.2	22
514/8	597	424/48	2
514/2	2369	424/94.61	4
514/12	2747	424/486	5
514/19	605	514/506	2
514/12	2747	424/94.65	2
514/11	602	514/317	1
514/10	70	530/322	2
514/14	230	514/400	1
514/15	444	424/141.1	1
514/12	2747	604/4.01	2
514/2	2369	530/395	1
514/12	2747	604/892.1	2
514/8	597	424/94.64	1
514/10	70	424/94.4	1
514/13	322	530/317	1
		435/6	1
514/21	546	424/130.1	4
514/19	605	424/479	1
514/12	2747	424/427	4
514/21	546	530/363	1
514/12	2747	530/379	1
514/8	597	530/300	1
514/18	732	424/408	1
514/3	267	424/133.1	2
514/4	99	424/487	1
514/2	2369	424/282.1	1
514/21	546	530/382	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	424/278.1	5
514/12	2747	424/164.1	1
514/2	2369	527/207	1
		435/7.1	3
514/9	340	424/141.1	1
514/2	2369	424/656	1
514/19	605	530/300	2
514/12	2747	424/279.1	1
514/2	2369	424/123	1
514/21	546	424/445	4
514/3	267	424/487	2
		424/94.61	1
514/11	602	424/718	1
514/8	597	424/133.1	1
514/12	2747	530/323	1
514/2	2369	435/14	1
514/6	223	424/85.1	1
514/2	2369	424/488	1
514/11	602	424/450	5
514/13	322	530/326	4
514/8	597	424/450	1
514/9	340	424/1.69	5
514/12	2747	424/133.1	2
514/2	2369	424/141.1	2
514/14	230	514/1.7	1
514/21	546	514/1.9	4
514/10	70	514/2.9	6
514/8	597	514/3.9	1
514/16	263	514/4.8	5
514/13	322	514/4.8	2
514/3	267	514/4.9	1
514/11	602	514/7.6	1
514/6	223	514/7.6	2
514/21	546	514/9.3	2
		514/9.4	7
514/13	322	514/11.3	1
514/14	230	514/13.3	1
514/12	2747	514/15.4	5
514/18	732	514/15.7	29
514/16	263	514/15.7	8
514/2	2369	514/16.4	4
514/16	263	514/18.4	2
514/11	602	514/18.6	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/19	605	514/18.8	1
514/10	70	514/18.9	2
514/13	322	514/19.1	2
514/14	230	514/19.3	4
514/18	732	514/20.2	6
514/13	322	514/20.6	2
514/3	267	514/1.1	30
514/9	340	514/1.6	2
514/19	605	514/1.7	17
514/2	2369	514/2.1	9
514/8	597	514/2.9	18
514/17	311	514/4.2	2
514/2	2369	514/7.4	23
514/14	230	514/7.8	1
514/3	267	514/8.5	1
514/12	2747	514/9.3	12
514/8	597	514/9.3	9
		514/9.9	10
514/12	2747	514/11.3	57
514/16	263	514/13.3	5
514/13	322	514/15.4	4
514/7	64	514/16.3	1
514/17	311	514/16.6	1
514/11	602	514/16.6	1
514/7	64	514/16.9	3
514/9	340	514/17.4	3
514/17	311	514/17.7	9
		514/19.1	4
514/13	322	514/20.2	1
514/8	597	514/21.92	5
514/16	263	514/1.1	18
514/8	597	514/1.4	3
514/9	340	514/1.9	5
514/4	99	514/2.4	1
514/14	230	514/3.8	5
514/8	597	514/4.1	2
514/10	70	514/4.4	2
		514/7.4	1
514/2	2369	514/7.7	20
514/8	597	514/8.2	3
514/15	444	514/9.9	21
514/8	597	514/10.1	4
514/18	732	514/10.7	4

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/16	263	514/11.3	5
514/18	732	514/11.5	1
514/16	263	514/11.8	1
514/13	322	514/11.9	1
514/19	605	514/13.3	6
514/6	223	514/13.4	65
514/17	311	514/13.6	1
514/18	732	514/16.5	2
514/15	444	514/16.8	1
514/19	605	514/20.4	5
514/8	597	514/20.4	1
514/18	732	514/20.6	2
514/19	605	514/20.9	1
514/12	2747	514/1.7	9
514/16	263	514/2.9	1
514/11	602	514/3.7	4
514/13	322	514/3.7	7
514/8	597	514/4.2	1
514/2	2369	514/4.3	1
514/12	2747	514/4.6	1
514/18	732	514/4.8	8
514/3	267	514/5.3	1
514/14	230	514/7.5	2
514/12	2747	514/8.6	3
514/15	444	514/12.2	11
514/19	605	514/12.3	2
514/9	340	514/13.2	2
514/6	223	514/13.5	3
514/21	546	514/13.6	15
514/11	602	514/15.4	9
514/18	732	514/15.6	6
514/8	597	514/15.7	2
514/11	602	514/16.8	1
514/21	546	514/17.8	1
514/11	602	514/18.3	4
514/6	223	514/18.7	1
514/8	597	514/18.9	3
514/2	2369	514/19.6	1
514/8	597	514/20.3	1
		514/1.9	1
514/9	340	514/2.8	4
514/16	263	514/3.7	3
514/19	605	514/3.7	9

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/11	602	514/4.4	2
514/21	546	514/6.8	2
514/9	340	514/8.3	1
514/8	597	514/11.9	1
514/19	605	514/12.2	10
514/18	732	514/12.6	1
514/11	602	514/13.6	3
514/19	605	514/13.7	22
514/11	602	514/15.6	2
514/19	605	514/16.7	1
514/21	546	514/17.2	13
514/18	732	514/17.5	7
514/15	444	514/17.8	3
514/19	605	514/19.3	19
514/14	230	514/21.4	1
514/9	340	514/2.4	4
514/12	2747	514/2.5	9
514/5	14	514/4.6	1
514/18	732	514/4.9	2
514/6	223	514/5.4	9
514/11	602	514/7.4	2
514/13	322	514/7.4	5
514/10	70	514/11.2	1
514/19	605	514/11.2	1
514/12	2747	514/13.1	1
514/18	732	514/14.7	5
514/7	64	514/15.7	4
514/11	602	514/17.7	7
514/7	64	514/17.8	1
514/18	732	514/18.7	2
514/12	2747	514/18.9	12
514/21	546	514/21.2	4
		514/21.92	11
514/10	70	514/1.4	1
514/21	546	514/3.3	2
514/7	64	514/3.8	3
514/19	605	514/4.1	3
		514/5.1	1
514/13	322	514/5.3	2
514/3	267	514/6.6	4
514/8	597	514/6.9	1
514/18	732	514/7.9	6
514/15	444	514/10.7	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/21	546	514/13.8	2
514/11	602	514/14.9	11
514/16	263	514/15.8	8
514/14	230	514/17.5	1
514/9	340	514/17.9	1
514/12	2747	514/18.6	2
514/17	311	514/19.3	15
514/9	340	514/19.9	2
514/2	2369	514/20.4	3
514/16	263	514/20.8	2
514/19	605	514/20.8	7
514/15	444	514/3.8	4
514/13	322	514/4.9	2
514/10	70	514/5.5	2
514/12	2747	514/5.8	10
		514/8.1	20
		514/9.1	40
		514/9.2	12
514/18	732	514/12.3	6
514/12	2747	514/15.2	5
514/13	322	514/17.4	3
514/9	340	514/17.6	1
514/13	322	514/18.3	3
514/17	311	514/18.3	6
514/19	605	514/20.2	5
514/12	2747	514/20.4	10
514/2	2369	514/21.3	10
514/14	230	514/21.5	9
		514/1.1	9
514/2	2369	514/4.4	1
514/12	2747	514/5.2	1
514/2	2369	514/7.4	2
		514/15.2	2
514/12	2747	514/2.8	1
		514/4.9	1
		514/13.3	1
514/18	732	514/15.5	1
514/16	263	514/15.6	1
514/19	605	514/19.3	2
514/2	2369	514/21.2	3
514/12	2747	514/3.7	2
514/8	597	514/1.1	14
514/2	2369	514/8.4	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	514/13.7	1
		514/16.6	1
514/4	99	514/19.3	1
514/2	2369	514/21.3	1
514/21	546	424/757	2
		424/443	8
514/12	2747	426/133	1
		435/69.1	3
514/19	605	564/80	3
		544/359	1
514/2	2369	604/501	1
		424/237.1	1
		424/94.62	1
514/19	605	424/48	1
514/8	597	424/499	1
514/12	2747	424/439	4
514/2	2369	424/278.1	8
514/12	2747	424/9.1	1
514/17	311	514/613	1
514/14	230	435/7.1	1
514/11	602	530/321	1
514/8	597	424/93.45	1
514/12	2747	530/356	1
		424/93.45	1
514/18	732	530/330	6
514/16	263	530/317	1
514/12	2747	424/464	3
		424/49	3
514/2	2369	424/451	2
514/11	602	424/1.37	1
514/12	2747	424/189.1	1
514/2	2369	424/256.1	1
514/13	322	424/94.64	2
514/2	2369	424/493	1
		530/416	1
514/21	546	530/392	1
514/8	597	424/94.62	1
514/12	2747	424/400	2
514/15	444	424/94.64	2
514/17	311	424/9.3	1
514/2	2369	435/68.1	2
514/21	546	424/447	1
514/11	602	424/94.4	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/8	597	424/408	1
514/12	2747	424/195.11	1
514/20	40	530/416	1
514/12	2747	530/358	1
		424/440	1
514/2	2369	424/93.51	2
		424/94.63	2
514/18	732	424/85.2	5
514/17	311	530/329	1
514/15	444	424/9.1	2
514/8	597	530/317	1
514/15	444	424/130.1	1
514/7	64	424/134.1	1
514/8	597	424/725	1
514/12	2747	424/1.69	20
514/2	2369	424/10.3	1
514/11	602	424/501	1
514/12	2747	514/478	1
514/11	602	424/433	2
514/19	605	424/85.4	1
514/21	546	426/15	1
514/8	597	424/94.4	1
514/21	546	424/94.64	6
514/8	597	514/476	1
514/7	64	424/450	1
514/18	732	424/499	1
514/12	2747	514/44 R	1
514/17	311	514/773	1
514/12	2747	424/9.3	1
514/18	732	424/464	1
514/2	2369	424/131.1	1
		424/445	2
514/9	340	514/348	1
		424/195.15	1
514/21	546	424/422	8
		424/431	1
514/12	2747	436/63	1
514/11	602	424/456	10
514/12	2747	424/533	1
		525/420	1
		424/449	1
		436/501	4
514/3	267	424/85.1	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/14	230	514/1.1	28
514/4	99	514/1.1	3
514/15	444	514/2.7	2
514/2	2369	514/4.6	1
514/17	311	514/6.9	3
514/19	605	514/6.9	5
		514/8.5	1
514/8	597	514/9.7	4
514/18	732	514/9.7	7
514/13	322	514/16.9	2
514/15	444	514/17.2	1
514/18	732	514/17.6	5
514/21	546	514/17.9	1
514/9	340	514/18.6	1
514/12	2747	514/19.1	12
514/6	223	514/20.7	2
514/12	2747	514/2.6	2
514/7	64	514/3.3	2
514/8	597	514/5.9	1
514/13	322	514/6.7	1
514/18	732	514/6.9	7
514/9	340	514/7.3	1
514/18	732	514/7.4	6
514/14	230	514/8.3	2
514/12	2747	514/8.8	37
514/3	267	514/10.9	1
514/14	230	514/11.5	1
514/17	311	514/13.4	1
514/19	605	514/14.9	13
514/8	597	514/15.1	1
514/6	223	514/15.1	3
514/17	311	514/15.8	9
514/11	602	514/16.7	10
514/20	40	514/16.8	1
514/2	2369	514/16.9	4
514/19	605	514/17.8	5
514/18	732	514/19.3	26
514/2	2369	514/20.6	5
514/15	444	514/21.7	1
514/17	311	514/1.2	3
		514/4.3	3
514/9	340	514/4.6	2
514/21	546	514/5.3	2

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/5	14	514/5.4	1
514/15	444	514/6.9	1
514/2	2369	514/7.3	6
514/21	546	514/7.5	1
514/3	267	514/12.5	1
514/12	2747	514/13.6	9
514/13	322	514/14.7	2
514/2	2369	514/15.2	9
514/8	597	514/15.4	2
514/18	732	514/18.3	14
514/15	444	514/19.4	2
514/11	602	514/20.5	53
514/12	2747	514/20.9	5
514/15	444	514/21.5	2
514/18	732	514/21.9	23
514/9	340	514/1.1	37
514/19	605	514/1.3	12
514/13	322	514/1.4	6
514/8	597	514/2.7	6
514/16	263	514/3.3	2
514/15	444	514/3.7	7
514/17	311	514/3.8	5
514/5	14	514/5.3	3
514/19	605	514/5.9	3
514/2	2369	514/6.3	1
514/14	230	514/9.3	3
514/2	2369	514/9.6	1
514/14	230	514/9.8	1
514/12	2747	514/10.1	6
514/18	732	514/12.2	14
514/8	597	514/13.2	3
514/19	605	514/16.4	5
514/7	64	514/17.2	2
514/15	444	514/18.4	1
514/19	605	514/18.6	4
514/12	2747	514/18.7	3
514/21	546	514/18.8	7
514/19	605	514/18.9	3
		514/19.2	4
514/12	2747	514/19.5	2
514/16	263	514/20.6	2
514/20	40	514/20.8	1
514/18	732	514/1.1	44

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/12	2747	514/1.2	28
514/8	597	514/1.2	4
514/9	340	514/2.3	9
514/11	602	514/2.5	1
514/10	70	514/3.7	1
514/2	2369	514/3.7	27
		514/4.5	14
514/17	311	514/7.9	5
514/19	605	514/7.9	1
514/2	2369	514/8.1	16
514/16	263	514/8.1	1
514/5	14	514/9.4	1
514/2	2369	514/10.8	3
514/9	340	514/11.1	9
514/8	597	514/14.1	1
514/6	223	514/16.6	1
514/9	340	514/16.9	1
514/12	2747	514/17.8	8
514/2	2369	514/17.8	10
514/9	340	514/20.1	2
514/12	2747	514/2.9	1
514/5	14	514/3.7	1
514/14	230	514/4.8	4
514/17	311	514/6.5	1
514/3	267	514/7.8	1
514/11	602	514/9.7	5
514/3	267	514/10.2	1
514/14	230	514/12.2	2
514/16	263	514/13.2	3
514/9	340	514/14.9	3
514/19	605	514/16.2	7
514/9	340	514/17.7	1
514/8	597	514/19.2	8
514/12	2747	514/19.2	3
		514/19.3	38
514/8	597	514/20.7	1
514/12	2747	514/21.7	1
514/10	70	514/1.1	4
514/15	444	514/1.2	6
514/18	732	514/1.5	5
514/13	322	514/1.7	2
514/15	444	514/1.9	1
514/11	602	514/2.4	56

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/2	2369	514/2.4	75
514/7	64	514/2.8	3
514/18	732	514/3.7	14
514/19	605	514/4.6	1
514/12	2747	514/4.8	66
514/2	2369	514/5.5	41
514/11	602	514/6.8	1
514/19	605	514/6.8	2
514/12	2747	514/7.4	11
514/2	2369	514/7.9	8
514/9	340	514/8.4	1
514/2	2369	514/9.2	3
514/19	605	514/9.4	1
514/21	546	514/9.7	4
514/17	311	514/10.1	1
514/12	2747	514/10.7	1
		514/13.5	19
514/9	340	514/13.8	4
514/19	605	514/15.4	7
514/12	2747	514/15.6	1
514/11	602	514/15.7	5
514/2	2369	514/16.5	6
514/17	311	514/17.5	5
514/12	2747	514/18.2	1
514/16	263	514/19.3	12
		514/5.5	1
514/2	2369	514/8.3	28
		514/8.8	12
514/16	263	514/9.8	5
514/12	2747	514/12.8	3
514/18	732	514/13.2	5
514/16	263	514/13.5	3
514/2	2369	514/13.8	2
514/18	732	514/16.2	2
514/8	597	514/17.3	1
		514/18.1	1
514/19	605	514/18.3	13
514/2	2369	514/18.7	1
514/14	230	514/18.8	1
514/19	605	514/20.1	14
514/14	230	514/21.1	1
514/18	732	514/21.91	1
514/2	2369	514/9.9	1

SEPTEMBER 7, 2010

PROJECT C-7157

DISPOSITION CLASSIFICATION(S) OF PATENTS
FROM ABOLISHED SUBCLASSES REPORT

Generated by Data Control Division

Source Classification	Number of ORs	New Classification	Number of ORs
514/13	322	514/20.6	1
514/14	230	514/12.9	1
		514/18.9	1
514/16	263	514/21.7	2
514/12	2747	514/11.9	1
514/18	732	514/5.5	1
514/7	64	514/17.7	1
514/12	2747	514/2.4	2
514/2	2369	514/7.2	1
514/19	605	514/21.9	2
514/21	546	514/21.92	2
514/2	2369	514/1.2	3
514/18	732	514/18.4	2
514/11	602	514/1.2	1
514/2	2369	514/6.7	1
514/12	2747	514/8.1	2
514/3	267	424/433	2
514/9	340	435/5	1
514/8	597	424/185.1	2
514/6	223	424/134.1	1
514/11	602	424/497	1
514/6	223	436/11	1
514/12	2747	424/184.1	6
514/2	2369	530/370	3
514/6	223	424/94.64	1
514/2	2369	514/75	1
		530/363	1
514/12	2747	424/43	5
		424/94.64	13
514/18	732	424/1.69	1
514/8	597	424/532	1
514/7	64	514/210.16	1
514/2	2369	424/484	2
514/12	2747	530/384	1
514/2	2369	530/303	1
514/11	602	424/10.1	1
514/21	546	424/530	1

SEPTEMBER 7, 2010

PROJECT C-7157

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	1.1	A61K	38/00
	1.2	A61K	38/00
		A61K	47/00
	1.3	A61K	38/00
		A61K	47/00
	1.4	A61K	38/00
		A61P	05/00
	1.5	A61K	38/00
		A61P	11/00
	1.6	A61K	38/00
	1.7	A61K	38/00
		A61P	11/06
	1.8	A61K	38/00
		C07K	14/47
	1.9	A61K	38/00
		A61P	09/10
		C07K	14/47
	2.1	A61K	38/00
		A61P	31/00
	2.2	A61K	38/17
		C07K	14/47
	2.3	A61K	38/00
		A61P	31/00
		A01N	37/18
	2.4	A61K	38/00
		A61P	31/04
		A01N	37/18
	2.5	A61K	38/40
		A61K	47/48
		A01N	37/18
		C07K	14/79
	2.6	A61K	38/04
		A01N	37/18
	2.7	A61K	38/04
		A01N	37/18
	2.8	A61K	38/04
		A01N	37/18
	2.9	A61K	38/04
		A61K	38/12
		A01N	37/18
	3.1	A61K	38/04
		A01N	37/18
	3.2	A61K	38/00
		A61P	31/04
	3.3	A61K	38/00
		A01N	37/18
		A61P	31/10

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	3.4	A61K	38/00
		A01N	37/18
		A61P	31/10
	3.5	A61K	38/00
		A01N	37/18
		A61P	31/10
	3.6	A61K	38/12
		A01N	37/18
		A61P	31/10
	3.7	A61K	38/00
		A01N	37/18
		A61P	31/12
	3.8	A61K	38/00
		A01N	37/18
		A61P	31/18
	3.9	A61K	38/00
		A01N	37/18
		A61P	31/10
	4.1	A61K	38/55
		A01N	37/18
		A61P	31/18
	4.2	A61K	38/00
		A01N	37/18
		A61P	31/22
	4.3	A61K	38/00
		A01N	37/18
		A61P	01/16
	4.4	A61K	38/00
		A01N	37/18
		A61P	33/02
	4.5	A61K	38/00
		A01N	37/18
	4.6	A61K	38/00
		A61P	33/00
	4.7	A61K	38/00
		A61P	15/14
	4.8	A61K	38/00
		A61P	03/04
	4.9	A61K	38/00
		A61P	03/04
	5.1	A61K	38/27
		A61P	03/04
	5.2	A61K	38/22
		A61P	03/04
	5.3	A61K	38/22
		A61P	03/04

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	5.4	A61K	38/00
	5.5	A61K	38/00
		A61P	03/02
	5.6	A61K	38/00
		A61P	03/02
		C07K	02/00
	5.7	A61K	38/00
		A61P	03/02
		C07K	02/00
	5.8	A61K	38/22
	5.9	A61K	38/28
		C07K	14/62
	6.1	A61K	38/28
	6.2	A61K	38/28
	6.3	A61K	38/28
	6.4	A61K	38/28
		A61K	33/30
	6.5	A61K	38/28
		A61P	05/50
	6.6	A61K	38/28
	6.7	A61K	38/00
		A61K	38/28
		A61P	05/50
	6.8	A61K	38/00
		A61P	03/08
		A61P	03/10
	6.9	A61K	38/00
		A61K	38/28
		A61P	03/10
		A61P	07/12
	7.1	A61K	38/31
		A61P	03/10
		A61P	07/12
	7.2	A61K	38/26
		A61P	03/10
		A61P	07/12
		C07K	14/605
	7.3	A61K	38/00
		A61P	03/10
		A61P	07/12
	7.4	A61K	38/00
		A61P	03/06
	7.5	A61K	38/00
		C07K	14/47
	7.6	A61K	38/18
		C07K	14/475

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	7.7	A61K	38/18
		A61P	07/06
		C07K	14/505
	7.8	A61K	38/18
		A61P	07/06
		C07K	14/52
	7.9	A61K	38/00
		A61P	07/00
		A61P	07/06
	8.1	A61K	38/18
	8.2	A61K	38/18
		C07K	14/49
	8.3	A61K	38/18
	8.4	A61K	38/18
		C07K	14/48
	8.5	A61K	38/30
		C07K	14/65
	8.6	A61K	38/30
		C07K	14/65
	8.7	A61K	38/00
		A61K	38/30
		C07K	14/65
	8.8	A61K	38/18
		C07K	14/51
	8.9	A61K	38/18
		C07K	14/495
	9.1	A61K	38/18
		C07K	14/50
	9.2	A61K	38/18
	9.3	A61K	38/39
		A61K	47/48
	9.4	A61K	38/00
		A61P	17/02
	9.5	A61K	38/22
		C07K	14/475
	9.6	A61K	38/22
		C07K	14/485
	9.7	A61K	38/22
		C07K	14/575
	9.8	A61K	38/00
		A61P	15/08
		A61P	15/16
		A61P	15/18
	9.9	A61K	38/24
		A61P	05/06
		C07K	14/59

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	10.1	A61K	38/24
		A61P	05/06
		C07K	14/59
	10.2	A61K	38/00
		A61P	05/24
	10.3	A61K	38/09
		A61P	05/02
	10.4	A61K	38/09
		A61P	05/02
	10.5	A61K	38/09
		A61P	05/02
		A61P	15/08
	10.6	A61K	38/09
		A61P	05/02
	10.7	A61K	38/34
		C07K	14/68
	10.8	A61K	38/35
		A61P	05/44
		C07K	14/695
	10.9	A61K	38/11
	11.1	A61K	38/31
		A61P	05/02
		C07K	14/655
	11.2	A61K	38/25
		C07K	14/60
	11.3	A61K	38/27
		A61P	05/06
	11.4	A61K	38/27
		A61P	05/06
	11.5	A61K	38 /22
		C07K	14/575
	11.6	A61K	38 /11
		A61P	05 /10
	11.7	A61K	38/26
		A61P	03/10
		A61P	07/12
		C07K	14/605
	11.8	A61K	38 /29
		A61P	05/18
		C07K	14/635
	11.9	A61K	38/23
		A61P	05/22
		C07K	14/585
	12.1	A61K	38/00
		A61P	13/06
		A61P	21/02

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	12.2	A61K	38/00
		A61P	29/00
	12.3	A61K	38/22
		C07K	14/595
	12.4	A61K	38/22
		C07K	14/58
	12.5	A61K	38/22
		C07K	14/575
	12.6	A61K	38/22
		C07K	14/595
	12.7	A61K	38/22
		C07K	14/64
	12.8	A61K	38/22
		C07K	14/645
	12.9	A61K	38/22
		C07K	14/575
	13.1	A61K	38/22
		C07K	14/575
	13.2	A61K	38/00
		A61P	01/04
	13.3	A61K	38/00
		A61P	35/00
		C07K	14/515
	13.4	A61K	38/41
		C07K	14/795
	13.5	A61K	38/00
		A61P	07/00
	13.6	A61K	38/36
		A61P	07/04
		C07K	14/75
		C07K	14/475
	13.7	A61K	38/36
		A61P	07/02
		C07K	14/745
	13.8	A61K	38/36
	13.9	A61K	38/36
		C07K	14/745
	14.1	A61K	38/37
		C07K	14/755
	14.2	A61K	38/57
	14.3	A61K	38/43
		A61K	38/57
		C07K	14/745
	14.4	A61K	38/57
		C07K	14/745
	14.5	A61K	38/57
		C07K	14/745

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	14.6	A61K	38/43
		A61K	38/49
		A61K	38/57
		C07K	14/745
	14.7	A61K	38/57
		C07K	14/745
		C07K	14/81
	14.8	A61K	38/58
		C07K	14/815
	14.9	A61K	38/36
	15.1	A61K	38/00
		A61P	39/06
	15.2	A61K	38/38
		A61K	47/48
		C07K	14/76
	15.3	A61K	38/00
		A61P	07/08
	15.4	A61K	38/00
		A61P	13/12
	15.5	A61K	38/00
		C07K	14/785
	15.6	A61K	38/00
		A61P	09/00
	15.7	A61K	38/00
		A61P	09/12
	15.8	A61K	38/55
		A61P	09/12
	15.9	A61K	38/55
		A61P	09/12
		C07K	05/00
	16.1	A61K	38/00
		C07K	14/575
		A61P	09/12
	16.2	A61K	38/57
		A61P	09/12
	16.3	A61K	38/55
		C07K	07/14
	16.4	A61K	38/00
		A61P	09/00
	16.5	A61K	38/00
		A61P	43/00
	16.6	A61K	38/00
		A61P	19/02
		A61P	29/00
	16.7	A61K	38/00
		A61P	19/08

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	16.8	A61K	38/00
		A61P	19/02
	16.9	A61K	38/00
		A61P	19/10
	17.1	A61K	38/00
		A61P	19/00
	17.2	A61K	38/39
		A61K	47/48
	17.3	A61K	38/00
		A61K	38/16
	17.4	A61K	38/00
		A61K	38/16
	17.5	A61K	38/00
		A61P	25/18
		A61P	25/22
	17.6	A61K	38/00
		A61P	25/24
	17.7	A61K	38/00
		A61P	03/04
		A61P	25/00
	17.8	A61K	38/00
		A61P	25/28
	17.9	A61K	38/00
		C07K	14/47
	18.1	A61K	38/00
		C07K	14/575
	18.2	A61K	38/00
		A61P	25/02
	18.3	A61K	38/00
		A61P	23/00
	18.4	A61K	38/00
		A61P	25/04
	18.5	A61K	38/00
		C07K	14/70
	18.6	A61K	38/00
		A61P	17/00
	18.7	A61K	38/00
		A61P	17/00
		A61P	29/00
	18.8	A61K	38/00
		A61P	17/00
	18.9	A61K	38/00
		A61P	43/00
	19.1	A61K	38/00
		C07K	14/705
	19.2	A61K	38/00
		A61P	35/00

C. CHANGES TO THE USPC-TO-IPC CONCORDANCE

USPC		IPC	
Class	Subclass	Subclass	Notation
514	19.3	A61K	38/00
		A61P	35/00
	19.4	A61K	38/00
		A61P	35/00
	19.5	A61K	38/00
		A61P	35/00
	19.6	A61K	38/00
		A61P	35/02
	19.7	A61K	38/10
		A61P	35/00
	19.8	A61K	38/00
		A61P	35/04
	19.9	A61K	38/12
		A61P	35/00
	20.1	A61K	38/48
		A61K	38/55
		C07K	14/81
	20.2	A61K	38/48
		A61K	38/55
		C07K	14/81
	20.3	A61K	38/55
		A61K	38/55
		C07K	14/81
	20.4	A61K	38/48
		A61K	38/55
	20.5	A61K	38/13
	20.6	A61K	38/00
		C07K	14/72
		C07K	14/705
	20.7	A61K	38/00
		A61P	17/14
	20.8	A61K	38/00
		A61P	09/10
		A61P	27/02
	20.9	A61K	38/14
	21.1	A61K	38/12
	21.2, 21.3	A61K	38/16
	21.4	A61K	38/10
		A61K	38/16
	21.5	A61K	38/10
	21.6-21.8	A61K	38/08
	21.9	A61K	38/06
		A61K	38/07
	21.91	A61K	38/05
	21.92	A61K	38/17

D. CHANGES TO THE DEFINITIONS

CLASS 106 – COMPOSITIONS: COATING OR PLASTIC

Definitions Modified

Subclass 124.1: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclass 1.1 for a therapeutic, bio-affecting composition containing peptide or protein.

Subclass 124.5: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92, especially subclasses 13.5-15.3 for therapeutic or bio-affecting compositions of that class containing a blood protein.

D. CHANGES TO THE DEFINITIONS

CLASS 424 – DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS

Definitions Modified

Subclass 9.34: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for polypeptides containing a heavy metal and used for therapeutic purposes.

Subclass 78.08: After the definition

Delete:

The (3) Note

Insert:

(3) Note. Carbohydrates, polypeptides, and cellulosic products and most of their derivatives are considered to be naturally occurring polymeric products with some exceptions. Polypeptides synthesized in a random sequence (e.g., the use of N-carboxy-anhydrides of alpha-amino acids, etc.) are considered solid synthetic organic polymers and are proper for this subclass or its indents when it is the DOAI. Polypeptides synthesized in an ordered sequence (e.g., the use of the Merrifield method, etc.) are not proper for this subclass or its indents.

Under SEE OR SEARCH CLASS:

Delete:

The reference to Class 514

D. CHANGES TO THE DEFINITIONS

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for a composition containing a peptide as a designated organic active ingredient (DOAI), subclasses 772.1-772.7 for a composition containing a designated nonactive solid synthetic organic polymer, subclasses 773-776 for a composition containing a nonactive peptide, and subclass 788.1 for a composition containing a nonactive solid synthetic organic polymer derived solely from hydrocarbon reactants.

Subclass 520: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for a composition containing an active proteinaceous ingredient produced by or extracted from animal tissue, subclass 23 for a composition containing an active carbohydrate, and subclass 169 for a composition containing lanolin or a steroid as an active ingredient.

Subclass 529: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 13.5-15.3 for therapeutic or bio-affecting compositions containing blood proteins.

Subclass 530: After the definition

Insert:

SEE OR SEARCH CLASS:

514, Drug, Bio-Affecting and Body Treating Compositions, subclass 15.3 for therapeutic or bio-affecting compositions containing plasma proteins.

D. CHANGES TO THE DEFINITIONS

Subclass 546: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 9.7-13.1 for sex hormones which are proteins, subclass 10.2 for peptides or proteins which affect sex hormones, and subclasses 169-182 for those which contain a cyclopentanohydrophenanthrene ring system with such hormones being used as body treating materials.

Subclass 556: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 5.9-6.6 for therapeutic or bio-affecting compositions containing insulin.

Subclass 562: After SEE OR SEARCH THIS CLASS, SUBCLASS, the reference to subclass 580

Insert:

SEE OR SEARCH CLASS:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 9.7-13.1 for therapeutic or bio-affecting compositions containing a peptide derived from the endocrine system.

Subclass 563: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

D. CHANGES TO THE DEFINITIONS

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclass 10.8 for a therapeutic or bio-affecting composition containing adrenocorticotropic hormone (ACTH).

D. CHANGES TO THE DEFINITIONS

CLASS 435 – MOLECULAR BIOLOGY AND MICROBIOLOGY

Definitions Modified

Subclass 69.1: Under SEE OR SEARCH CLASS

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for a therapeutic or bio-affecting body treating composition containing a peptide as a designated organic active ingredient (DOAI).

Subclass 69.4: Under SEE OR SEARCH CLASS

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 9.7 -13.1 for therapeutic or bio-affecting compositions containing a peptide hormone.

Subclass 69.51: Under SEE OR SEARCH CLASS

Delete:

The references to Classes 424 and 514

Insert:

424, Drug, Bio-Affecting and Body Treating Compositions, subclasses 85.4-85.7 for compositions of that class containing an interferon.

Subclass 69.52: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

D. CHANGES TO THE DEFINITIONS

Insert:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 85.2 for compositions of that class containing interleukin.

Subclass 69.6: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 13.5-15.3 for therapeutic or bio-affecting compositions containing blood proteins, especially subclass 13.4 for a blood substitute.

Subclass 70.3: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Subclass 71.3: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for compositions of that class containing an antibiotic or toxin which is a protein or polypeptide.

Subclass 174: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 424

D. CHANGES TO THE DEFINITIONS

Insert:

424, Drug, Bio-Affecting and Body Treating Compositions, subclasses 94.1-94.67 for a therapeutic or bio-affecting composition containing an enzyme or coenzyme.

D. CHANGES TO THE DEFINITIONS

CLASS 436 – CHEMISTRY: ANALYTICAL AND IMMUNOLOGICAL TESTING

Definitions Modified

Subclass 86: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for a therapeutic or bio-affecting composition containing a peptide or protein.

Subclass 518: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for a therapeutic or bio-affecting composition containing a peptide or protein.

D. CHANGES TO THE DEFINITIONS

CLASS 514 – DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS

Definitions Abolished

Subclasses

2-21

Definitions Established

1.1 Peptide (e.g., protein, etc.) containing DOAI:
This subclass is indented under subclass 1. Subject matter wherein the designated organic active ingredient (DOAI) contains two or more amino acids joined covalently by peptide bonds.

(1) Note. A peptide bond is an amide bond between the carboxyl group of one amino acid and the amino group of another. For purposes of classification, the terms “peptide” and “protein” are used interchangeably.

(2) Note. For the purposes of this and indented subclasses, language such as “a pharmaceutical (or medicinal, bio-affecting, etc.) composition comprising protein ‘X’” is considered a composition and is proper for this area as if it is a true composition comprising two or more ingredients.

(3) Note. A derivative is classified with the peptide when its function or utility is analogous to the named peptide and its structure corresponds to approximately half or more of the amino acid residues of the named peptide. The product of side chain substitution, C or N terminal chain will be classified with the named peptide as related peptides. The product of a replacement reaction will be classified as a related peptide so long as less than half the amino acid residues of the named peptide have been replaced. The product of a removal reaction or a partial sequence (i.e., fragments) will be classified as a related peptide if half the amino acid residues of the named peptide are present. Polypeptides which are formed by joining the named peptide of identical sequence to the named peptide should be originally classified on the basis of the named peptide and cross-referenced to the appropriate subclasses.

(4) Note. In the case where peptides are joined by covalent bonding, as by S-S bonds through cysteine, the number of amino acids in the peptide is the sum of the individual chains.

(5) Note. Subclasses herein provide for the delivery of a peptide (DOAI) which has a biological effect. For subclasses wherein the terms “affecting” or “utilizing” are used, the peptide administered is not always the substance named in the

D. CHANGES TO THE DEFINITIONS

subclass title, rather the peptide administered may have an effect on this substance which may be naturally occurring within the living body.

(6) Note. A peptide acting as a potentiator or synergist for a nonpeptide active ingredient (DOAI) is considered as being an active ingredient (DOAI).

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclasses 94.1-94.67 for enzyme containing pharmaceutical or bio-affecting compositions.

530, Chemistry: Natural Resins or Derivatives; Peptides or Proteins; Lignins or Reaction Products Thereof, subclasses 300-345 for peptides, per se, and methods of preparing same; and subclasses 350-427 for proteins, per se, and methods of preparing the same.

930, Peptide or Protein Sequence, subclasses 10-320 for peptide or protein sequences or four or more amino acids.

1.2 Transporter affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a transporter peptide, or wherein a peptide is administered which has an effect on a transporter.

(1) Note. Transporters facilitate the carrying of molecular contents across the cell membrane.

1.3 Prodrug utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is part of a molecule capable of being converted in vivo by chemical or enzymatic modifications of its structure into an active agent.

1.4 Sepsis affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide affects an acute systemic (bodywide) inflammatory response (also known as systemic inflammatory response syndrome (SIRS)) to the spread of a micro-organism or its toxin in the blood or tissues.

(1) Note. In sepsis, widespread release of inflammatory cytokines (especially, interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha)) and cytotoxic enzymes damage the endothelium which can result in tissue edema, hypotension, and intravascular thrombosis, and ultimately organ dysfunction or failure, and death.

(2) Note. The terms “sepsis,” “severe sepsis,” and “septic shock” are used to denote different extents of inflammation and infection. Severe sepsis is sepsis with organ dysfunction, hypotension, or hyperperfusion. Septic shock is sepsis-induced hypotension despite adequate fluid resuscitation.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH THIS CLASS, SUBCLASS:

2.3, through 3.2, for a peptide composition which is effective in destroying or inhibiting the growth of a micro-organism when sepsis is not present.

15.6, for a peptide composition which affects the pressure of blood flow against the walls of the arteries, either to raise or lower said pressure.

1.5 Respiratory distress syndrome (e.g., ARDS, IRDS, etc.) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating respiratory distress syndrome (RDS) including acute/adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS).

(1) Note. ARDS is respiratory failure in adults or children resulting from various injuries to the lung including massive transfusion, chest trauma, neurological injury, and sepsis. It is characterized by pulmonary edema, difficult rapid breathing, and hypoxemia.

(2) Note. Infant respiratory distress syndrome (IRDS) or neonatal respiratory distress syndrome is also called hyaline membrane disease. It is a condition in newborn babies, in which the lungs are deficient in surfactant, preventing their proper expansion and causing the formation of hyaline material in the lung spaces.

SEE OR SEARCH THIS CLASS, SUBCLASS:

15.5, for a peptide composition which affects or utilizes surfactant protein (e.g., SP-A, SP-B, etc.).

1.6 Pneumonia affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating pneumonia, an illness of the lung characterized by inflammation, abnormal alveolar filling with fluid, and consolidation of lung tissue followed by resolution.

(1) Note. Pneumonia is chiefly caused by infection and is usually accompanied by fever, cough, chest pain, and difficulty in breathing.

(2) Note. Included but not limited thereto are bacterial pneumonia, viral pneumonia, atypical pneumonia, bronchial pneumonia, etc.

1.7 Asthma affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating asthma, a chronic respiratory system disorder marked by recurring episodes of airway obstruction that is triggered by various stimuli such as allergens, rapid change in air temperature, and environmental tobacco smoke.

D. CHANGES TO THE DEFINITIONS

1.8 Cystic fibrosis affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating cystic fibrosis, a hereditary disease involving the functional disorder of the exocrine (mucus) glands of the lungs, liver, pancreas, and intestines, wherein abnormally viscous mucus is produced.

(1) Note. Cystic fibrosis is manifested by faulty digestion due to a deficiency of pancreatic enzymes, by difficulty in breathing due to mucus accumulation in airways, and by excessive loss of salt in the sweat. It is also called fibrocystic disease of the pancreas, mucoviscoidosis, or mucoviscidosis.

1.9 Arteriosclerosis (e.g., atherosclerosis, etc.) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating arteriosclerosis, an abnormal thickening and hardening of the arterial walls.

(1) Note. Different types of arteriosclerosis are atherosclerosis, arteriosclerosis obliterans, medial calcific sclerosis, etc.

(2) Note. Atherosclerosis is the most common form of arteriosclerosis. It is a hardening of an artery specifically due to an atheromatous plaque containing cholesterol (free lipid), atheroma (abnormal fatty deposits), etc.

(3) Note. Arteriosclerosis is distinct from arteriolosclerosis, which is the hardening of arterioles.

2.1 Endotoxin (e.g., LPS, etc.) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects endotoxin.

(1) Note. Endotoxin is a poisonous substance found inside pathogens such as bacteria. It is a structural component in the bacteria, for example, lipopolysaccharide (LPS) and lipooligosaccharide (LOS), separable from the cell body only when the bacteria are lysed. It may cause fever and inflammation in a host.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.4, for endotoxin affecting peptide compositions used in the treatment of sepsis.

2.2 Bactericidal/permeability-increasing (BPI) protein affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is bactericidal/permeability increasing protein (BPI), or wherein the peptide administered has an effect on BPI.

(1) Note. Antibiotic BPI can be used to kill bacteria or inhibit their growth by binding to bacterial lipopolysaccharides.

D. CHANGES TO THE DEFINITIONS

2.3 Micro-organism destroying or inhibiting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is effective in destroying or inhibiting the growth of a single-celled organism which is of microscopic or ultramicroscopic size (0.2-200 micrometers).

(1) Note. For the purposes of this subclass and indented subclasses, the term "micro-organism" includes bacteria, actinomycetales, fungi (e.g., molds), protozoa, and viruses.

SEE OR SEARCH THIS CLASS, SUBCLASS:

804, for a cross-reference art collection of subject matter containing a phleomycin peptide or derivative.

2.4 Bacterium (e.g., Bacillus, etc.) destroying or inhibiting:
This subclass is indented under subclass 2.3. Subject matter wherein the peptide administered is effective in destroying bacteria or in inhibiting their growth.

(1) Note. The destroying or inhibiting can involve treating a living host that has a bacterial infection or to preclude the possible infection of a living host by a bacteria. Furthermore, a peptide that is useful in destroying or inhibiting the growth of bacteria in any nonliving environment is also properly classified herein, e.g., room, etc.

(2) Note. Bacteria are microscopic single-cell organisms that have neither a membrane-bounded nucleus or other membrane bounded organelles.

2.5 Lactoferrin:
This subclass is indented under subclass 2.4. Subject matter wherein the peptide administered is lactoferrin, an iron-binding protein of very high affinity found in milk, tears, mucus, bile, and some white blood cells.

2.6 Streptococcus:
This subclass is indented under subclass 2.4. Subject matter wherein the bacterium is of the genus Streptococcus.

(1) Note. Streptococcus is a spherical Gram-positive bacterium.

(2) Note. Streptococcus bacteria can cause streptococcal pharyngitis or streptococcal sore throat (strep throat), meningitis, endocarditis, etc.

2.7 Staphylococcus (e.g., Staphylococcus aureus, etc.):
This subclass is indented under subclass 2.4. Subject matter wherein the bacterium is of the genus Staphylococcus.

(1) Note. Staphylococcus is a Gram-positive spherical bacterium.

D. CHANGES TO THE DEFINITIONS

(2) Note. Staphylococcus bacteria are generally responsible for, for example, toxic shock syndrome, food poisoning, etc.

2.8 Gram negative bacterium (e.g., Escherichia coli, salmonella, Helicobacter, etc.):
This subclass is indented under subclass 2.4. Subject matter wherein the bacterium is considered to be Gram negative or does not retain the purple dye when stained by Gram's stain.

(1) Note. Gram staining is an empirical method to distinguish Gram-positive and Gram-negative bacteria based on structural and composition differences in their cell walls. Gram-negative bacterium has a lipid outer layer and a thinner inner layer than Gram-positive bacterium and loses the purple color after decolorization in the Gram test. It is proper to classify an organism here considered to be Gram negative on the basis of phylogenetic relationship but which does not display the expected Gram staining characteristics, e.g., it stains Gram positive, etc.).

2.9 Cyclopeptide utilizing:
This subclass is indented under subclass 2.4. Subject matter wherein the peptide administered is a cyclic structure, wherein the cyclic structure is formed by peptide bonding, disulfide bonding, hydrocarbon bonding, or other types of bonding and has at least a dipeptide as an integral part thereof.

SEE OR SEARCH THIS CLASS, SUBCLASS:

3.6, for a composition containing a cyclopeptide used in the treatment of a fungal infection.

21.1, for a composition containing a cyclopeptide for a function/utility not provided by a specific function/utility subclass in this class.

SEE OR SEARCH CLASS:

930, Peptide or Protein Sequence, subclass 260 for peptides or proteins with intrachain cysteine-cysteine bridges and subclass 270 for other cyclic peptides or proteins.

3.1 Glycopeptide utilizing:
This subclass is indented under subclass 2.4. Subject matter wherein the peptide administered is bonded to a carbohydrate.

SEE OR SEARCH THIS CLASS, SUBCLASS:

20.9, for a composition containing a glycopeptide for a function/utility not provided by a specific function/utility subclass in this class.

804, for a cross-reference art collection of subject matter containing a phleomycin peptide or derivative.

D. CHANGES TO THE DEFINITIONS

3.2 Amphiphilic or oligomer modified peptide (e.g., magainin, peptide nucleic acid, or PEGylated peptide, etc.) utilizing:
This subclass is indented under subclass 2.4. Subject matter wherein the peptide administered is characterized by the coexistence of a hydrophobic domain and a hydrophilic domain which can be due to a chemically attached lipophilic group or spatial segregation of hydrophobic and hydrophilic amino acid residues in the tertiary structure (e.g., alpha-helix, etc.), or the peptide administered is covalently functionalized by repeated organic functional moieties (e.g., nucleic acid or ethylene glycol, etc.).

(1) Note. Examples of peptides included in this subclass are magainin, peptide nucleic acid, and PEGylated peptide.

3.3 Fungus (e.g., athlete's foot, ringworm, etc.) destroying or inhibiting:
This subclass is indented under subclass 2.3. Subject matter wherein the peptide administered is effective in destroying fungi or in inhibiting their growth.

(1) Note. The destroying or inhibiting can involve treating a living host that has a fungal infection or to preclude the possible infection of a living host with a fungus. Furthermore a peptide that is useful in destroying or inhibiting the growth of fungus in any nonliving environment is also properly classified herein (e.g., room, etc.).

(2) Note. Fungi are organisms that belong to the kingdom Fungi. They contain a chitinous cell wall (e.g., molds, yeasts, etc.).

3.4 Candida (e.g., Candida albicans, etc.):
This subclass is indented under subclass 3.3. Subject matter wherein the fungus is of the genus Candida.

(1) Note. Candida albicans is the most common cause of vaginal infection Candidiasis is also called yeast infection or thrush.

3.5 Yeast:
This subclass is indented under subclass 3.3. Subject matter wherein the fungus is a yeast.

3.6 Cyclopeptide utilizing:
This subclass is indented under subclass 3.3. Subject matter wherein the peptide administered is a cyclic structure, wherein the cyclic structure is formed by peptide bonding, disulfide bonding, hydrocarbon bonding, or other types of bonding, and has at least a dipeptide as an integral part thereof.

SEE OR SEARCH THIS CLASS, SUBCLASS:

21.1, for a composition containing a cyclopeptide for a function/utility not provided by a specific function/utility subclass in this class.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

930, Peptide or Protein Sequence, subclass 260 for peptides or proteins with intrachain cysteine-cysteine bridges and subclass 270 for other cyclic peptides or proteins.

3.7 Virus destroying or inhibiting:
This subclass is indented under subclass 2.3. Subject matter wherein the peptide administered is effective in destroying a virus or in inhibiting its growth.

(1) Note. The destroying or inhibiting can involve treating a living host that has a viral infection or to preclude the possible infection of a living host with a virus. Furthermore, a peptide that is useful in destroying or inhibiting the growth of a virus in any nonliving environment is also properly classified herein (e.g., room, etc.).

(2) Note. A virus is encapsulated RNA or DNA enclosed within a protective protein coat. Outside of a host cell a virus is unable to grow or reproduce.

(3) Note. The following are some of the diseases caused by a virus (e.g., Polio, smallpox, the common cold, chickenpox, shingles, herpes, rabies, Ebola, AIDS, etc.).

3.8 Human immunodeficiency virus (HIV):
This subclass is indented under subclass 3.7. Subject matter wherein the virus is the human immunodeficiency virus (HIV), the causative agent of Acquired Immunodeficiency Syndrome (AIDS).

(1) Note. HIV refers to any of a group of viruses that infect and destroy cells of the immune system causing the marked reduction in their numbers that leads to a diagnosis of AIDS.

3.9 Cluster of differentiation protein (e.g., CD4, etc.) affecting:
This subclass is indented under subclass 3.8. Subject matter wherein the peptide administered affects cluster of differentiation molecules found on the surface of a leukocyte.

(1) Note. Cluster of differentiation proteins are a group of cell surface molecules present on leukocytes.

(2) Note. CD4 is a primary receptor used by the human immunodeficiency virus (HIV) to gain entry into host T-cells.

4.1 HIV protease inhibitor affecting or utilizing:
This subclass is indented under subclass 3.8. Subject matter wherein the peptide administered affects the activity of an HIV protease inhibitor or wherein the peptide administered is a protease inhibitor which inhibits the activity of an HIV protease.

D. CHANGES TO THE DEFINITIONS

4.2 Herpesviridae:
This subclass is indented under subclass 3.7. Subject matter wherein the virus is of the family herpesviridae, which can cause inflammation of the skin or mucous membranes characterized by watery blisters.

(1) Note. Some members of the herpesviridae family of viruses which cause disease in humans include herpes simplex virus-1, herpes simplex-2, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, etc.

4.3 Hepatitis:
This subclass is indented under subclass 3.7. Subject matter wherein the virus is the hepatitis virus (e.g., hepatitis A, B, C, D, E, etc.) which damages the liver.

4.4 Protozoa destroying or inhibiting:
This subclass is indented under subclass 2.3. Subject matter wherein the peptide administered is effective in destroying a unicellular eukaryotic organism or in inhibiting its growth (e.g., amoebas, ciliates, flagellates, sporozoans, etc.).

4.5 Insect destroying or inhibiting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is effective in destroying insects or in inhibiting their growth.

(1) Note. Insects are arthropods of the class Insecta.

(2) Note. Included but not limited thereto are cockroaches, ants, beetles, moths, grasshoppers, bees, wasps, helicoverpa zea, lepidoptera, etc.

4.6 Parasite (e.g., tapeworm, roundworm, nematode, etc.) destroying or inhibiting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is effective in destroying parasites or in inhibiting their growth.

(1) Note. A parasite is an organism that lives in or on a host (another organism) to the detriment of the host organism.

(2) Note. Parasites include tapeworms, roundworms, nematodes, trematodes (i.e., flukes), etc.

4.7 Lactation affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the formation or secretion of milk by the mammary glands of female animals.

4.8 Weight regulation affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects body weight (e.g., treating obesity, increasing feed efficiency and weight gain of animals, varying the fat-flesh ratio, etc.).

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

426, Food or Edible Material: Processes, Compositions, and Products, for compositions wherein the nutritional ingredients (e.g., fat, carbohydrate, or protein, etc.) are varied to achieve a certain fat-flesh ratio in an animal, or for compositions intended to nourish an animal by natural oral ingestion, which may contain an additive necessary to maintain the normal metabolism of the animal (e.g., vitamins, minerals, amino acids, etc.).

4.9 Appetite or satiation affecting:
This subclass is indented under subclass 4.8. Subject matter wherein the peptide administered affects hunger sensations, cravings, or the sensation of fullness or gratification derived from oral consumption of food.

5.1 Growth hormone (GH) or derivative utilizing:
This subclass is indented under subclass 4.8. Subject matter wherein the peptide administered is growth hormone or a derivative thereof.

(1) Note. Growth hormone is alternatively known as somatotrophin, somatotropin, somatotropic hormone, somatotrophic hormone, STH, human growth hormone.

(2) Note. Somatotrophin contains 191 amino acids.

(3) Note. Somatotrophin has important functions, which include stimulating body growth and strengthening bones and tendons in humans.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

5.2 Neuropeptide (e.g., NPY, PYY, dynorphin, etc.) or derivative utilizing:
This subclass is indented under subclass 4.8. Subject matter wherein the peptide administered is a neuropeptide derived from neural tissues or a derivative thereof.

(1) Note. Neuropeptide Y (NPY) is a 36 amino acid peptide neurotransmitter found in the brain and autonomic system. NPY increases food intake and increases the proportion of energy stored as fat.

(2) Note. Peptide YY (PYY) is a 36 amino acid peptide produced by neurons in the brainstem, and released by L cells in the gastrointestinal tract, especially the ileum and colon in response to feeding. It inhibits gastric motility, increases efficiency of digestion and nutrient absorption, and decreases appetite.

(3) Note. Dynorphin is an opioid peptide that arises from the precursor protein prodynorphin. Dynorphin is produced in the arcuate nucleus and in orexin neurons of the lateral hypothalamus and affects the control of appetite.

D. CHANGES TO THE DEFINITIONS

5.3 Peptide hormone or derivative utilizing:
This subclass is indented under subclass 4.8. Subject matter wherein the peptide administered is a hormone or a derivative thereof.

5.4 Iron affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered promotes or inhibits iron absorption, uptake, storage, or recycling to treat conditions including iron insufficiency and iron overload (e.g., by reducing gastrointestinal side effects, improving bioavailability, or binding iron).

(1) Note. Iron as a metal is an important component of proteins and enzymes responsible for regulating cell growth, differentiation, and oxygen transport.

5.5 Nutrition enhancement or support:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered contributes to improved absorption or utilization of a nutrient, or wherein the peptide composition administered to nourish an animal is designed to be delivered to the animal via routes other than the alimentary canal (e.g., by rectal or parenteral injection, etc.) or via a tube through the alimentary canal or stomach wall.

(1) Note. Improved absorption or utilization of nutrients may promote wound healing or increase resistance to disease.

SEE OR SEARCH CLASS:

426, Food or Edible Material: Processes, Compositions, and Products, for compositions intended to nourish an animal by natural oral ingestion, which may contain an additive necessary to maintain the normal metabolism of the animal (e.g., vitamins, minerals, amino acids, etc.).

5.6 Containing whey:
This subclass is indented under subclass 5.5. Subject matter wherein the composition administered includes whey.

5.7 Containing casein:
This subclass is indented under subclass 5.5. Subject matter wherein the composition administered includes casein.

5.8 Leptin or derivative affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is leptin or a derivative thereof, or wherein the peptide is administered which has an effect on leptin.

(1) Note. Leptin is a naturally occurring hormone which affects appetite and regulates energy intake and energy expenditure.

(2) Note. Leptin has a molecular weight of 16,000 daltons.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

5.9 Insulin or derivative utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is insulin or a derivative thereof, in which neither a peptide chain nor a disulfide link between chains is broken.

(1) Note. Insulin is a peptide hormone produced in the Islets of Langerhans in the pancreas. While the position and/or kind of amino acids in the chain(s) may vary (depending on the animal from which it originates), it appears that insulin contains at least an “A” chain of 21 acid units linked by disulfide moieties to a “B.” An additional disulfide moiety bridges the 6 and 11 positions of chain A.

(2) Note. A synthetic form of insulin is classified as if it is naturally occurring.

(3) Note. It is proper to classify a peptide here if it is characterized as insulin or a derivative thereof.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.5, for a composition containing an insulin-like growth factor.

SEE OR SEARCH CLASS:

530, Chemistry: Natural Resins or Derivatives; Peptides or Proteins; Lignins or Reaction Products Thereof, subclass 303 for insulin, per se.

6.1 Truncated insulin:
This subclass is indented under subclass 5.9. Subject matter wherein the insulin contains fewer amino acids than natural insulin (i.e., one or more of the amino acid residues on the insulin molecule are absent (e.g., Phe at B25 position is deleted, etc.).

SEE OR SEARCH THIS CLASS, SUBCLASS:

6.2, for insulin wherein an amino acid of the A-chain is substituted with another amino acid and the insulin contains the same number of amino acids as natural insulin.

6.3, for insulin wherein an amino acid of the B-chain is substituted with another amino acid and the insulin contains the same number of amino acids as natural insulin.

6.2 A-chain modified insulin:
This subclass is indented under subclass 5.9. Subject matter wherein the A-chain structure of insulin is changed (e.g., one or more amino acids are added to the A-chain, a

D. CHANGES TO THE DEFINITIONS

different amino acid is substituted for the amino acid normally found in that position of the A-chain, etc.).

6.3 B-chain modified insulin:
This subclass is indented under subclass 5.9. Subject matter wherein the B-chain structure of insulin is changed (e.g., one or more amino acids are added to the B-chain, a different amino acid is substituted for the amino acid found in that position of the B-chain, etc.).

6.4 Zinc containing:
This subclass is indented under subclass 5.9. Subject matter wherein the insulin contains zinc.

6.5 With an additional active ingredient:
This subclass is indented under subclass 5.9. Subject matter wherein the insulin is admixed with another active ingredient.

(1) Note. A potentiator is considered as an active ingredient and can be an additional peptide or a nonpeptide.

6.6 With protamine:
This subclass is indented under subclass 6.5. Subject matter wherein the insulin or derivative is admixed with protamine.

(1) Note. Protamine is a positively charged polypeptide which prolongs the effect of insulin.

6.7 Insulin affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects insulin.

6.8 Blood sugar affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered has an effect on the concentration of sugar in the blood.

(1) Note. Glucose and other sugars are transported via the blood stream, and are the primary sources of energy for the cells.

(2) Note. Glucose is the primary blood sugar.

6.9 Diabetes:
This subclass is indented under subclass 6.8. Subject matter wherein the peptide administered is useful in treating diabetes.

(1) Note. Diabetes as defined by the American Diabetes Association (2008) is a condition where a subject has a fasting plasma glucose level (FPG) above 126 mg/dl, while a level between 100 and 125 mg/dl is considered pre-diabetes. For purposes of this subclass, any FPG level of 100 mg/dl or higher is considered as being diabetic.

D. CHANGES TO THE DEFINITIONS

7.1 Somatostatin or derivative affecting or utilizing:
This subclass is indented under subclass 6.9. Subject matter wherein the peptide administered is somatostatin or a derivative thereof, or wherein a peptide is administered which has an effect on somatostatin.

(1) Note. Somatostatin is alternatively known as growth hormone inhibiting hormone (GHIH) or somatotropin release-inhibiting factor (SRIF).

(2) Note. Somatostatin is secreted in the digestive system and in the hypothalamus. It inhibits both insulin and glucagon secretion.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

806, for a cross-reference art collection of subject matter involving peptide compositions having somatostatin-like activity.

7.2 Glucagon, glucagon-like peptide (e.g., GLP-1, etc.) or derivative affecting or utilizing:
This subclass is indented under subclass 6.9. Subject matter wherein the peptide administered is glucagon, a glucagon-like peptide, or a derivative thereof, or wherein a peptide is administered which has an effect on glucagon or a glucagon-like peptide.

(1) Note. Glucagon is a 29 amino acid polypeptide hormone that is produced by the pancreas that promotes an increase in the sugar content of the blood by increasing the rate of glycogen breakdown in the liver.

(2) Note. GLP-1 is derived from the same precursor as glucagon, which is proglucagon. GLP-1 inhibits glucagon and stimulates secretion of insulin.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

7.3 Type I diabetes:
This subclass is indented under subclass 6.9. Subject matter wherein the peptide administered is useful in treating Type I diabetes (i.e., Insulin-Dependent Diabetes Mellitus (IDDM)), an autoimmune disease that results in destruction of insulin-producing beta cells of the pancreas.

7.4 Lipid or cholesterol affecting (e.g., dyslipidemia, etc.):
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered has an effect on lipid or cholesterol levels in the body.

(1) Note. Lipid (e.g., fats, oils, sterols, waxes, etc.) is a water-insoluble biomolecule or organic compound which is a structural constituent of a living cell affecting,

D. CHANGES TO THE DEFINITIONS

modulating, or regulating cellular metabolic functions together with carbohydrates and proteins or peptides.

(2) Note. Cholesterol is an important constituent of cell membranes as a lipid, responsible for permeability of metabolites and nutrients across the cell membrane of an animal cell.

(3) Note. Dyslipidemia is characterized by abnormal concentrations of lipids or lipoproteins in the blood.

7.5 Protein tyrosine kinase (PTK) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects protein tyrosine kinase (PTK) which catalyzes the phosphorylation of tyrosine residues in a protein.

(1) Note. Phosphorylation of proteins by kinases is an important mechanism in signal transduction for regulation of enzyme activity.

7.6 Growth factor or derivative affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a growth factor or a derivative thereof, which regulates cell proliferation, development, migration, or differentiation of cells or tissues, or wherein the peptide administered has an effect on a growth factor.

(1) Note. The term “growth factor” is meant to encompass any secretory factor that is growth stimulatory or growth inhibitory (i.e., that will stimulate or inhibit clonal expansion of cells).

(2) Note. The term “growth factor” is sufficient for placement of a peptide into this subclass.

(3) Note. Cytokines produced by both immune cells (i.e., antigen-presenting cells, lymphocytes, basophils, dendritic cells, granulocytes, helper T-cells, leukocytes, macrophages, and mast cells) and other cell types and cytokines where the origin is unspecified (not claimed, disclosed, or otherwise known) are cross-referenced here as appropriate.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.7, through 13.1, for a peptide hormone, especially subclass 11.3 for a growth hormone.

18.9, for a peptide composition which affects apoptosis.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclasses 85.1-85.7 for compositions containing cytokines, soluble immune mediators, produced by the cells of the immune system (i.e., antigen-presenting cells, lymphocytes, basophils, dendritic cells, granulocytes, helper T-cells, leukocytes, macrophages, and mast cells) and cytokines produced by both immune cells and other cell types.

7.7 Erythropoietin (EPO) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is erythropoietin (EPO) or a derivative thereof, or wherein the peptide administered has an effect on erythropoietin.

(1) Note. EPO is a glycoprotein (a protein with a sugar attached to it). It is a growth hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. Human EPO has a molecular weight of approximately 34,000 daltons.

(2) Note. It is proper to classify a peptide in this subclass if it is characterized as an erythropoietin growth factor regardless of function.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

7.8 Thrombopoietin (TPO) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is thrombopoietin (TPO) or a derivative thereof, or wherein the peptide administered has an effect on TPO.

(1) Note. TPO is a glycoprotein (a protein with a sugar attached to it). It is a hormone produced mainly by the liver and the kidney that regulates the production of platelets by the bone marrow.

(2) Note. It is proper to classify a peptide in this subclass if it is characterized as an thrombopoietin growth factor regardless of function.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

7.9 Hematopoiesis affecting:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a growth factor that has an effect on the formation and development of blood cells.

D. CHANGES TO THE DEFINITIONS

8.1 Vascular endothelial growth factor (e.g., VEGF-A, VEGF-B, etc.) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is vascular endothelial growth factor or a derivative thereof, or wherein the peptide administered has an effect on vascular endothelial growth factor.

(1) Note. Vascular endothelial growth factor is a signaling peptide that stimulates the formation of new blood vessels, as well as new blood vessels from pre-existing ones. It is also important in the development of the embryonic circulatory system.

(2) Note. Vascular endothelial growth factors (e.g., VEGF-A, VEGF-B, VEGF-C, placenta growth factor (PIGF), etc.) are a subfamily of growth factors.

(3) Note. It is proper to classify a peptide in this subclass if it is characterized as an endothelial or vascular growth factor regardless of function.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

13.3, for a peptide composition which affects angiogenesis.

8.2 Platelet-derived growth factor (PDGF) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is platelet-derived growth factor (PDGF) or a derivative thereof, or wherein the peptide administered has an effect on PDGF.

(1) Note. PDGF plays a significant role in blood vessel formation, as well as the growth of blood vessels from already existing blood vessel tissue.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.3 Nerve tissue or nerve cell growth affecting:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a growth factor which affects the proliferation, development, migration, or differentiation of nerve cells or nerve tissues.

(1) Note. Nervous tissue is the material composed of neurons that make up the brain, spinal cord, and network of nerves around the body.

8.4 Nerve growth factor (NGF) or derivative:
This subclass is indented under subclass 8.3. Subject matter wherein the peptide administered is nerve growth factor (NGF) or a derivative thereof, or wherein the peptide administered has an effect on NGF.

D. CHANGES TO THE DEFINITIONS

(1) Note. NGF is a naturally occurring peptide in the body which stimulates growth and differentiation of the sympathetic sensory nerves. It consists of alpha, beta, and gamma polypeptide chains.

(2) Note. It is proper to classify a peptide in this subclass if it is characterized as a nerve growth factor regardless of function.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.5 Insulin-like growth factor (IGF) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is an insulin-like growth factor (IGF) or a derivative thereof, or wherein the peptide administered has an effect on IGF.

(1) Note. IGF may also be called somatomedin.

(2) Note. Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), etc. are part of a complex system that cells use to communicate with their physiologic environment and which has a high sequence similarity to insulin.

(3) Note. IGF-1 is also called somatomedin C and IGF-2 is also called somatomedin A.

(4) Note. It is proper to classify a peptide in this subclass if it is categorized as IGF, regardless of use.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.6 Insulin-like growth factor 1 (IGF-1) or derivative:
This subclass is indented under subclass 8.5. Subject matter wherein the peptide administered is insulin-like growth factor 1 (IGF-1) or a derivative thereof, or wherein the peptide administered has an effect on IGF-1.

(1) Note. IGF-1 may also be called somatomedin C.

(2) Note. IGF-1 is a natural hormone consisting of 79 amino acids in a single chain with 3 intra-molecular disulfide bridges with a molecular weight of 7,649 daltons.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

D. CHANGES TO THE DEFINITIONS

8.7 Insulin-like growth factor binding protein (IGFBP) or derivative:
This subclass is indented under subclass 8.5. Subject matter wherein the peptide administered is insulin-like growth factor binding protein (IGFBP) or a derivative thereof, or wherein the peptide administered has an effect on IGFBP.

(1) Note. IGFBP is a family of cysteine rich (16-20 cysteines) proteins which binds IGF.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.8 Bone morphogenic protein (BMP) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a bone morphogenic protein (BMP) or derivative thereof, or wherein the peptide administered has an effect on BMP.

(1) Note. BMPs are generally involved in the formation of bone or cartilage.

(2) Examples of BMPs include osteogenic protein-1 (OP-1), BMP-3, OP-2, BMP-4, etc.

(3) Note. It is proper to classify a peptide in this subclass if it is categorized as BMP, regardless of use.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

8.9 Transforming growth factor (TGF) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a transforming growth factor (TGF) or a derivative thereof, or wherein the peptide administered has an effect on TGF.

(1) Note. TGF (e.g., TGF-beta, etc.) is generally involved in inducing cellular transformation and in stimulating the growth of normal cells.

(2) Note. It is proper to classify a peptide in this subclass if it is characterized as TGF, regardless of use.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.1 Fibroblast growth factor (FGF) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a fibroblast growth factor (FGF) or a derivative thereof, or wherein the peptide administered has an effect on FGF.

D. CHANGES TO THE DEFINITIONS

(1) Note. FGFs are particularly involved in wound healing, angiogenesis, and embryonic development.

(2) Note. The FGF family consists of four members: FGFR1, FGFR2, FGFR3, and FGFR4.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.4, for a peptide composition which affects wound healing or repair.

13.3, for a peptide composition which affects angiogenesis.

9.2 Keratinocyte growth factor (KGF) or derivative:
This subclass is indented under subclass 9.1. Subject matter wherein the fibroblast growth factor administered is keratinocyte growth factor (KGF) or a derivative thereof, or wherein the peptide administered has an effect on KGF.

(1) Note. KGF, also known as fibroblast growth factor 7 (FGF7), has an important role in wound healing or repair.

(2) Note. KGF stimulates the growth of epithelial cells in the skin and in the lining of the mouth, stomach, and intestines.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.4, for a peptide composition which affects wound healing or repair.

9.3 Fibronectin or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is fibronectin or a derivative thereof, or wherein the peptide administered has an effect on fibronectin.

(1) Note. Fibronectin is a glycopeptide growth factor of 2,000 daltons molecular weight with two polypeptide chains linked by disulfide bonds.

(2) Note. Functions of fibronectin include cellular adhesion mediation, cell shape, and migration control.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

D. CHANGES TO THE DEFINITIONS

9.4 Wound healing or wound repair affecting:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is a growth factor or derivative thereof, which affects the natural process of regenerating internal or external tissues which have been damaged, or wherein the peptide administered has an effect on a growth factor whose function is to regenerate internal and external tissues which have been damaged.

(1) Note. Wound healing or repair is a complex and dynamic process of restoring cellular structures and tissue layers.

9.5 Hepatocyte growth factor (HGF) or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is hepatocyte growth factor (HGF) or a derivative thereof, or wherein the peptide administered has an effect on HGF.

(1) Note. HCF, also known as scatter factor, is a polypeptide involved in cellular growth, motility, and morphogenesis.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.6 Epidermal growth factor (EFG) or epidermal growth factor-like or derivative:
This subclass is indented under subclass 7.6. Subject matter wherein the peptide administered is an epidermal growth factor (EGF) or epidermal growth factor-like (EGF-like), or a derivative thereof, or wherein the peptide administered has an effect on EFG.

(1) Note. EGF stimulates and sustains the replication of epidermal cells (of ectodermal or endodermal origin).

(2) Note. Human EGF is a 6,045-dalton protein with 53 amino acid residues and 3 intramolecular disulfide bonds.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.7 Hormone or derivative affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a hormone, which affects, enhances, or modulates the carrying of information for metabolic function from host cell to target cell or wherein the peptide administered has an effect on a hormone.

(1) Note. The term “hormone” is sufficient for placement of a peptide into this subclass. It is not necessary that the peptide described as a “hormone” be used for that purpose.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

9.8 Fertility:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide administered is a hormone, or a derivative thereof, which affects the physiological mechanisms or conditions that inhibit or promote ability to produce offspring, or wherein a peptide is administered which has an effect on a hormone which is involved in inhibiting or promoting the ability to produce offspring.

9.9 Follicle-stimulating hormone (FSH) or derivative:
This subclass is indented under subclass 9.8. Subject matter wherein the peptide hormone administered is follicle stimulating hormone (FSH), which is normally produced by the pituitary gland or a derivative thereof, or wherein the peptide administered has an effect on FSH.

(1) Note. FSH promotes reproductive function by stimulating the growth of follicles in the ovary or inducing the formation of sperm in the testes.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

10.1 Luteinizing hormone (LH) or derivative:
This subclass is indented under subclass 9.8. Subject matter wherein the peptide hormone administered is luteinizing hormone (LH) or a derivative thereof, or wherein the peptide administered has an effect on LH.

(1) Note. LH controls the length and sequence of the female menstrual cycle, including ovulation, preparation of the uterus for implantation of a fertilized egg, and ovarian production of both estrogen and progesterone. In males, it stimulates the testes to produce androgen.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

10.2, for a peptide which affects androgen or estrogen.

10.2 Androgen (e.g., testosterone, etc.) or estrogen affecting:
This subclass is indented under subclass 9.8. Subject matter wherein the peptide administered has an effect on androgen or estrogen levels in the body.

(1) Note. Androgens include testosterone.

(2) Note. Estrogen is secreted by the ovaries.

D. CHANGES TO THE DEFINITIONS

10.3 Gonadotropin-releasing hormone (GnRH) or derivative:
This subclass is indented under subclass 9.8. Subject matter wherein the peptide hormone administered is gonadatropin-releasing hormone (GnRH) or a derivative thereof, or wherein the peptide administered has an effect on gonadatropin-releasing hormone.

(1) Note. GnRH, also known as luteinizing-hormone releasing hormone (LHRH), is a decapeptide which stimulates the synthesis and secretion of the gonadotropins from the anterior pituitary.

(2) Note. Gonadotropins include luteinizing hormone (LH), follicle stimulating hormone (FSH), and human chorionic gonadotropin (hCG).

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

800, for a cross-reference art collection of subject matter involving compositions containing peptides that influence the release of luteinizing hormone.

10.4 Cetrorelix, leuprolide, or deslorelin utilizing:
This subclass is indented under subclass 10.3. Subject matter wherein the peptide administered is cetrorelix, leuprolide, or deslorelin, synthetic analogues of naturally occurring gonadotropin-releasing hormone.

(1) Note. Cetrorelix is a synthetic decapeptide which acts as an injectable GnRH antagonist.

(2) Note. Leuprorelin, which is a synonym for leuprolide, is a synthetic nonapeptide analogue of GnRH.

(3) Note. Deslorelin is a synthetic nonapeptide analogue of the natural GnRH.

10.5 Ovulation affecting:
This subclass is indented under subclass 10.3. Subject matter wherein the gonadotropin-releasing hormone (i.e., GnRH) or derivative thereof, administered affects the process in the menstrual cycle during which a mature ovarian follicle ruptures and discharges an ovum (i.e., oocyte, female gamete, egg).

10.6 Synthetic gonadotropin-releasing hormone antagonist:
This subclass is indented under subclass 10.3. Subject matter wherein the peptide administered is a synthetic peptide that competes with gonadotropin-releasing hormone (GnRH) for its receptor, thus decreasing or blocking GnRH action.

10.7 Melanocortin (e.g., melanocyte-stimulating hormone (MSH), etc.) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is a melanocortin, which is normally produced by the pituitary gland or a derivative thereof, or wherein the peptide administered has an effect on a melanocortin.

D. CHANGES TO THE DEFINITIONS

(1) Note. Melanocortins are known to be involved in regulating other hormones involved in cell pigmentation.

(2) Melanocortins include melanocyte-stimulating hormone (MSH), etc.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

10.8 Corticotropin or derivative:
This subclass is indented under subclass 10.7. Subject matter wherein the melanocortin administered is corticotropin, which is normally produced by the pituitary gland, or a derivative thereof, or wherein the peptide administered has an effect on corticotropin.

(1) Note. Corticotropin is also known as adrenocorticotropin (ACTH).

(2) Note. Corticotropin stimulates the adrenal glands to produce cortisol and other steroid hormones.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

805, for a cross-reference art collection of subject matter involving a peptide composition having adrenocorticotropic activity.

10.9 Vasopressin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is vasopressin, which is normally produced by the pituitary gland, or a derivative thereof, or wherein the peptide administered has an effect on vasopressin.

(1) Note. Vasopressin, also called antidiuretic hormone (ADH), is involved in the regulatory function of the circulatory system, including constricting blood vessels, raising blood pressure so as to help keep a regular balance of salts in the blood, and controlling the amount and frequency of urination. Without vasopressin, too much water is lost in the urine.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.6, for a composition containing oxytocin or a derivative thereof.

807, for a cross-reference art collection of subject matter involving a peptide composition related to oxytoxin, vasopressin, or a derivative thereof.

D. CHANGES TO THE DEFINITIONS

11.1 Somatostatin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is somatostatin or a derivative thereof, or wherein the peptide administered has an effect on somatostatin.

(1) Note. Somatostatin is also known as growth hormone inhibiting hormone (GHIH) or somatotropin release-inhibiting factor (SRIF).

(2) Note. Somatostatin is secreted in the digestive system and in the hypothalamus. Somatostatin inhibits both insulin and glucagon secretion and also inhibits the secretion of several gastrointestinal hormones (e.g., gastrin, etc.) and affects nutrient absorption and motility in the gastrointestinal tract.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

806, for a cross-reference art collection of subject matter involving peptide compositions having somatostatin-like activity.

11.2 Growth-hormone-releasing hormone (GHRH) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is growth hormone-releasing hormone (GHRH) or a derivative thereof, which stimulates the release of growth hormone, or wherein the peptide administered has an effect on GHRH.

(1) Note. GHRH is also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.3 Growth hormone (GH) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is growth hormone (GH), normally produced by the anterior lobe of pituitary gland which stimulates growth and cell reproduction in humans and other animals, or a derivative thereof, or wherein the peptide administered has an effect on GH.

(1) Note. GH is alternatively known as somatotrophin, somatotropin, somatotropic hormone, somatotrophic hormone, STH, and human growth hormone (hGH).

(2) Note. Human somatotrophin contains 191 amino acids.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

D. CHANGES TO THE DEFINITIONS

11.4 Human growth hormone (hGH) or derivative:
This subclass is indented under subclass 11.3. Subject matter wherein the growth hormone administered is human growth hormone (hGH) or a derivative thereof, or wherein the peptide administered has an effect on hGH.

(1) Note. HGH consists of 191 amino acids and has a molecular weight of 22,124 daltons.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.5 Prolactin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is prolactin, which is normally produced by the pituitary gland, or a derivative thereof, or wherein the peptide administered has an effect on prolactin.

(1) Note. Prolactin is alternatively known as lactogenic hormone, lactotropin, luteotropic hormone, and luteotropin.

(2) Note. Human prolactin is a single chain polypeptide of 199 amino acids with a molecular weight of approximately 24,000 daltons. The molecule is folded due to the activity of three disulfide bonds.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.6 Oxytocin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is oxytocin or a derivative thereof, or wherein the peptide administered has an effect on oxytocin.

(1) Note. Oxytocin is a polypeptide hormone secreted by the posterior portion of the pituitary gland. Oxytocin stimulates the contraction of smooth muscle of the uterus during childbirth and facilitates ejection of milk from the mammary glands.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

807, for a cross-reference art collection of subject matter involving a peptide composition related to oxytoxin, vasopressin, or a derivative thereof.

D. CHANGES TO THE DEFINITIONS

11.7 Glucagon, glucagon-like peptide (e.g., GLP-1, GLP-2, etc.) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is glucagon or a glucagon-like peptide, or a derivative thereof, or wherein the peptide administered has an effect on glucagon or glucagon-like peptide.

(1) Note. Glucagon is a polypeptide hormone that is produced by the pancreas that promotes an increase in the sugar content of the blood by increasing the rate of glycogen breakdown in the liver.

(2) Note. Examples of glucagon-like peptides include GLP-1 which inhibits glucagon and stimulates the release of insulin, and GLP-2 which enhances intestinal growth and function.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.8 Parathyroid hormone (PTH) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is parathyroid hormone (PTH), which is derived from the parathyroid gland, or a derivative thereof, or wherein the peptide administered has an effect on PTH.

(1) Note. PTH, also known as parathormone, is a polypeptide containing 84 amino acids produced by the parathyroid glands that regulate the amount of calcium and phosphorus in the body. PTH has a molecular weight of approximately 9,500 daltons.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

11.9 Calcitonin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is calcitonin or a derivative thereof, or wherein the peptide administered has an effect on calcitonin.

(1) Note. Calcitonin is a peptide hormone containing 32 amino acids produced by the thyroid gland that lowers the levels of calcium and phosphate in the blood and promotes the formation of bones.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

808, for a cross-reference art collection of subject matter involving a peptide composition related to calcitonin or a derivative thereof.

D. CHANGES TO THE DEFINITIONS

12.1 Muscle contraction affecting (e.g., muscle twitch, muscle relaxation, etc.):
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered affects the process leading to shortening or tensing of a muscle or muscle fiber in action or movement, or wherein the peptide administered has an effect on a hormone which affects muscle contraction.

(1) Note. The muscle may lengthen, shorten, or remain the same while under tension.

(2) Note. A muscle relaxant alleviates muscle contraction and reduces muscle spasm and twitch.

12.2 Anti-inflammatory:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered affects conditions characterized by redness, warmth, swelling, or pain, or wherein the peptide administered has an effect on a hormone which affects inflammation.

SEE OR SEARCH THIS CLASS, SUBCLASS:

18.7, for skin affecting anti-inflammatory peptide compositions which are not hormones.

803, for a cross-reference art collection of subject matter wherein the peptide composition has kinin-like activity.

12.3 Gastrin hormone or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is gastrin, which is normally produced by the G cells, or a derivative thereof, or wherein the peptide administered has an effect on gastrin.

(1) Note. G cells are specialized cells in the stomach that secrete gastrin.

(2) Note. Forms of gastrin include gastrin-34, gastrin-17, gastrin-14, etc.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

19.7, for a composition containing bombesin or a derivative thereof.

12.4 Natriuretic peptide or derivative (e.g., atrial natriuretic peptide, brain natriuretic peptide, etc.):
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is a natriuretic peptide, which induces natriuresis, or a derivative thereof, or wherein the peptide administered has an effect on a natriuretic peptide hormone.

D. CHANGES TO THE DEFINITIONS

(1) Note. Examples of natriuretic peptides include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), etc.

(2) Note. Natriuresis is the process of excretion of sodium in the urine via the action of the kidneys. Natriuresis lowers the concentration of sodium in the blood and also tends to lower blood volume because osmotic forces tend to make water follow sodium out of the body's blood circulation and into the urine.

12.5 Bradykinin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is bradykinin or a derivative thereof, or wherein the peptide administered has an effect on bradykinin.

(1) Note. Bradykinin is a nonapeptide that that causes blood vessels to enlarge, and therefore causes blood pressure to lower.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

803, for a cross-reference art collection of subject matter wherein the peptide composition has kinin-like activity.

12.6 Cholecystokinin (CCK) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is cholecystokinin (CCK), or a derivative thereof, or wherein the peptide administered has an effect on CCK.

(1) Note. CCK, also known as pancreozymin, is a peptide hormone secreted especially by the duodenal mucosa that regulates the emptying of the gallbladder and secretion of enzymes by the pancreas, and that has also been found in the brain.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

12.7 Relaxin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is relaxin or a derivative thereof, or wherein the peptide administered has an effect on relaxin.

(1) Note. Relaxin is a peptide hormone produced by the corpus luteum that facilitates birth by causing relaxation of the pelvic ligaments.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

D. CHANGES TO THE DEFINITIONS

12.8 Secretin or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is secretin or a derivative thereof, or wherein the peptide administered has an effect on secretin.

(1) Note. Secretin is an intestinal hormone capable of stimulating secretion of digestive enzymes from the pancreas and bile from the liver.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

12.9 Thymosin (e.g., thymosin alpha 1, thymosin beta 4, etc.) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is thymosin or a derivative thereof, or wherein the peptide administered has an effect on thymosin.

(1) Note. Thymosin is an actin-binding protein in cells isolated from the thymus.

(2) Note. Examples of thymosins include thymosin alpha 1, thymosin beta 4, etc.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

13.1 Vasoactive intestinal peptide (VIP) or derivative:
This subclass is indented under subclass 9.7. Subject matter wherein the peptide hormone administered is vasoactive intestinal peptide (VIP) or a derivative thereof, or wherein the peptide administered has an effect on VIP.

(1) Note. VIP is a peptide hormone containing 28 amino acid residues produced in many areas of the human body, including the gut, pancreas, and suprachiasmatic nuclei of the hypothalamus in the brain.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

13.2 Digestive tract ulcer affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is useful in treating or preventing the erosion of the lining of the gastrointestinal (GI) tract.

(1) Note. Ulcers are normally caused by the imbalance of the acidic environment in the regions of the GI tract which include the stomach, duodenum, and intestines.

D. CHANGES TO THE DEFINITIONS

13.3 Angiogenesis affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects angiogenesis, the process of developing new blood vessels.

13.4 Blood substitute:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is part of a biocompatible composition which in its use mimics blood in performing the normal vital physiological functions normally associated with blood in a living organism.

SEE OR SEARCH THIS CLASS, SUBCLASS:

13.5, for a peptide composition containing a blood protein or a peptide composition which affects the blood.

13.5 Blood affecting or blood protein utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a blood protein, or wherein the peptide administered affects the specialized biological fluid as an essential carrier or medium of metabolic nutrients, oxygen, carbon dioxide, and other waste products in a living organism.

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclasses 529-534 for therapeutic or body treating compositions containing an extract or material of undetermined chemical constitution derived from blood.

13.6 Fibrin or derivative affecting or utilizing:
This subclass is indented under subclass 13.5. Subject matter wherein the peptide administered is fibrin, an essential component for blood clotting over a wound site, or a derivative thereof, or wherein a peptide is administered which has an effect on fibrin.

(1) Note. Fibrin is formed by the action of thrombin on fibrinogen when blood clots.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

802, for a cross-reference art collection of subject matter wherein the peptide composition is related to fibrinopeptides, blood-coagulation factors, or derivatives.

13.7 Coagulation affecting:
This subclass is indented under subclass 13.5. Subject matter wherein the peptide administered affects the process by which the blood forms clots.

(1) Note. Coagulation is an important part of hemostasis (i.e., the cessation of blood loss from a damaged vessel) whereby a damaged blood vessel wall is covered by

D. CHANGES TO THE DEFINITIONS

clot-forming constituents to stop bleeding and begin repair of the damaged vessel.

SEE OR SEARCH THIS CLASS, SUBCLASS:

802, for a cross-reference art collection of subject matter wherein the peptide composition is related to fibrinopeptides, blood-coagulation factors, or derivatives.

13.8 Platelet aggregation or adhesion affecting:
This subclass is indented under subclass 13.7. Subject matter wherein the peptide administered affects the process by which platelets clump together or attach to the collagen that is exposed by endothelial damage.

13.9 Glycoprotein IIb/IIIa affecting:
This subclass is indented under subclass 13.8. Subject matter wherein the peptide administered affects glycoprotein IIb/IIIa (GP IIb/IIIa), an integrin found on the surface of platelets.

(1) Note. GP IIb/IIIa is a receptor for fibrinogen and aids in platelet activation.

(2) Note. GP IIb/IIIa inhibitors can be used to prevent blood clots in an effort to decrease the risk of heart attack or stroke.

14.1 Factor VIII or derivative affecting or utilizing:
This subclass is indented under subclass 13.7. Subject matter wherein the peptide administered is factor VIII or a derivative thereof, or wherein the peptide administered has an effect on blood coagulation factor VIII.

(1) Note. Factor VIII is a glycoprotein found in blood plasma that plays a crucial role in blood clotting.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

14.2 Plasma protease affecting:
This subclass is indented under subclass 13.7. Subject matter wherein the peptide administered affects a plasma protease.

14.3 Factor VIIa affecting:
This subclass is indented under subclass 14.2. Subject matter wherein the peptide administered affects coagulation factor VIIa.

(1) Note. Factor VIIa (trypsin-like serine protease) is the activated form of factor VII.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing factor VIIa.

14.4 Factor Xa affecting:
This subclass is indented under subclass 14.2. Subject matter wherein the peptide administered affects coagulation factor Xa, a serine endopeptidase which cleaves prothrombin to yield the active thrombin.

(1) Note. Factor Xa may also be known as thrombokinase.

(2) Note. Factor Xa is the activated form of Factor X.

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing factor Xa.

14.5 Tissue factor pathway inhibitor (TFPI) utilizing:
This subclass is indented under subclass 14.4. Subject matter wherein the peptide administered is tissue factor pathway inhibitor (TFPI) or a derivative thereof, or wherein the peptide administered has an effect on tissue factor pathway inhibitor, a single-chain polypeptide which can reversibly inhibit factor Xa.

14.6 Urokinase affecting:
This subclass is indented under subclass 14.2. Subject matter wherein the peptide administered affects urokinase, a proteolytic enzyme involved in the process of thrombolysis, which is the dissolution of blood clots.

(1) Note. Urokinase may also be known as urokinase-type plasmninogen activator (uPA).

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing urokinase.

14.7 Thrombin affecting:
This subclass is indented under subclass 14.2. Subject matter wherein the peptide administered affects thrombin, the coagulation protein formed from prothrombin that facilitates the clotting of blood by catalyzing conversion of soluble fibrinogen to insoluble strands of fibrin.

(1) Note. Thrombin may also be known as factor IIa.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing thrombin.

14.8 Hirudin or derivative utilizing:
This subclass is indented under subclass 14.7. Subject matter wherein the peptide administered is hirudin or a derivative thereof.

(1) Note. Hirudin contains 65 amino acids.

(2) Note. Hirudin is normally derived from the buccal glands of leeches and affects the coagulation properties of blood and is known to inhibit thrombin.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

14.9 Thrombosis affecting:
This subclass is indented under subclass 13.7. Subject matter wherein the peptide affects the undesired formation of a clot, or thrombus, inside a blood vessel obstructing the flow of blood through the circulatory system (e.g., by preventing the formation of a clot or dissolving an existing clot).

15.1 Oxidative stress affecting:
This subclass is indented under subclass 13.5. Subject matter wherein the peptide administered affects the condition of increased oxidant production in blood cells, characterized by the release of free oxygen radicals and resulting in cellular degeneration, or a disorder resulting from a shortage of oxygen, such as ischemia or reperfusion injury.

15.2 Albumin or derivative affecting or utilizing:
This subclass is indented under subclass 13.5. Subject matter wherein the peptide administered is albumin, a common protein found in the blood, or a derivative thereof, or wherein the peptide administered has an effect on albumin.

(1) Note. Albumin is a major plasma protein which is an integral transporter of nutrients within the body. Albumin may also assist in maintaining blood volume in the arteries and veins.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

15.3 Plasma protein affecting or utilizing:
This subclass is indented under subclass 13.5. Subject matter wherein the peptide administered is a plasma protein, or wherein the peptide administered has an effect on a plasma protein.

D. CHANGES TO THE DEFINITIONS

(1) Note. Plasma is the liquid part of the blood and lymphatic fluid, which makes up about half of its volume. Plasma is the colorless constituent of the blood in which the red and white blood corpuscles are suspended and is composed of water, dissolved proteins, glucose, clotting factors, etc.

15.4 Kidney affecting:
The subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the kidney, an organ with numerous metabolic functions, whose primary role is to maintain the homeostatic balance of bodily fluids.

(1) Note. Three important homeostatic functions of the kidney include:

(a) Filter waste materials out of the blood and pass them out of the body as urine.

(b) Regulate blood pressure and the levels of metabolites (e.g., water, salts, minerals in the body, etc.).

(c) Produce hormones that control other body functions.

SEE OR SEARCH THIS CLASS, SUBCLASS:

15.6, for a peptide composition which affects blood pressure.

15.5 Surfactant protein (e.g., SP-A, SP-B, etc.) or derivative affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is surfactant protein or a derivative thereof, or wherein the peptide administered has an effect on a surfactant protein.

(1) Note. Surfactant protein is a component of the pulmonary surfactant system. Pulmonary surfactant is a lipid-protein complex which is synthesized and secreted by the respiratory epithelium of the lungs to the alveolar spaces. The main function of the pulmonary surfactant is to reduce the surface tension at the air/liquid interface in the lung, thereby minimizing the work of breathing.

(2) Note. Surfactant proteins include SP-A, SP-B, SP-C, and SP-D.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

1.5, for a peptide composition which affects respiratory distress syndrome (e.g., ARDS, IRDS, etc.).

D. CHANGES TO THE DEFINITIONS

15.6 Blood pressure affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the pressure of blood flow against the walls of the arteries, either to raise or lower said pressure.

SEE OR SEARCH THIS CLASS, SUBCLASS:

803, for a cross-reference art collection of subject matter wherein the peptide composition has kinin-like activity.

15.7 Hypertension:
This subclass is indented under subclass 15.6. Subject matter wherein the peptide administered is useful in treating patients who suffer from high blood pressure (i.e., a systolic pressure of 120 mm/Hg or higher and a diastolic pressure of 80 mm/Hg or higher).

(1) Note. Technically, patients having a systolic blood pressure of 140 mm/Hg and a diastolic blood pressure of 90 mm/Hg are considered as having hypertension, or high blood pressure, whereas patients whose systolic pressure is between 120 and 139 mm/Hg, and whose diastolic pressure is between 80 and 90 mm/Hg are considered pre-hypertensive. For purposes of this subclass, pre-hypertension is considered to be the same as hypertension.

15.8 Renin inhibitor affecting or utilizing:
This subclass is indented under subclass 15.7. Subject matter wherein the peptide administered affects the activity of a renin inhibitor, or wherein the peptide administered is a renin inhibitor and inhibits the enzyme renin.

(1) Note. Renin is a part of the renin-angiotensin system which is a group of related substances which act together to regulate blood pressure as well as the body's salt and water balance. Renin, also known as angiotensinogenase, is an enzyme secreted by the kidneys that catalyzes the formation of angiotensin 1.

15.9 Dipeptide renin inhibitor:
This subclass is indented under subclass 15.8. Subject matter wherein the peptide administered, which inhibits rennin, consists of an uninterrupted chain of only two amino acid residues.

.

16.1 Endothelin (e.g., ET-2, ET-3, etc.) or derivative affecting or utilizing:
This subclass is indented under subclass 15.7. Subject matter wherein the peptide administered is endothelin, which is produced by the vascular endothelium, or a derivative thereof, or wherein the peptide administered has an effect on endothelin.

(1) Note. Endothelin is a 21-amino acid peptide that functions as a vasoconstricting peptide and also maintains a delicate balance between vasodilation and vasoconstriction in controlling hypertension.

D. CHANGES TO THE DEFINITIONS

(2) Note. Examples of endothelin include endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3).

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

16.2 Angiotensin converting enzyme (ACE) affecting:
This subclass is indented under subclass 15.7. Subject matter wherein the peptide administered affects angiotensin converting enzyme (ACE) that converts angiotensin I to its activated form, angiotensin II.

(1) Note. Angiotensin II is a peptide that can act as a vasoconstricting agent (causing blood vessels to narrow).

(2) Note. Peptides which inhibit or slow the activity of the enzyme ACE (ACE inhibitors), thereby decreasing the production of Angiotensin II, can lower the effects of hypertension by dilating blood vessels.

(3) Note. ACE is alternatively known as angiotensin I converting enzyme, carboxycathepsin, dipeptidyl carboxypeptidase I, kininase II, peptidase P, and peptidyl dipeptidase I.

16.3 Angiotensin converting enzyme (ACE) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects angiotensin converting enzyme (ACE) that converts angiotensin I to its activated form, angiotensin II.

(1) Note. Angiotensin II is a peptide that can act as a vasoconstricting agent (causing blood vessels to narrow).

(2) Note. ACE is alternatively known as angiotensin I converting enzyme, carboxycathepsin, dipeptidyl carboxypeptidase I, kininase II, peptidase P, and peptidyl dipeptidase I.

16.4 Cardiac disease (i.e., heart disease) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the structure or a function of the heart to treat disease.

(1) Note. This subclass only refers to the cardiac muscle and its related pathological condition.

16.5 Tissue development affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the progression of a cell cluster over time, from its formation to its mature structure.

D. CHANGES TO THE DEFINITIONS

16.6 Rheumatoid arthritis affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating a chronic autoimmune disease, called rheumatoid arthritis, characterized by pain, swelling, inflammation, and destruction of the joints.

16.7 Bone affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the rigid calcified connective tissue that constitutes the skeletal framework of living organisms, or is useful in preventing conditions that affect the bone.

(1) Note. Bone is composed of a matrix of collagen, phosphate, and other minerals.

SEE OR SEARCH THIS CLASS, SUBCLASS:

17.1, for a peptide composition which affects cartilage.

17.2, for a peptide composition wherein collagen or a derivative is affected or utilized.

16.8 Osteoarthritis:
This subclass is indented under subclass 16.7. Subject matter wherein the peptide is useful in treating the loss of the connective tissue between two or more bones, or in preventing the onset of osteoarthritis.

(1) Note. Osteoarthritis develops when the cartilage (cushioning at the ends of the bones) breaks down.

16.9 Osteoporosis:
This subclass is indented under subclass 16.7. Subject matter wherein the peptide is useful in treating the loss of bone density caused by reduced calcium absorption, or in preventing the onset of osteoporosis.

(1) Note. Osteoporosis is a disease condition that leads to reduction of bone mineral density, or disruption of microarchitecture resulting in increased risk of fracture.

17.1 Cartilage affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the connective tissue that covers the ends of bones, or is useful in preventing the onset of conditions that affect cartilage.

17.2 Collagen or derivative affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is collagen or a derivative thereof, or wherein a peptide is administered which has an effect on collagen.

(1) Note. For the purposes of this subclass, gelatin is considered a derivative of collagen.

D. CHANGES TO THE DEFINITIONS

(2) Note. Collagen's molecular weight is approximately 130,000 daltons. The collagen molecule contains three peptide chains, each having 1,000 amino acids. Nearly one third of all the residues are glycine, with typical repeating sequences being Gly-Pro-Hyp and Gly-Pro-Ala. The chains are arranged in a triple helix and contain intramolecular cross-links.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

801, for a cross-reference art collection of subject matter wherein the peptide composition contains collagen, gelatin, or derivatives.

17.3 N-methyl-d-aspartate (NMDA) receptor affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects a type of glutamate receptor, called N-methyl-d-aspartate (NMDA) receptor, that participates in excitatory neurotransmission.

(1) Note. Activation of NMDA receptors results in the opening of an ion channel that is nonselective to cations which allows flow of sodium and small amounts of calcium into the cell and potassium out of the cell.

SEE OR SEARCH THIS CLASS, SUBCLASS:

17.4, for a peptide composition which affects an ion channel protein.

17.4 Ion channel protein affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects a pore-forming protein complex, called ion channel protein, which resides at the cell periphery.

(1) Note. Ion channel proteins facilitate the diffusion of ions across biological membranes or phospholipid bilayers.

(2) Note. Ion channels provide a high conducting, hydrophilic pathway across the hydrophobic interior of the membrane.

.

17.5 Mental disorder or mental illness (e.g., psychoses, etc.) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating a condition of psychological or clinical impairment or a disorder of the normal emotional or behavioral function in an individual.

(1) Note. Disorders include, but are not limited to, mood, anxiety, psychotic, eating, developmental, personality, etc.

17.6 Anti-depressant or derivative affecting or utilizing:
This subclass is indented under subclass 17.5. Subject matter wherein the peptide administered is an antidepressant, an agent used to prevent or treat clinical depression, or

D. CHANGES TO THE DEFINITIONS

a derivative thereof, or wherein the peptide administered has an effect on an anti-depressant.

(1) Note. Clinical depression is characterized by pervasive low mood, loss of interest in normal activities, and diminished ability to experience pleasure.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

17.7 Nervous system (e.g., central nervous system (CNS), etc.) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects conditions or processes of the central or peripheral nervous systems.

(1) Note. The central nervous system consists of the brain and spinal cord. The peripheral nervous system (PNS) extends outside the central nervous system (CNS) and its primary purpose is to connect the CNS to the limbs and organs.

17.8 Alzheimer's disease:
This subclass is indented under subclass 17.7. Subject matter wherein the peptide is useful in treating the disease called Alzheimer's disease, marked by loss of cognitive ability typically associated with abnormal tissue and protein deposit buildup in the cerebral cortex.

17.9 Multiple sclerosis:
This subclass is indented under subclass 17.7. Subject matter wherein the peptide is useful in treating the disease called multiple sclerosis, a chronic, progressive disease marked by gradual degeneration of the nerve cells in the central nervous system that control voluntary muscle movement.

18.1 Neurotransmitter or derivative affecting or utilizing:
This subclass is indented under subclass 17.7. Subject matter wherein the peptide administered is a neurotransmitter, a substance which relays, amplifies, and modulates signals between a neuron and another cell or a derivative thereof, or wherein the peptide administered has an effect on a neurotransmitter.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term "derivative."

18.2 Neuropathy affecting:
This subclass is indented under subclass 17.7. Subject matter wherein the peptide is useful in treating an abnormal condition or disorder, called neuropathy, characterized by inflammation and degeneration of peripheral nervous system.

18.3 Pain affecting:
This subclass is indented under subclass 17.7. Subject matter wherein the peptide administered suppresses or alleviates pain or treats hyperanalgesia by increasing the body's response to a painful stimulus.

D. CHANGES TO THE DEFINITIONS

18.4 Opioid receptor affecting:
This subclass is indented under subclass 18.3. Subject matter wherein the peptide administered binds to receptors in the brain and other organs to alleviate pain.

(1) Note. Opioids are narcotic drugs that are generally prescribed to manage pain.

18.5 Enkephalin or derivative affecting or utilizing:
This subclass is indented under subclass 18.3. Subject matter wherein the peptide administered is enkephalin, a pentapeptide, or a derivative thereof, or wherein the peptide administered has an effect on enkephalin.

(1) Note. Enkephalin performs opiate and analgesic activities and has a marked affinity for opiate receptors.

(2) Note. Forms of enkephalin include Met-enkephalin, Leu-enkephalin, etc.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

809, for a cross-reference art collection of subject matter involving neurological peptides related to enkephalin or endorphin.

18.6 Skin affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects a natural protective body covering, excluding hair and nails, which is the site of the sense of touch.

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 78.02 for a topical body preparation containing solid synthetic organic polymer as designated organic active ingredient (DOAI).

18.7 Anti-inflammatory:
This subclass is indented under subclass 18.6. Subject matter wherein the peptide administered is useful in treating inflammatory conditions of the skin characterized by redness, warmth, swelling, or pain.

18.8 Cosmetic enhancement or care:
This subclass is indented under subclass 18.6. Subject matter wherein the peptide administered is useful in beautifying and improving the appearance of the skin.

(1) Note. Included herein are skin creams for the improvement of beauty, especially that of the complexion of the skin.

D. CHANGES TO THE DEFINITIONS

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 59 for a topical sun or radiation screening, or tanning preparation; subclass 62 for a composition which bleaches or removes color from live skin; subclass 63 for a composition which is applied topically for coloring the skin in either a limited or overall area (e.g., blemish cover, cheek rouge, eye shadow, etc.); subclass 69 for face or body powders for grooming, adorning, or absorbing; subclass 70.1 for a nontherapeutic composition for grooming or adorning the scalp; and subclass 78.02 for a topical body preparation containing solid synthetic organic polymer as designated organic active ingredient (DOAI).

18.9 Apoptosis affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the death of cells characterized by a programmed sequence of events which leads to the elimination of cells without releasing harmful substances into the surrounding area.

19.1 Cellular adhesion affecting or cell adhesion molecule (CAM) affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the cell adhesion process or the peptide administered is a cell adhesion molecule.

(1) Note. Cellular adhesion is the binding of a cell to another cell or to an extracellular matrix. Cellular adhesion is regulated by specific CAMs that interact with molecules on opposing cells or surfaces.

(2) Note. CAMs are integral membrane proteins that have cytoplasmic, transmembrane, and extracellular domains.

(3) Note. Examples of CAMs include intercellular adhesion molecule (ICAM), vascular-cell adhesion molecule (VCAM), endothelial leukocyte adhesion molecule-1 (ELAM-1), etc.

19.2 Neoplastic condition affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is useful in treating or preventing the abnormal growth of cells in a tissue (e.g., tumor, etc.).

19.3 Cancer:
This subclass is indented under subclass 19.2. Subject matter wherein the peptide administered is useful in treating or preventing a malignant growth caused by abnormal and uncontrolled cell division.

19.4 Breast:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered is useful in treating or preventing a malignant growth associated with the breast.

D. CHANGES TO THE DEFINITIONS

19.5 Prostate:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered is useful in treating or preventing a malignant growth associated with the prostate gland.

19.6 Leukemia:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered is useful in treating or preventing a malignant condition of the blood or bone marrow, called leukemia, which is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes).

19.7 Bombesin or derivative affecting or utilizing:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered is bombesin, or a derivative thereof, or wherein the peptide administered has an effect on bombesin.

(1) Note. Bombesin is a polypeptide which has been shown to play a role in cancer. Bombesin may stimulate the growth or migration of certain cancer cells.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

19.8 Metastasis affecting:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered affects the spreading, settling down, and growth of a cancerous tumor from one organ or part to another nonadjacent healthy organ or part.

19.9 Cyclopeptide utilizing:
This subclass is indented under subclass 19.3. Subject matter wherein the peptide administered is a cyclic structure, wherein the cyclic structure is formed by peptide bonding, disulfide bonding, hydrocarbon bonding, or other types of bonding, and has at least a dipeptide as an integral part thereof.

SEE OR SEARCH CLASS:

930, Peptide or Protein Sequence, subclass 260 for peptides or proteins with intrachain cysteine-cysteine bridges and subclass 270 for other cyclic peptides or proteins.

20.1 Protease inhibitor affecting or utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects the activity of a protease inhibitor or wherein the peptide administered is a protease inhibitor and inhibits the activity of protease.

(1) Note. Protease inhibitors prevent proteases from splitting proteins into peptides.

D. CHANGES TO THE DEFINITIONS

(2) Note. A protease is an enzyme which degrades proteins into smaller component peptides.

20.2 Cysteine protease inhibitor affecting or utilizing:
This subclass is indented under subclass 20.1. Subject matter wherein the peptide administered affects the activity of a cysteine protease inhibitor, or wherein the peptide administered is a cysteine protease inhibitor and inhibits the activity of a cysteine protease.

20.3 Serine protease inhibitor affecting or utilizing:
This subclass is indented under subclass 20.1. Subject matter wherein the peptide administered affects the activity of a serine protease inhibitor, or wherein the peptide administered is a serine protease inhibitor and inhibits the activity of a serine protease.

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing serine proteases.

20.4 Elastase inhibitor affecting or utilizing:
This subclass is indented under subclass 20.3. Subject matter wherein the peptide administered affects the activity of an elastase inhibitor or wherein the peptide administered is an elastase inhibitor and inhibits the activity of the enzyme elastase.

(1) Note. Elastase hydrolyzes proteins, including elastin which is responsible for the elastic properties of vertebrate tissues.

(2) Note. Elastases include pancreatic elastase, neutrophil elastase, etc.

SEE OR SEARCH CLASS:

424, Drug, Bio-Affecting and Body Treating Compositions, subclass 94.64 for therapeutic or body-treating compositions containing elastase.

20.5 Cyclosporine or derivative utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a cyclic oligopeptide, called cyclosporine, or a derivative thereof.

(1) Note. Cyclosporine is used to inhibit organ transplant rejection.

(2) Note. Cyclosporine is also known as ciclosporin and cyclosporin.

SEE OR SEARCH THIS CLASS, SUBCLASS:

1.1, for definition of the term “derivative.”

D. CHANGES TO THE DEFINITIONS

20.6 G-protein coupled receptor (GPCR) affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered affects G-protein coupled receptor (GPCR), which affects signal transmission into the cell.

(1) Note. GPCRs constitute a large and diverse family of proteins whose primary function is to transduce extracellular stimuli into intracellular signals. GPCRs are found only in eukaryotes.

20.7 Hair affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating or preventing conditions affecting the fine, flexible peptide strands that grow from the follicles on the skin.

20.8 Eye affecting:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide is useful in treating or preventing conditions of the eye, the organ that detects light and sends signals along the optic nerve to the visual and other areas of the brain.

20.9 Glycopeptide utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is bonded to a carbohydrate.

21.1 Cyclopeptide utilizing:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is a cyclic structure, wherein the cyclic structure is formed by peptide bonding, disulfide bonding, hydrocarbon bonding, or other types of bonding, and has at least a dipeptide as an integral part thereof.

SEE OR SEARCH CLASS:

930, Peptide or Protein Sequence, subclass 260 for peptides or proteins with intrachain cysteine-cysteine bridges and subclass 270 for other cyclic peptides or proteins.

21.2 100 or more amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 100 or more amino acid residues.

21.3 25 to 99 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 25 to 99 amino acid residues.

21.4 16 to 24 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 16 to 24 amino acid residues.

D. CHANGES TO THE DEFINITIONS

21.5 12 to 15 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 12 to 15 amino acid residues.

21.6 9 to 11 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 9 to 11 amino acid residues.

21.7 7 or 8 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 7 or 8 amino acid residues.

21.8 5 or 6 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 5 or 6 amino acid residues.

21.9 3 or 4 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 3 or 4 amino acid residues.

21.91 2 amino acid residues in the peptide chain:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered consists of an uninterrupted chain of 2 amino acid residues.

21.92 Produced by or extracted from animal tissue:
This subclass is indented under subclass 1.1. Subject matter wherein the peptide administered is derived from animal material.

FOR 109 Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI:
Foreign art collection which contains a protein or its reaction product, e.g., peptides, peptones, fibrinogen, etc., wherein the protein molecule is not degraded to the constituent amino-acids.

(1) Note. The term “peptide unit” used herein is intended to mean the group N-C-(=O) or beta-alanine.

FOR 110 Insulin or derivative:
Foreign art collection identical to the extract of the pancreas, known as insulin or a derivative thereof, in which neither a peptide chain nor a disulfide link between chains is broken.

(1) Note. While the position and/or kind of amino acids in the chain(s) may vary (depending on the animal from which derived), it appears that insulin contains at least an “A” chain of 21 acid units linked by disulfide moieties to a “B.” An additional disulfide moiety bridges the 6 and 11 positions of chain A.

FOR 111 With an additional active ingredient:
Foreign art collection which contains insulin and an additional active ingredient.

D. CHANGES TO THE DEFINITIONS

(1) Note. For this subclass, an organic potentiator for insulin is considered an active ingredient.

FOR 112 Iodine containing:
Foreign art collection in which the peptide moiety contains iodine or the peptide moiety is reacted with or complexed to iodine containing compound.

FOR 113 Heavy metal containing (e.g., hemoglobin, etc.):
Foreign art collection which contains a heavy metal atom.

(1) Note. See Glossary for a definition of the term “heavy metal.”

FOR 114 Phosphorus containing:
Foreign art collection which contains phosphorus in the peptide compound.

FOR 115 Glycoprotein (carbohydrate containing):
Foreign art collection which contains a carbohydrate or derivative thereof attached to the peptide.

FOR 116 Cyclopeptides:
Foreign art collection wherein the amino acid chain forms a cyclic structure; said cyclo structures can be formed by peptide bonding, disulfide bonding, hydrocarbon bonding or other types of connection that define the cyclo structures as having at least a dipeptide as an integral part thereof.

FOR 117 Bicyclic:
Foreign art collection wherein a compound has two cyclic groups containing an amino acid chain.

FOR 118 Monocyclic:
Foreign art collection wherein a compound has only one cyclic group containing an amino acid chain.

FOR 119 25 or more peptide repeating units in known peptide chain structure:
Foreign art collection wherein a peptide chain has 25 or more peptide units in an uninterrupted chain.

FOR 120 16 to 24 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 16 to 24 peptide units.

FOR 121 12 to 15 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 12 to 15 peptide units.

FOR 122 9 to 11 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 9 to 11 peptide units.

D. CHANGES TO THE DEFINITIONS

FOR 123 7 or 8 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 7 or 8 peptide units.

FOR 124 5 or 6 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 5 or 6 peptide units.

FOR 125 3 or 4 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 3 or 4 peptide units.

FOR 126 2 peptide repeating units in known peptide chain:
Foreign art collection which contains an uninterrupted peptide chain of 2 peptide units.

FOR 127 Guanidine containing:
Foreign art collection wherein the peptide compound contains the guanidine group.

FOR 128 Produced by or extracted from animal tissue:
Foreign art collection which is derived from animal material.

D. CHANGES TO THE DEFINITIONS

CLASS 530 – CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF

Definitions Modified

Subclass 300: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1-21.92 and cross-reference art collections 800-809 which provide for therapeutic or body treating compositions containing a peptide or protein as an organic active ingredient.

Subclass 350: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1-21.92 and cross-reference art collections 800-809 which provide for therapeutic or body treating compositions containing a peptide or protein as an organic active ingredient.

Subclass 387.1: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

D. CHANGES TO THE DEFINITIONS

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1-21.92 and cross-reference art collections 800-809 which provide for therapeutic or body treating compositions containing a peptide or protein as an organic active ingredient.

Subclass 403: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1-21.92 and cross-reference art collections 800-809 which provide for therapeutic or body treating compositions containing a peptide or protein as an organic active ingredient.

D. CHANGES TO THE DEFINITIONS

CLASS 930 – PEPTIDE OR PROTEIN SEQUENCE

Definitions Modified

Subclass 10: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 1.1-21.92 for therapeutic or bio-affecting compositions containing peptides.

Subclass 23: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclass 11.8 for a therapeutic or bio-affecting composition containing a thyroid hormone or derivative (e.g., T3, T4, etc.) affecting peptide.

Subclass 25: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclass 5.4 for a therapeutic or bio-affecting composition containing an iron affecting peptide and subclass 13.4 for blood substitute.

D. CHANGES TO THE DEFINITIONS

Subclass 260: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 2.9, 3.6, 19.9, 20.5, and 21.1 for therapeutic or bio-affecting compositions containing cyclopeptides.

Subclass 270: Under SEE OR SEARCH CLASS

Delete:

The reference to Class 514

Insert:

514, Drug, Bio-Affecting and Body Treating Compositions, subclasses 2.9, 3.6, 19.9, 20.5, and 21.1 for therapeutic or bio-affecting compositions containing cyclopeptides.